

FORM PTO-1390  
(REV. 11-2000)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

10365/07304

TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

Unassisted **09/937052**

INTERNATIONAL APPLICATION NO.

PCT/US00/07995

INTERNATIONAL FILING DATE

23 March 2000 (23.03.00)

PRIORITY DATE CLAIMED

23 March 1999 (23.03.99)

TITLE OF INVENTION

FUNGAL BETA-TUBULIN GENES

APPLICANT(S) FOR DO/EO/US

Rajinder S. SIDHU, et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. ☐ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ has been communicated by the International Bureau.
  - c. ☒ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
  - a. ☐ is attached hereto.
  - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
  - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ have been communicated by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

## Items 11 to 20 below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☐ A **FIRST** preliminary amendment.
14. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
15. ☐ A substitute specification.
16. ☐ A change of power of attorney and/or address letter.
17. ☒ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
18. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. ☒ Other items or information: **Statement under WIPO Standard ST.25**

EXPRESS MAIL NO. EL794555629US DATE OF DEPOSIT 19 September 2001  
 deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated  
 above and is addressed to the Assistant Commissioner for Patents, Box PCT, Washington, D.C. 20231 on 19 September 2001 (Date of Deposit)

I hereby certify that this correspondence is being

page 1 of 2

Derrick Gordon (Name of Depositor)

(Signature)

Date of Signature: 19 September 2001

U.S. APPLICATION NO. (37 CFR 1.53) Unassigned <b>09/937052</b>	INTERNATIONAL APPLICATION NO. PCT/US00/07995	ATTORNEY'S DOCKET NUMBER 10365/07304
---	---	---

21. <input checked="" type="checkbox"/> The following fees are submitted: <b>BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):</b> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO. .... \$1000.00  International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO ..... \$860.00  International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... \$710.00  International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... \$690.00  International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) ..... \$100.00 <b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>	<b>CALCULATIONS PTO USE ONLY</b>          <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; text-align: right;">\$ 860.00</td> <td style="width: 50%;"></td> </tr> <tr> <td style="text-align: right;">\$ 130.00</td> <td></td> </tr> </table>	\$ 860.00		\$ 130.00	
\$ 860.00					
\$ 130.00					

Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$	
Total claims	141 - 20 =	121	x \$18.00	\$2178.00	
Independent claims	16 - 3 =	13	x \$80.00	\$1040.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$270.00	\$ 270.00	
<b>TOTAL OF ABOVE CALCULATIONS =</b>				\$4478.00	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$ 2239.00	
<b>SUBTOTAL =</b>				\$2239.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	
<b>TOTAL NATIONAL FEE =</b>				\$2239.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$	
<b>TOTAL FEES ENCLOSED =</b>				\$2239.00	
				Amount to be refunded:	\$
				charged:	\$

a. ☐ A check in the amount of \$ \_\_\_\_\_ to cover the above fees is enclosed.

b. ☒ Please charge my Deposit Account No. 18-1260 in the amount of \$2239.00 to cover the above fees.  
 A duplicate copy of this sheet is enclosed.


c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any  
 overpayment to Deposit Account No. 18-1260. A duplicate copy of this sheet is enclosed.

d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card  
 information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

**NOTE:** Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR  
 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:  
 Eugenia S. Hansen  
 Sidley Austin Brown & Wood  
 717 N. Harwood, Suite 3400  
 Dallas, Texas 75201

  
 SIGNATURE  
 Karen L. Knezek  
 NAME  
 39,253  
 REGISTRATION NUMBER

09/937052

## FUNGAL BETA-TUBULIN GENES

## TECHNICAL FIELD OF THE INVENTION

The invention relates to a bio-affecting composition and to a biological diagnostic and experimental agent.

## BACKGROUND OF THE INVENTION

5 TAXOL® (Bristol-Myers-Squibb), generically known as paclitaxel (hereinafter referred to as "taxol"), is a complex diterpenoid which has demonstrated anti-tumor activity against breast and ovarian cancer (Rowinsky, E.K. and Donehower, R.C. 1991. "The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics," *Pharmacol Ther* 52:35-84). Its anti-tumor activity is due to its ability to bind to beta-tubulin in  
10 assembled microtubules (MTs) and stabilize them (Manfredi, J.J. and Horwitz, S.B. 1984. "Taxol: an antimitotic agent with a new mechanism of action," *Pharmacol Ther* 25:83-125; and Horwitz, S.B. 1992. "Mechanism of action of taxol," *Trends Pharmacol Sci* 13:134-136). *In vivo*, taxol affects spindle function during mitosis, resulting in cell cycle arrest in G2/M phase. *In vitro*, taxol promotes MT assembly and prevents their disassembly under  
15 conditions which would otherwise cause depolymerization (Schiff, et al. 1979. "Promotion of microtubule assembly in vitro by taxol" *Nature* 277:665-667; and Pamesh, J. and Horwitz, S.B. 1981 "Taxol binds to polymerized tubulin *in vitro*," *J Cell Biol* 91:479-487). The taxol binding site on beta-tubulin has been characterized by photo cross-labeling, electron crystallography, and mutagenesis, and involves several regions of beta-tubulin (Rao, et al.  
20 1994. "3'-(p-Azidobenzamido) taxol photolabels the N-terminal 31 amino acids of  $\beta$ -tubulin," *J Biol Chem* 269:3132-3134; Rao, et al. 1995. "Characterization of the taxol binding site on the microtubule," *J Biol Chem* 270:20235-20238; Nogales, et al. 1998. "Structure of the  $\alpha\beta$  tubulin dimer by electron crystallography," *Nature* 391:199-203; Nogales, et al. 1999. "High-resolution model of the microtubule," *Cell* 95:79-88; and  
25 Giannakakou, et al. 1997. "Paclitaxel-resistant human ovarian cancer cells have mutant  $\beta$ -tubulins that exhibit impaired paclitaxel-driven polymerization," *J Biol Chem* 272:17118-17125).

Taxol was found originally in the inner bark of pacific yew trees (*Taxus brevifolia*) by Wani et al. (Wani, et al. 1971. "Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from *Taxus brevifolia*," *J Am Chem Soc* 93:2325-2327), and noted to constitute about 0.02% of dry phloem weight. The limited resource of yew trees made it advantageous to locate additional sources for taxol.

In 1993, Stierle et al. reported the isolation of a taxol-producing fungus, *Taxomyces andreanae*, an endophyte associated with *T. brevifolia* (Stierle, et al. 1993. "Taxol and taxane production by *Taxomyces andreanae*, an endophytic fungus of pacific yew," *Science* 260:214-216). *T. andreanae* produces authentic taxol, though at very low levels (24-50 ng/liter of liquid culture). Recently, additional taxol-producing fungi have been isolated, including various strains of *Pestalotiopsis microspora* (Li, et al. 1996. "Endophytic taxol-producing fungi from bald cypress, *Taxodium distichum*," *Microbiolog* 142:223-226; Li, et al. 1998. "The induction of taxol production in the endophytic fungus-*Periconia* sp. from *Torreya grandifolia*," *J Ind Microbiol Biotechnol* 20:259-264; Strobel, et al. 1996. "Taxol from fungal endophytes and the issue of biodiversity," *J Ind Microbiol* 17:417-423; and Strobel, et al. 1996. "Taxol from *Pestalotiopsis microspora*, an endophytic fungus of *Taxus wallachiana*," *Microbiolog* 142:435-440). One *P. microspora* strain, Ne32, was isolated from the inner bark of Himalayan yew *T. wallachiana*, and produces approximately 50 µg taxol per liter of liquid culture (Strobel, et al. 1996. *Microbiolog* 142:435-440; and Li, et al. 1998. "Stimulation of taxol production in liquid culture of *Pestalotiopsis microspora*," *Mycol Res* 102:461-464). The taxol produced from fungal sources has been reported to be spectroscopically and chromatographically identical to taxol isolated from yew trees, and has shown similar pharmacological effects on cancer cell lines (Strobel, et al. 1996. *Microbiolog* 142:435-440). The production of taxol from fungal sources has provided broader resources of taxol, reduced production costs, and a means of meeting the increasing demand for taxol.

While taxol has been shown to be toxic to cells from a wide range of organisms including mammals, sea urchin, *Drosophila*, *Xenopus*, *Physarum*, *Haemanthus*, and *Trypanosoma* (Baum, et al. 1981. "Taxol, a microtubule stabilizing agent, blocks the replication of *Trypanosoma cruzi*," *Proc Natl Acad Sci USA* 78:4571-4575; Kellogg, et al. 1989. "Proteins in the centrosome, spindle, and kinetochore of the early *Drosophila*

embryo," *J Cell Biol* 109:2977-2991; and Manfredi, J.J. and Horwitz, S.B. 1984.

*Pharmacol Ther* 25:83-125), variable sensitivity to taxol has been reported in fungi. Young et al. tested taxol toxicity on representative species from different fungal groups (Young, et al. 1992. "Antifungal properties of taxol and various analogues," *Experientia* 48:882-885).

5 In Young's study, five oomycete species were identified as sensitive to taxol ( $IC_{50}$  0.4-5.9  $\mu$ M), including the plant pathogens *Pythium ultimum* and *Phytophthora capsici*. In *P. capsici*, taxol inhibited nuclear division at low concentrations, indicating that it acts through a mechanism similar to that in mammalian cells. In contrast, four ascomycete species were identified as resistant to taxol ( $IC_{50} > 50 \mu$ M). This resistance was reported to be due to the  
10 reduced ability of fungal microtubules to interact with taxol. Taxol was also shown to be unable to stabilize MTs assembled with purified *S. cerevisiae* tubulin (Bames, et al. 1992. "Yeast proteins associated with microtubules *in vitro* and *in vivo*," *Mol Biol Cell* 3:29-47) and only weakly stabilize MTs from *Aspergillus nidulans* (Yoon, Y. and Oakley, B.R. 1995. "Purification and characterization of assembly-competent tubulin from *Aspergillus*  
15 *nidulans*," *Biochem* 34:6373-6381).

Because of the anticancer properties of taxol and the variability of fungi to taxol sensitivity, there is a continuing need for isolating and/or identifying novel beta-tubulin genes useful for developing isogenic fungal strains that are either taxol-sensitive or taxol-resistant. These beta-tubulin genes and/or isogenic fungal strains can then be applied to  
20 anticancer drug screening and for developing diagnostic tests for tumor sensitivity assays.

## SUMMARY OF THE INVENTION

In one aspect, the invention is a purified DNA segment encoding a beta-tubulin of the fungal species *Pestalotiopsis microspora* or a portion thereof. Preferably, the DNA segment encodes at least one taxol binding site. For some uses, it is preferable that the DNA  
25 segment encodes a protein having taxol binding site I and taxol binding site II. For DNA segments that encode proteins which function as beta-tubulins, the DNA segment encodes a protein which has taxol binding site I and taxol binding site II and is able to interact with alpha-tubulin. An exemplary DNA segment comprises at least a portion of SEQ ID NO:1. Another exemplary DNA segment comprises a portion of SEQ ID NO:1 comprising the  
30 nucleotide sequence from nucleotide 75 through nucleotide 167 of SEQ ID NO:1, with or without substitution. Another exemplary DNA segment comprises a portion of SEQ ID

NO:1 comprising the nucleotide sequence from nucleotide 708 through nucleotide 764 of SEQ ID NO:1, with or without substitution. Another exemplary DNA segment comprises a portion of SEQ ID NO:1 comprising the nucleotide sequence from nucleotide 708 through nucleotide 764 of SEQ ID NO:1, wherein either nucleotide 729, nucleotide 730 or  
5 nucleotide 731 or mixtures thereof are substituted. Another exemplary DNA segment comprises the nucleotide sequence from nucleotide 75 to nucleotide 1412 of SEQ ID NO:1 wherein the DNA segment encodes a beta-tubulin. Another exemplary DNA segment comprises the nucleotide sequence from nucleotide 75 to nucleotide 1412 of SEQ ID NO:1 wherein at least one nucleotide in the nucleotide sequence is substituted and wherein the  
10 taxol binding capacity of the beta-tubulin is not altered. Another exemplary DNA segment comprises the nucleotide sequence from nucleotide 75 to nucleotide 1412 of SEQ ID NO:1 wherein at least one nucleotide in the nucleotide sequence is substituted and wherein the taxol binding capacity of the beta-tubulin is altered.

In another aspect, the invention is an amino acid sequence comprising at least a  
15 portion of a beta-tubulin of the fungal species *Pestalotiopsis microspora*. Preferably, the amino acid sequence comprises at least one taxol binding site. For some uses, it is preferable that the amino acid sequence is a protein having taxol binding site I and taxol binding site II. For amino acid sequences that can function as beta-tubulins, the amino acid sequence has taxol binding site I and taxol binding site II and is able to interact with alpha-  
20 tubulin. An exemplary amino acid sequence comprises at least a portion of the beta-tubulin as depicted in SEQ ID NO:2. Another exemplary amino acid sequence comprises a portion of SEQ ID NO:2 comprising Amino Acids 1-31, with or without substitution. Another exemplary amino acid sequence comprises a portion of SEQ ID NO:2 comprising Amino Acids 212-230, with or without substitution. Another exemplary amino acid sequence  
25 comprises a portion of SEQ ID NO:2 comprising Amino Acids 212-230 with an amino acid substitution at Amino Acid 219. Another exemplary amino acid sequence comprises a portion of SEQ ID NO:2 consisting essentially of Amino Acids 1-446 wherein the portion behaves as a taxol-resistant beta-tubulin. Another exemplary amino acid sequence comprises a portion of SEQ ID NO:2 consisting essentially of Amino Acids 1-446 the  
30 portion contains at least one amino acid substitution that alters the taxol binding property of the portion. Another exemplary amino acid sequence comprises a portion of SEQ ID NO:2 consisting essentially of Amino Acids 1-446 the portion contains at least one amino acid

substitution that does not alter the taxol binding property of the portion. Another exemplary amino acid sequence is substituted with any amino acid which perturbs the three-dimensional structure of the amino acid sequence surrounding Amino Acid 219 as numbered in SEQ ID NO:2.

5 In another aspect, the invention is a purified DNA segment encoding a beta-tubulin of the fungal species *Pythium ultimum* or a portion thereof. Preferably, the DNA segment encodes at least one taxol binding site. For some uses, it is preferable that the DNA segment encodes a protein having taxol binding site I and taxol binding site II. For DNA segments that encode proteins which function as beta-tubulins, the DNA segment encodes a protein  
10 which has taxol binding site I and taxol binding site II and is able to interact with alpha-tubulin. An exemplary DNA segment comprises at least a portion of SEQ ID NO:3. Another exemplary DNA segment comprises a portion of SEQ ID NO:3 comprising nucleotide 92 through nucleotide 184, with or without substitution. Another exemplary DNA segment comprises a portion of SEQ ID NO:3 comprising the nucleotide sequence  
15 from nucleotide 725 through nucleotide 781, with or without substitution. Another exemplary DNA segment comprises a portion of SEQ ID NO:3 comprising the nucleotide sequence from nucleotide 725 through nucleotide 781, wherein either nucleotide 746, nucleotide 747 or nucleotide 748 or mixtures thereof are substituted. Another exemplary DNA segment comprises the nucleotide sequence from nucleotide 92 to nucleotide 1429 of  
20 SEQ ID NO:3, wherein the DNA segment encodes a beta-tubulin. Another exemplary DNA segment comprises the nucleotide sequence from nucleotide 92 to nucleotide 1429 of SEQ ID NO:3 with at least one nucleotide substitution in the nucleotide sequence and wherein the taxol binding capacity of the beta-tubulin is not altered. Another exemplary DNA segment comprises the nucleotide sequence from nucleotide 92 to nucleotide 1429 of SEQ ID NO:3  
25 with at least one nucleotide substitution in the nucleotide sequence and wherein the taxol binding capacity of the beta-tubulin is altered.

In another aspect, the invention is an amino acid sequence comprising at least a portion of a beta-tubulin of the fungal species *Pythium ultimum*. Preferably, the amino acid sequence comprises at least one taxol binding site. For some uses, it is preferable that the  
30 amino acid sequence is a protein having taxol binding site I and taxol binding site II. For amino acid sequences that can function as beta-tubulins, the amino acid sequence has taxol

binding site I and taxol binding site II and is able to interact with alpha-tubulin. An exemplary amino acid sequence comprises at least a portion of the beta-tubulin as depicted in SEQ ID NO:4. Another exemplary amino acid sequence comprises a portion of SEQ ID NO:4 comprising Amino Acids 1-31, with or without substitution. Another exemplary amino acid sequence comprises a portion of SEQ ID NO:4 comprising Amino Acids 212-230, with or without substitution. Another exemplary amino acid sequence comprises a portion of SEQ ID NO:4 comprising Amino Acids 212-230, wherein the amino acid at Amino Acid 219 is substituted. Another exemplary amino acid sequence comprises a portion of SEQ ID NO:4 consisting essentially of Amino Acids 1-446 and wherein the portion behaves as a taxol-sensitive beta-tubulin. Another exemplary amino acid sequence comprises a portion of SEQ ID NO:4 consisting essentially of Amino Acids 1-446 having at least one amino acid substitution that alters the taxol binding property of the portion. Another exemplary amino acid sequence comprises a portion of SEQ ID NO:4 consisting essentially of Amino Acids 1-446 having at least one amino acid substitution that does not alter the taxol binding property of the portion. Another exemplary amino acid sequence is substituted with any amino acid which perturbs the three-dimensional structure of the amino acid sequence surrounding Amino Acid 219 as numbered in SEQ ID NO:4.

In another aspect, the invention is a purified DNA segment encoding a beta-tubulin of the fungal species *Phytophthora cinnamomi* or a portion thereof, wherein the DNA segment consists essentially of at least a portion of SEQ ID NO:5. An exemplary DNA segment comprises a portion of SEQ ID NO:5 comprising the nucleotide sequence from nucleotide 11 through nucleotide 103. Another exemplary DNA segment comprises a portion of SEQ ID NO:5 comprising the nucleotide sequence from nucleotide 11 through nucleotide 103, wherein at least one nucleotide in the nucleotide sequence is substituted, providing that when nucleotide substitution changes only one amino acid code nucleotide 80 cannot consist of adenine while nucleotide 81 is thymine and nucleotide 82 is adenine, cytosine or thymine. Another exemplary DNA segment comprises a portion of SEQ ID NO:5 comprising nucleotide sequence from nucleotide 644 through nucleotide 700. Another exemplary DNA segment comprises a portion of SEQ ID NO:5 comprising nucleotide sequence from nucleotide 644 through nucleotide 700, wherein at least one nucleotide in the nucleotide sequence is substituted, providing that when nucleotide substitution changes only one amino acid code nucleotide 665 cannot be adenine while



nucleotide 666 is adenine and nucleotide 667 is cytosine or thymine. Another exemplary DNA segment comprises a portion of SEQ ID NO:5 comprising the nucleotide sequence from nucleotide 11 to nucleotide 1342 and wherein the DNA segment encodes a beta-tubulin. Another exemplary DNA segment comprises a portion of SEQ ID NO:5

5 comprising the nucleotide sequence from nucleotide 11 to nucleotide 1342, wherein at least one nucleotide in the nucleotide sequence is substituted, providing that when nucleotide substitution changes only one amino acid code, nucleotide 665 cannot be adenine while nucleotide 666 is adenine and nucleotide 667 is cytosine or thymine. Another exemplary DNA segment comprises a portion of SEQ ID NO:5 comprising the nucleotide sequence from nucleotide 11 to nucleotide 1342, wherein at least one nucleotide in the nucleotide sequence is substituted, providing that when nucleotide substitution changes only one amino acid code, nucleotide 665 cannot be adenine while nucleotide 666 is adenine and nucleotide 667 is cytosine or thymine, and wherein the taxol binding capacity of the beta-tubulin is not altered. Another exemplary DNA segment comprises a portion of SEQ ID NO:5 comprising the nucleotide sequence from nucleotide 11 to nucleotide 1342, wherein at least one nucleotide in the nucleotide sequence is substituted, providing that when nucleotide substitution changes only one amino acid code, nucleotide 665 cannot be adenine while nucleotide 666 is adenine and nucleotide 667 is cytosine or thymine, and wherein the taxol binding capacity of the beta-tubulin is altered.

20 In another aspect, the invention is an amino acid sequence comprising at least a portion of a beta-tubulin of the fungal species *Phytophthora cinnamomi* as depicted in SEQ ID NO:6. An exemplary amino acid sequence comprises a portion of SEQ ID NO:6 comprising Amino Acids 1-31. An exemplary amino acid sequence comprises a portion of SEQ ID NO:6 comprising Amino Acids 1-31, having at least one amino acid substituted, providing that when only one amino acid is substituted Amino Acid 24 is not isoleucine. Another exemplary amino acid sequence comprises a portion of SEQ ID NO:6 comprising Amino Acids 212-230. Another exemplary amino acid sequence comprises a portion of SEQ ID NO:6 comprising Amino Acids 212-230, having at least one amino acid substituted, providing that when only one amino acid is substituted Amino Acid 219 is not asparagine. Another exemplary amino acid sequence comprises a portion of SEQ ID NO:6 comprising Amino Acids 212-230 with an amino acid substitution at Amino Acid 219, wherein the Amino Acid 219 is not substituted with asparagine. Another exemplary amino acid

sequence comprises a portion of SEQ ID NO:6 consisting essentially of Amino Acids 1-446, wherein the portion behaves as a taxol-sensitive beta-tubulin. Another exemplary amino acid sequence comprises a portion of SEQ ID NO:6 consisting essentially of Amino Acids 1-446, wherein the portion contains at least one amino acid substitution, providing that when only one amino acid is substituted Amino Acid 219 is not asparagine, and wherein the amino acid substitution alters the taxol binding property of the portion. Another exemplary amino acid sequence comprises a portion of SEQ ID NO:6 consisting essentially of Amino Acids 1-446, wherein the portion contains at least one amino acid substitution, providing that when only one amino acid is substituted Amino Acid 219 is not asparagine, and wherein the amino acid substitution does not alter the taxol binding property of the portion. Another exemplary amino acid sequence is substituted at Amino Acid 219 with any amino acid except asparagine which perturbs the three-dimensional structure of the amino acid sequence surrounding Amino Acid 219.

In another aspect, the invention is a vector comprising a purified DNA segment encoding a beta-tubulin of the fungal species *Pestalotiopsis microspora* or a portion thereof. Preferably, the vector comprises a portion encoding at least one taxol binding site.

In another aspect, the invention is a vector comprising a purified DNA segment encoding a beta-tubulin of the fungal species *Pythium ultimum* or a portion thereof. Preferably, the vector comprises a portion encoding at least one taxol binding site.

In another aspect, the invention is a vector comprising a purified DNA segment encoding a beta-tubulin of the fungal species *Phytophthora cinnamomi* wherein the DNA segment consists essentially of SEQ ID NO:5 or a portion thereof. Preferably, the vector comprises a portion encoding at least one taxol binding site.

In another aspect, the invention is a method of determining the taxol binding capacity of a beta-tubulin or beta-tubulin-like compound comprising providing antibodies raised against amino acid sequences comprising at least one taxol binding site of a beta-tubulin from a taxol-resistant *Pestalotiopsis microspora*, a taxol-sensitive *Pythium ultimum*, or taxol-sensitive *Phytophthora cinnamomi* as depicted in SEQ ID NO:6 to form a reagent, such antibodies distinguishing between taxol-binding and non-taxol-binding properties; contacting the beta-tubulin or beta-tubulin-like compound with the reagent; and determining

degree of binding between the antibodies in the reagent and the beta-tubulin or beta-tubulin-like compound; whereby binding of antibodies raised against a taxol-resistant *Pestalotiopsis microspora* to the beta-tubulin or beta-tubulin-like compound indicates taxol resistance and whereby binding of antibodies which specifically recognize taxol-binding properties indicate taxol sensitive; whereby binding of antibodies which specifically recognize taxol-non-binding properties indicate taxol resistance. In one embodiment, the antibodies in the reagent are raised against an amino acid sequence comprising at least one taxol binding site of a beta-tubulin from a taxol-resistant *Pestalotiopsis microspora*. In another embodiment, the antibodies in the reagent are raised against an amino acid sequence comprises at least one taxol binding site from SEQ ID NO:2. In another embodiment, the antibodies in the reagent are raised against an amino acid sequence comprising at least one taxol binding site of a beta-tubulin from a taxol-sensitive *Pythium ultimum*. In another embodiment, the antibodies in the reagent are raised against an amino acid sequence comprises at least one taxol binding site from SEQ ID NO:4. In another embodiment, the antibodies in the reagent are raised against an amino acid sequence comprising at least one taxol binding site of a beta-tubulin from a taxol-sensitive *Phytophthora cinnamomi* as depicted in SEQ ID NO:6. In another embodiment, the antibodies in the reagent are raised against an amino acid sequence comprises at least one taxol binding site from SEQ ID NO:678. In this method, the beta-tubulin or beta-tubulin-like compound are selected from the group consisting of recombinantly expressed protein, exogenously isolated protein, synthetic peptides, and cell cultures.

In another aspect, the invention is a method of screening a composition of matter for the presence of taxol or taxol-like compounds comprising providing beta-tubulins with amino acid sequences comprising both taxol binding sites from *Pythium ultimum* or taxol-sensitive *Phytophthora cinnamomi* as depicted in SEQ ID NO:6 in addition to alpha-tubulin from any taxol-sensitive organism to form a reagent; contacting the composition of matter with the reagent; and determining the ability of the composition of matter to promote MT assembly or ability to prevent depolymerization of assembled MTs under depolymerizing conditions; whereby the ability to promote microtubule assembly or prevent depolymerization indicate the possible presence of taxol or taxol-like compounds in the composition of matter.

In another aspect, the invention is a method of screening a composition of matter for the presence of taxol or taxol-like compounds comprising providing mycelia of taxol-sensitive *Pythium ultimum* or a taxol-sensitive *Phytophthora cinnamomi* which harbors beta-tubulin in SEQ ID NO:6; contacting the composition of matter with the mycelia in the presence of the labeled taxol; and determining the degree of competitive inhibition of binding between the beta-tubulins and the labeled taxol by the composition of matter, whereby the composition of matter is determined to possess taxol or taxol-like compounds if it is able to block labeled taxol binding to the beta-tubulins from the taxol-sensitive *Pythium ultimum* or *Phytophthora cinnamomi*.

In another aspect, the invention is a method of altering the taxol binding property of a recombinantly expressed beta-tubulin or a portion thereof comprising determining the identity of the codon at Amino Acid 219 as numbered in SEQ ID NO:1 in the coding region of the vector; and if the codon at Amino Acid 219 codes for any amino acid except threonine, substituting nucleotides in the codon to code for threonine at Amino Acid 219 to alter a non-taxol-binding beta-tubulin or portion thereof to a taxol-binding beta-tubulin or portion thereof, or if the codon at Amino Acid 219 codes for threonine, substituting nucleotides in the codon to code for any amino acid except threonine at Amino Acid 219 to alter a taxol-binding beta-tubulin or portion thereof to a non-taxol-binding beta-tubulin or portion thereof.

In another aspect, the invention is a method of developing a taxol-sensitive fungal cell from a taxol-resistant fungal cell comprising transforming the non-taxol-sensitive fungal cell by introducing a DNA segment encoding taxol-binding beta-tubulin comprising threonine at Amino Acid 219 as numbered in SEQ ID NO:2; wherein the transformed fungal cell expresses the DNA segment under the control of a suitable constitutive or inducible promoter when exposed to conditions which permit expression.

In another aspect, the invention is a transgenic taxol-sensitive fungal cell transformed by introducing a DNA segment encoding taxol-binding beta-tubulin comprising threonine at Amino Acid 219 as numbered in SEQ ID NO:2, wherein the transformed fungal cell expresses the DNA segment under the control of a suitable constitutive or inducible promoter when exposed to conditions which permit expression.

In another aspect, the invention is a method of developing a taxol-resistant fungal cell from a taxol-sensitive fungal cell comprising transforming the taxol-sensitive fungal cell by introducing a DNA segment encoding non-taxol-binding beta-tubulin wherein the amino acid at Amino Acid 219 as numbered in SEQ ID NO:2 is not threonine; wherein the transformed fungal cell over-expresses the DNA segment under the control of a suitable constitutive or inducible promoter when exposed to conditions which permit expression.

In another aspect, the invention is a transgenic taxol-sensitive fungal cell transformed by introducing a DNA segment encoding taxol-binding beta-tubulin comprising threonine at Amino Acid 219 as numbered in SEQ ID NO:2, wherein the transformed fungal cell over-expresses the DNA segment under the control of a suitable constitutive or inducible promoter when exposed to conditions which permit expression.

In another aspect, the invention is a method of screening a composition of matter for the presence of taxol or taxol-like compounds comprising providing distinguishable taxol-resistant and taxol-sensitive fungal cells; contacting the composition of matter with the fungal cells; and determining the growth of inhibition of the fungal cells; whereby the composition of matter is determined to possess taxol or taxol-like compounds if it is able to inhibit the growth of taxol-sensitive fungal cells but not able to inhibit the growth of taxol-resistant fungal cells. The method can be performed wherein the distinguishable taxol-resistant and taxol-sensitive fungal cells consists essentially of transgenic taxol-resistant and taxol-sensitive isogenic fungal cells. The method can also be performed with taxol-resistant fungal cells derived from one fungus which is unrelated to the fungi from which the taxol-sensitive fungal cells are derived.

In another aspect, the invention is a method for controlling the growth of a plant pathogen comprising determining the taxol sensitivity of the plant pathogen; and if the pathogen is determined to be taxol-sensitive, the plant and soil surrounding the plant are treated with a taxol-producing *P. microspora*. In an exemplary method, the taxol sensitivity of the plant pathogen is determined by identifying Amino Acid 219, wherein the plant is designated as taxol-sensitive if Amino Acid 219 is threonine.

## BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 is a graph depicting the effect of taxol on mycelial growth in *P. microspora*, *P. ultimum*, *P. cinnamomi* and *A. klebsiana*. Fungal mycelia were grown on potato dextrose agar (PDA) plates containing different concentrations of taxol. The inhibitory effect of taxol was assessed by colony diameter, and compared to mycelia grown in the absence of taxol. Experiments were conducted in duplicate, and data presented are an average of several experiments.

Fig. 2 depicts the nucleotide and deduced amino acid sequence of beta-tubulin from *P. microspora* Ne32 cDNA, TUBB-pm. Numerals on the left indicate nucleotide position, and numerals on the right indicate amino acid position. The sequences of the gene-specific primers NETUB5 and NETUB6 are underlined. The translation initiation codon ATG is underlined, the translation termination codon is marked by an asterisk, and the putative polyadenylation signal is double underlined.

Fig. 3 depicts the nucleotide and deduced amino acid sequence of beta-tubulin from *P. ultimum* cDNA, TUBB-pu. Numerals on the left indicate nucleotide position, and numerals on the right indicate amino acid position. The sequences of the gene-specific primers WT1L-U and WT1L-L are underlined. The translation initiation codon ATG is underlined, the translation termination codon is marked by an asterisk, and the two putative polyadenylation signals are double underlined. The arrow at nucleotide 1507 indicates the position of the poly (A) tract in the shorter 1537 bp cDNA.

Fig. 4 depicts the nucleotide and deduced amino acid sequence of beta-tubulin from *P. cinnamomi* cDNA, TUBB-pc. Numerals on the left indicate nucleotide position, and numerals on the right indicate amino acid position. The sequences of the gene-specific primers PCBTUB1U, PCBTUB2U and PCBTUB4L are underlined. The translation initiation codon ATG is marked by ###, and the translation termination codon is marked by an asterisk. Nucleotides and amino acids which differ between TUBB-pc and the sequence U22050 (Genbank accession number) reported by Weerakoon et al. (Weerakoon et al. 1998. "Isolation and characterization of the single  $\beta$ -tubulin gene in *Phytophthora cinnamomi*," *Mycologia* 90:85-95) are double underlined.

Fig. 5 compares the amino acid sequence of *P. cinnamomi* beta-tubulins ("TUBB-pc") reported herein and previously by Weerakoon et al. (Weerakoon, et al. 1998. *Mycologia* 90:85-95) ("U22050"). The deduced amino acid sequence of *P. cinnamomi* TUBB-pc is shown in its entirety, and the eight residues (Amino Acids 24, 219, 249, 251-253, 359, and 428) which differ from the U22050 sequence (Genbank accession number) reported by Weerakoon et al. (1998) are shown below the TUBB-pc sequence. Amino Acids 1-31 and 212-231 (denoted herein as taxol binding region I and II, respectively) are indicated by a line above the sequence.

Fig. 6A and 6B depict the amino acid sequence alignment of beta-tubulins. The alignment was obtained using the ClustalW alignment program. The amino acid sequence of *P. microspora* beta-tubulin is shown in its entirety, and residues which differ in other beta-tubulins are shown below. Numerals on the right indicate amino acid positions. Sequences underlined indicate regions important for GTP binding (Amino Acids 63-77), phosphate binding (Amino Acids 140-146), and  $Mg^{2+}$  binding (Amino Acids 203-206). Amino Acids 1-31 and 212-231 (denoted here as taxol binding region I and II, respectively) are indicated by a line above the sequence. Amino Acids Phe270, Leu273 and Ser364 are marked above with #. Amino acids which are important for fungal resistance to benzimidazoles (Amino Acids 6, 165, 167, 198, 200 and 241) are marked above by asterisks. Gaps in alignment are indicated by dashes, and the end of each sequence is marked by "\$". The Genbank accession numbers for beta-tubulins from *N. crassa*, *A. nidulans* benA, *A. klebsiana* and human  $\beta 2$  are listed in Table I. The *P. cinnamomi* depicted is SEQ ID NO:6.

Fig. 7A and 7B are graphs depicting the specific binding of [ $^3$ H]taxol to *P. ultimum* but not to *P. microspora*. Fig. 7A demonstrates that specific binding of [ $^3$ H]taxol to *P. ultimum* increased as a function of [ $^3$ H]taxol concentration, while *P. microspora* showed no or very little specific binding. Actively growing fungal cells were incubated with different concentrations of [ $^3$ H]taxol at room temperature for 2 hours before quenching. Specific binding was calculated as the difference between binding of [ $^3$ H]taxol in the presence and absence of a 100-fold excess of unlabeled taxol. Specific binding represents 30-70% of the total binding to *P. ultimum* but less than 5% of the total binding to *P. microspora*. Binding of [ $^3$ H]taxol to *P. microspora* cells was performed in the presence of Triton X-100 (0.1%

v/v) to disrupt the cell membrane. Fig. 7B depicts the reduction of specific binding of [<sup>3</sup>H]taxol to *P. ultimum* in the presence and absence of the microtubule-depolymerizing drug thiabendazole in a dose-dependent manner. Cells were either not treated (0 μM) or treated with different concentrations of thiabendazole for three hours at room temperature.

Subsequently, cells were incubated with 5 nM [<sup>3</sup>H]taxol in the presence or absence of a 100-fold excess of unlabeled taxol for two hours before quenching. The specific binding of [<sup>3</sup>H]taxol to untreated cells was defined as 100%. The experiments depicted in Fig. 7A and 7B were conducted in duplicate, and data presented are representative of several experiments.

Fig. 8 depicts the amino acid sequences of the taxol binding region I (Amino Acids 1-31) and II (Amino Acids 212-231) of beta-tubulins from different organisms. The amino acid sequences of the taxol binding regions I and II for pig beta-tubulin are shown in their entirety and residues which differ are shown for other beta-tubulins. The taxol sensitivity of each organism is indicated, "s" for sensitive and "r" for resistant. Amino Acids 15-25 and 212-222, which have been shown to be involved in taxol binding by both cross-linking and electron crystallography, are marked with asterisks. The taxol binding region II of *A. klebsiana* is between Amino Acids 211-230 due to a gap in its sequence. Pig beta-tubulin is described by Nogales, et al. (Nogales, et al. 1999. *Nature* 391:199-203), and Genbank accession numbers for other sequences are listed in Table I. The sequence for *P. cinnamomi* presented herein is depicted in SEQ ID NO:6.

## DETAILED DESCRIPTION

One aspect of the present invention is an isolated gene comprising an open reading frame coding for the protein beta-tubulin or a portion thereof. The corresponding cDNA have been isolated and characterized for taxol-resistant *Pestalotiopsis microspora* Ne32, taxol-sensitive *Pythium ultimum*, and taxol-sensitive *Pythium cinnamomi*. The nucleotide and deduced amino acid sequences of beta-tubulin for *Pestalotiopsis microspora* Ne32 are given in SEQ ID NO:1 and SEQ ID NO:2, respectively; for *Pythium ultimum*, in SEQ ID NO:3 and SEQ ID NO:4, respectively; and for *Pythium cinnamomi*, in SEQ ID NO:5 and SEQ ID NO:6, respectively. Through characterization of the taxol sensitivity of the beta-tubulins encoded by the genes of the present invention, it has been found that the identity of Amino Acid 219 of beta-tubulin as numbered in SEQ ID NO:2, SEQ ID NO:4, or SEQ ID



NO:6 is an indicator of taxol sensitivity. The presence of threonine at Amino Acid 219 ("Thr219") indicates taxol sensitivity, while the presence of asparagine ("Asn219") or glutamine ("Gln219") indicate taxol resistance.

In another aspect, the present invention is the beta-tubulin protein or protein fragments encoded by the novel genes disclosed herein. Since the *P. ultimum* and *P. cinnamomi* beta-tubulin proteins of the present invention are capable of binding taxol, proteins and protein fragments comprising taxol-binding sites derived from the genes coding for beta-tubulin described herein can be produced by heterologous expression in *E. coli* and other systems, purified by standard procedures, and used in an *in vitro* assay for detecting taxol and taxol-like substances by using methods well known in the art (Schiff, et al. 1979. *Nature* 277:665-667). For example, the beta-tubulin proteins of the present invention can be used to screen plant or fungal extracts as well as synthetic compounds for taxol or taxol-like substances as possible anticancer drugs. Beta-tubulins produced by making specific amino acid substitutions, deletions, or alterations can be used as experimental tools to further determine the molecular basis of taxol binding to the beta-tubulin protein.

In another aspect, antibodies (polyclonal or monoclonal) raised against all or portions of the beta tubulins of the present invention can be used to determine if a composition of matter has taxol binding properties. In one method, antibodies capable of binding to taxol-sensitive beta-tubulin and/or taxol-resistant beta tubulins are exposed to a composition of matter prepared for *in situ* hybridization (Ausubel, et al. 1997. *Current Protocols in Molecular Biology*, John Wiley & Sons), Elisa, or Western blot. Visualization of antibody-antigen binding is mediated through any means known in the art, e.g., secondary radiolabeled or fluorescent antibodies or colorimetric methods using peroxidase and/or alkaline phosphatase (Harlow, E.D. and Lane, D. 1988. *Antibodies: A Laboratory Manual*). For example, antibodies raised to a portion of SEQ ID NO:4 comprising Amino Acid 219 would bind to a beta-tubulin which had threonine at Amino Acid 219 but would not bind to a beta-tubulin having a different amino acid at Amino Acid 219, so that detectable binding would indicate the presence of threonine at Amino Acid 219, and hence, sensitivity to taxol. This type of assay is useful for screening a variety of compositions of matter, including living matter such as plants or microorganisms, or non-living matter such as plant materials, patient samples, or compound libraries for the presence of beta-tubulin.

In another aspect, the present invention is a method of designing taxol analogs or other compounds which mimic the interaction of taxol with beta-tubulin based on the identification of specific amino acids in the beta-tubulins corresponding to taxol-binding and taxol-sensitivity. The previously reported three-dimensional structure (Nogales, et al. 1998, *Nature* 391:199-203) can be applied to developing and optimizing antineoplastic and antifungal compounds with respect to Amino Acid 219 and the surrounding area. Further, such information can also be used to generate mutant beta-tubulins with altered taxol sensitivity by substituting amino acids at specific positions in the beta-tubulin protein.

In another aspect, the present invention is a method of generating isogenic strains of fungi using a gene of the present invention, which allows studies of taxol related pharmacology to be performed against a known background. Further, the present invention is a method of using these isogenic fungal strains, one of which is taxol sensitive and the other taxol resistant, to screen plant extracts, fungal extracts, extracts from other organisms, and synthetic compounds for taxol-like substances as possible anticancer agents. The present invention is also a method of using two unrelated fungal strains, one of which is taxol sensitive and the other taxol resistant, to screen plant extracts, fungal extracts, extracts from other organisms, and synthetic compounds for taxol-like substances as possible anticancer agents.

The genes and proteins of the present invention are characterized in the following examples. It is to be understood that the examples are exemplary of the invention and are intended to be illustrative of the invention, but are not to be construed to limit the scope of the invention in any way. Modifications may be made in the structural features of the invention without departing from the scope of the invention.

#### **Example 1: Differential taxol sensitivity in selected fungi**

Taxol sensitivity was established for the fungal strains used in the isolation of the beta-tubulin cDNAs of the present invention.

*Pestalotiopsis microspora* strain Ne32, previously disclosed in U.S. Patent No. 5,861,302, was licensed from Montana State University. *Pythium ultimum* (ATCC 26083), *Achlya klebsiana* (ATCC 52605), and *Pythium cinnamomi* (ATCC 200982) were purchased

from American Type Culture Collection (Manassas, VA). Taxol was obtained from Sigma Chemical Company (St. Louis, MO).

The effect of taxol on the growth of *P. microspora* Ne32, *P. ultimum*, and *P. cinnamomi* was examined. For comparison, *A. klebsiana*, an oomycete closely related to *P. ultimum*, was also included in these experiments. As shown in Fig. 1, the growth of *P. microspora* was highly resistant to taxol up to 11.7  $\mu$ M. By comparison, *A. klebsiana* showed moderate sensitivity, and its growth was reduced by 40% in 11.7  $\mu$ M taxol. Finally, *P. ultimum* and *P. cinnamomi* were shown to be the most sensitive of the four species. Growth of *P. ultimum* and *P. cinnamomi* was inhibited even at low concentrations of taxol (IC<sub>50</sub> 0.1  $\mu$ M). This sensitivity is comparable to the level of taxol (0.25  $\mu$ M) that inhibits Hela cell division (Schiff, et al. 1979. *Nature* 277:665-667).

#### Example 2: Isolation of $\beta$ -tubulin cDNA sequences

Beta-tubulin cDNA sequences were determined for *P. microspora* Ne32, *P. ultimum*, and *P. cinnamomi* from RNA isolated from fungal mycelia. Automated dideoxynucleotide sequencing was performed by a contracting laboratory. Sequence comparison was performed using the BLAST program at the Internet site of the National Center for Biotechnology Information. The amino acid sequence alignment was performed using ClustalW program, and other analysis using MacVector program.

To isolate beta-tubulin cDNA sequences from *P. microspora* Ne32 and *P. ultimum*, four degenerate primers were designed according to conserved motifs in fungal beta-tubulin amino acid sequences. A forward degenerate primer BTUB1, 5'-CTGGGCYAAGGGYC AYTACACYGAG-3' (SEQ ID NO:7, was designed corresponding to amino acid residues Trp-Ala-Lys-Gly-His-Tyr-Thr-Glu (or WAKGHYTE in single letter amino acid code; SEQ ID NO:8); a reverse primer BTUB2, 5'-CGAAGAARTGRARNCGRGGGAARGG-3' (SEQ ID NO:9), corresponding to amino acid residues Pro-Phe-Pro-Arg-Leu-His-Phe-Phe (or PFPRLHFF in single letter amino acid code; SEQ ID NO:10); a forward primer BTUB3, 5'-CGAGCCYTACAACGCYACYCT-3' (SEQ ID NO:11), corresponding to amino acid residues Glu-Pro-Tyr-Asn-Ala-Thr-Leu (or EPYNATL in single letter amino acid code; SEQ ID NO:12); and a reverse primer BTUB4, 5'-CTCGTTCATGTTRSWCTCRGCCTC-3' (SEQ ID NO:13), corresponding to amino acid residues Glu-Ala-Glu-Ser-Asn-Met-Asn-Asp

(or EAESNMND in single letter amino acid code; SEQ ID NO:14). All primers were synthesized by a contracting laboratory according to our specifications.

In order to isolate beta-tubulin cDNA from *P. microspora* Ne32, five micrograms (5 µg) of total RNA from mycelia grown for 5 days was used to synthesize first-strand cDNA using primer BTUB4 in a 20 microliter (20 µl) reaction. One microliter (1 µl) of the cDNA product was used as template in Polymerase Chain Reactions (PCR). The cycling program contained 8 cycles of an annealing temperature of 52°C, followed by 22 cycles with an annealing temperature of 62°C. Degenerate primers BTUB3 and BTUB4 generated an amplification product of 0.8 kb, whereas BTUB2 and BTUB3 generated a product of 0.3 kb.

The desired bands were gel-purified using GeneClean (BIO 101, Vista, CA), ligated into the pPCR2.1 vector (Invitrogen; San Diego, CA), and transformed into *E. coli* XL1 -Blue cells. Inserts were sequenced and used to synthesize a gene-specific forward primer NETUB5, 5'-GGGTGTCACCACTTGCTTGC GTTT-3' (SEQ ID NO:15), and a reverse primer NETUB6, 5'-TCGAGTTTCCGACGAAAGTGGACGA-3' (SEQ ID NO:16). To obtain full-length

clones, a Marathon cDNA Library was constructed using one microgram (1 µg) mRNA according to manufacturer (Clontech; Palo Alto, CA). One microliter (1 µl) of this library was diluted 250-fold, and five microliters (5 µl) were used in Rapid Amplification of cDNA Ends (RACE) reactions using the PCR cycling program recommended by the manufacturer.

For 5' RACE, library adaptor primer AP1 (Clontech) and primer NETUB6 generated a product of 1.3 kb. For 3' RACE, primers AP1 and NETUB5 generated a product of 1.0 kb. The desired bands were gel-purified and cloned into the pPCRII-TOPO vector (Invitrogen, Carlsbad, CA). The region between 1 to 1105 bp from the 5' RACE product was ligated at an internal *Bam*HI site with the region between 1106 to 1668 bp from the 3' RACE product to form the composite cDNA (Fig. 2). The resulting composite cDNA from *P. microspora*

was 1668 bp long, designated as TUBB-pm, and its nucleotide and deduced amino acid sequence are shown in SEQ ID NO:1 and SEQ ID NO:2, respectively, as well as Fig 2. This cDNA encodes a protein of 446 amino acids with a calculated Mr of 49,832 and pI of 4.6. It contains 74 nucleotides in the 5' untranslated region (UTR), and 229 nucleotides in the 3' UTR followed by a 24 nucleotide poly (A) tail. A sequence AATAA (nucleotides 1539-1543 of SEQ ID NO:1) with the closest similarity to the animal and viral polyadenylation signal AATAAA (Proudfoot, N.J. and Brownlee, G.G. 1976. "3' Non-coding region

sequences in eukaryotic messenger RNA," *Nature* 263:211-214) was located 103 bp upstream of the poly (A) tract.

In order to isolate beta-tubulin cDNA from *P. ultimum*, five micrograms (5 µg) of total RNA from mycelia grown for six days was used to synthesize first strand cDNA with oligo-dT primer (GibcoBRL; Gaithersburg, MD) in a twenty microliter (20 µl) reaction. Two microliters (2 µl) of cDNA product were used as the template in PCR reactions with a cycling program similar to that described above. Degenerate primers BTUB1 and BTUB4 generated a product of 1.0 kb, whereas BTUB1 and BTUB2 amplified a product of 0.5 kb. The desired bands were gel-purified and ligated into the pPCR2.1 vector. Inserts were sequenced and used to design a gene-specific forward primer WTIL-U, 5'-CTAT CATGTGCACGTACTCGGTGTGC-3' (SEQ ID NO:17), and a reverse primer WTIL-L, 5'-CTGGGACGGTCAAAGCACGGTACTGC-3' (SEQ ID NO:18). For 5' RACE, first-strand cDNA was synthesized using primer WTIL-L and used as template in PCR reactions. Primers WTIL-L and Cap-Switch (Clontech) generated a 0.95 kb product using Advantage-GC cDNA PCR kit (Clontech). For 3' RACE, first strand cDNA was synthesized using CapFinder cDNA Library Construction kit (Clontech). With the resulting cDNAs as template, primers WTIL-U and CDS/3' (Clontech) generated two PCR products of 1.0 and 1.1 kb, respectively. PCR fragments were gel-purified and cloned into the pPCR2.1 vector. In *P. ultimum*, isolated tubulin cDNAs were of two types, one composite cDNA was 1650 bp long, and the other was 1537 bp long. These two cDNAs differ only in the position at which the poly (A) tail has been added. The region between 1 to 824 bp from the 5' RACE product was ligated at an internal *MfeI* site with the region between 825 to 1650 bp from the 1.1 kb 3' RACE product to form the composite 1650 bp cDNA designated as TUBB-pu, and its nucleotide and deduced amino acid sequence are shown in SEQ ID NO:3 and SEQ ID NO:4, respectively, as well as Fig. 3. This cDNA encodes a protein of 446 amino acids with a calculated Mr of 50,047 and pI of 4.6. It contains 91 nucleotides in the 5' UTR, and 199 nucleotides in the 3' UTR followed by a 19 nucleotide poly (A) tract. Two imperfect polyadenylation signals were tentatively identified, ATATA at 57 bp upstream of poly (A) tract in the 1537 bp cDNA (nucleotides 1445-1449 of SEQ ID NO:3), and AATATT at 80 bp upstream of poly (A) tail in the 1650 bp cDNA (nucleotides 1546-1551 of SEQ ID NO:3). The sizes of these cDNAs match well with transcript sizes in Northern analysis as shown below, indicating they are complete.

Four gene-specific primers were synthesized based on the reported beta-tubulin cDNA sequence from *P. cinnamomi* (Weerakoon, et al. 1998. *Mycologia* 90:85-95). The forward primer PCBTUB1U (5'-CAGCGACAACATGAGAGAGCTCG-3'; SEQ ID NO:19) corresponds to region 270-292 in its cDNA sequence, the forward primer PCBTUB2U (5'-CGATGAGGTCATGTGCCTGGATAA-3'; SEQ ID NO:20) corresponds to region 867-890; the reverse primer PCBTUB3L (5'-AAACGGAGGCACGTGGTGATG-3'; SEQ ID NO:21) corresponds to region 984-1005; the reverse primer PCBTUB4L (5'-CGCGTC TATCTCATCCATTCCTCG-3'; SEQ ID NO:22) corresponds to region 1596-1619.

Five micrograms (5 µg) of total RNA from *P. cinnamomi* mycelia grown for 5 days was used to synthesize first-strand cDNA using oligo-dT primer in a 20 µl reaction. One microliter (1 µl) of the cDNA product was used as template for PCR. The cycling program comprised 30 cycles with an annealing temperature of 62°C. Primer PCBTUB1U and PCBTUB4L generated an amplification product of 1.3 kb, and primer PCBTUB2U and PCBTUB4L generated an amplification product of 0.75 kb. Primer PCBTUB1U or PCBTUB2U in combination with PCBTUB3L did not generate any product. The desired bands were gel-purified using GeneClean (BIO101), ligated into the pPCR2.1 vector (Invitrogen), and transformed into *E. coli* XL1-Blue cells. Four clones of the 1.3 kb fragment (clone # C16-1, 4, 9 and 10) and one clone of the 0.75 kb fragment (clone # C10-5) were sequenced from both directions and found to conform to the same sequence. The nucleotide and deduced amino acid sequence of the 1.3 kb long cDNA, designated as TUBB-pc, are shown in SEQ ID NO:5 and SEQ ID NO:6, respectively, as well as Fig. 4. It encodes a 444 amino acid long beta-tubulin protein, with a calculated Mr of 50 kDa, and a pI of 4.7. There are 10 nucleotides in the 5' untranslated region (UTR), and 5 nucleotides in the 3' UTR.

A sequence encoding *P. cinnamomi* beta-tubulin has been previously reported (Weerakoon, et al. 1998. *Mycologia* 90:85-95; Genbank accession number U22050), and the deduced amino acid sequence of *P. cinnamomi* beta-tubulin disclosed herein was compared to that disclosed by Weerakoon et al. The TUBB-pc cDNA sequence shown in SEQ ID NO:5 and Fig. 4 differs by 36 nucleotides (2.7%) within the coding region from the one reported by Weerakoon et al. An alignment of the beta-tubulin amino acid sequences deduced from TUBB-pc (SEQ ID NO:6) and the one previously reported by Weerakoon

("U22050"; SEQ ID NO:23) is shown in Fig 5. The two sequences differ by 8 amino acids. Four are conserved changes, while the other four are nonconserved changes. One change is within each of the taxol-binding sites. In the taxol-binding region I (Amino Acids 1-31), Amino Acid V24 (valine at Amino Acid 24) in TUBB-pc differs from I24 (isoleucine at Amino Acid 24) in U22050. In the taxol-binding region II (Amino Acids 212-231), Amino Acid T219 (threonine at Amino Acid 219) in TUBB-pc differs from N219 (asparagine at Amino Acid 219) in U22050.

The deduced amino acid sequence of beta-tubulin from *P. microspora* (SEQ ID NO:2), *P. ultimum* (SEQ ID NO:4), and *P. cinnamomi* (SEQ ID NO:6) show features expected of beta-tubulin, as shown by an alignment with human  $\beta$ 2-tubulin (SEQ ID NO:24) and from beta-tubulins from *Neurospora crassa* (SEQ ID NO:25), *A. nidulans* benA (SEQ ID NO:26), and *A. klebsiana* (SEQ ID NO: 27) depicted in Fig. 6. These sequences can be divided into N-terminal (Amino Acids 1-205), intermediate (Amino Acids 206-381) and C-terminal domains (Nogales, et al.1998. *Nature* 391:199-203). Their N-terminal domain contains conserved motifs important for GTP binding [Ala-Ile-Leu-Val-Asp-Leu-Glu-Pro-Gly-Thr-Met-Asp-Ser-Val-Arg or AILVDLEPGTMDSVR in single letter amino acid code (SEQ ID NO:28) and Ala-Val-Leu-Val-Asp-Leu-Glu-Pro-Gly-Thr-Met-Asp-Ser-Val-Arg or AVLVDLEPGTMDSVR in single letter amino acid code (SEQ ID NO:29) between Amino Acids 63-77 in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:26, and between Amino Acids 62-76 in SEQ ID NO:27], phosphate binding [Gly-Gly-Gly-Thr-Gly-Ser-Gly or GGGTGSG in single letter amino acid code (SEQ ID NO:30) between Amino Acids 140-146 in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:26, and between Amino Acids 139 and 145 in SEQ ID NO:27], and  $Mg^{2+}$  binding (Asp-Asn-Glu-Ala or DNEA in single letter amino acid code (SEQ ID NO:31) between Amino Acids 203-206 in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:26, and between Amino Acids 202-205 in SEQ ID NO:27) (Linse, K. and Mandelkow, E.M. 1988. "The GTP-binding peptide of  $\beta$ -tubulin: localization by direct photoaffinity labeling and comparison with nucleotide-binding proteins," *J Biol Chem* 263:15205-15210; and Farr, G.W. and Stemlicht, H. 1992. "Site-directed mutagenesis of the GTP-binding domain of  $\beta$ -tubulin," *J Mol Biol* 227:307-321). In addition, the N-terminal Met-Arg-Glu-Ile (or MREI

in single letter amino acid code; (SEQ ID NO:32) motif has been shown to autoregulate the stability of beta-tubulin mRNA in animal cells (Yen, et al. 1988. "Autoregulated instability of  $\beta$ -tubulin mRNAs by recognition of the nascent amino terminus of  $\beta$ -tubulin," *Nature* 334:580-585). This motif and a variant Met-Arg-Glu-Leu (or MREL in single letter amino acid code; SEQ ID NO:33) are present in the fungal beta-tubulins shown in Fig. 6, and they may function similarly. The C-terminal domain has been reported to be important for interactions with microtubule-associated proteins (MAPS) and motor proteins (Nogales, et al. 1998 *Nature* 391:199-203). Sequences near the C-terminus are hypervariable and acidic, a common feature of beta-tubulins (Sullivan, K.F. 1988. "Structure and utilization of tubulin isotypes," *Ann Rev Cell Biol* 4:687-716).

The amino acid sequence of beta-tubulins from different organisms are well conserved and exhibit at least 63% identity (Oakley, B.R. 1994. "Gamma-tubulin." In: Hyams JS, Lloyd CW (eds) *Microtubules*. Wiley-Liss, New York, pp. 38-45). Table I shows the percentage identity between the beta-tubulin amino acid sequence of *P. microspora* and *P. ultimum* with beta-tubulins of other organisms. The beta-tubulin from *P. microspora* shares the highest identity (93-97%) with filamentous ascomycetes such as *A. flavus*, *A. nidulans* benA and *N. crassa*, and lower identity (73-78%) with single-cell ascomycetes and oomycetes. Its identity (78-85%) with beta-tubulin from non-fungal organisms is also relatively low. In contrast, beta-tubulin from *P. ultimum* shows the highest identity (96-97%) with beta-tubulin from two oomycetes, *A. klebsiana* and *P. cinnamomi*, but shares limited identity (71-78%) with beta-tubulin from ascomycetes. The beta-tubulin from *P. ultimum* also shows relatively high identity (86-93%) with beta-tubulin from non-fungal organisms such as the green algae *C. reinhardtii*, the protozoa *T. thermophila*, the slime mold *Physarum polycephalum*, and various animals.

### Example 3: Extraction of genomic DNA and Southern analysis

Since multiplicity within the genes that encode beta-tubulin could affect the taxol-dependent property of microtubules, Southern analysis was used to determine whether *P. microspora* Ne32 and *P. ultimum* harbor one or more copies of beta-tubulin gene.

Mycelia of *P. microspora* Ne32 or *P. ultimum* grown for three days were harvested, and genomic DNA was isolated using Elu-Quik Hi-Volume Genomic kit (Schleicher



**Table I: Amino Acid Sequence Identity Between Beta-tubulin from  
*P. microspora* or *P. ultimum* and Other Organisms<sup>a</sup>**

Organism	Accession No.	Percentage of Identical Amino Acids	
		<i>P. Microspora</i>	<i>P. ultimum</i>
<i>Saccharomyces cerevisiae</i>	VO 1296	73	71
<i>Schizosaccharomyces pombe</i>	M10347	78	76
<i>Aspergillus flavus</i>	M38265	94	77
<i>Aspergillus nidulans</i> benA	M17519	93	77
<i>Neurospora crassa</i>	A25377	97	78
<i>Achlya klebsiana</i>	P20802	78	97
<i>Phytophthora cinnamomi</i>	U22050	77	96
<i>Chlamydomonas reinhardtii</i> ( $\beta$ 1 and $\beta$ 2)	P04690	78	91
<i>Tetrahymena thermophila</i> ( $\beta$ 1 and $\beta$ 2)	P41352	80	93
<i>Physarum polycephalum</i> (slime mold) ( $\beta$ 1)	P07436	81	90
<i>Drosophila melanogaster</i> (fruit fly) ( $\beta$ 1)	M20419	83	86
<i>Xenopus laevis</i> ( $\beta$ 4)	P30883	85	89
chicken ( $\beta$ 2)	P32882	84	88
mouse ( $\beta$ 3)	C25437	84	89
human ( $\beta$ 2)	P05217	84	89

<sup>a</sup> The amino acid sequences of beta-tubulin were retrieved from Genbank or Swiss-Prot. Pairwise identity was performed either with ClustalW or BLAST program.

5 Schuelle, Neene, NH). Five micrograms (5  $\mu$ g) of genomic DNA was digested with restriction enzymes for 4 hours at 37°C, separated on 0.8% agarose gel, transferred to Nylon filters (Tropix, Bedford, MA), and wet filters were cross-linked using GS Gene Linker UV Chamber (Biorad; Hercules, CA). Southern blotting was performed under stringent conditions according to standard protocols (Sambrook et al. 1989. *Molecular Cloning: A*

*Laboratory Manual*. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY). A 413 bp PCR fragment of *P. microspora* beta-tubulin was generated with primers NETUB5 and NETUB6, while a 377 bp PCR fragment of *P. ultimum* beta-tubulin was generated with primers WT1L-U and WT1L-L. PCR products were gel-purified and labeled with  $\alpha$ -<sup>32</sup>P dCTP using Ready-to-Go beads (Pharmacia, Piscataway, NJ) by random priming. Probes were purified with Micro Bio-Spin columns (Biorad).

In *P. microspora*, the beta-tubulin probe hybridized to a single band from genomic DNA digested with *Eco*RI, *Hind*III, or *Sal*I, and two bands from *Bam*HI digested sample. In *P. ultimum*, the beta-tubulin probe hybridized to a single band from genomic DNA digested with *Bam*HI, *Sal*I, *Pvu*I, or *Pst*I, and two bands from *Eco*RI digested sample. The sizes of these fragments match those predicted from the restriction endonuclease map of the corresponding cDNA clones. Since beta-tubulin genes are typically highly conserved, these results show that both *P. microspora* and *P. ultimum* contain a single copy of the beta-tubulin gene, consistent with previous reports that fungi generally have one, or at most a few, beta-tubulin genes (Neff, et al. 1983. "Isolation of the  $\beta$ -tubulin gene from yeast and demonstration of its essential function *in vivo*," *Cell* 33:211-219; Hiraoka, et al. 1984. "The NDA3 gene of fission yeast encodes  $\beta$ -tubulin: a cold sensitive *nda3* mutation reversibly blocks spindle formation and chromosome movement in mitosis," *Cell* 39:349-358; Orbach, et al. 1986. "Cloning and characterization of the gene for  $\beta$ -tubulin from a benomyl-resistant mutant of *Neurospora crassa* and its use as a dominant selectable marker," *Mol Cell Biol* 6:2452-2461; Cameron et al. 1990. "Cloning and analysis of  $\beta$ -tubulin gene from a protoctist," *JBiol Chem* 265:15245-15252; and Weerakoon et al. 1998. *Mycologia* 90:85-95; May, et al. 1987. "*Aspergillus nidulans*  $\beta$ -tubulin genes are usually divergent," *Gene* 55:231-243; Panaccione et al. 1988. "*Colletotrichum graminicola* transformed with homologous and heterologous benomyl-resistance genes retains expected pathogenicity to corn," *Mol Plant Microbe Interact* 1:113-120; and Goldman et al. 1993. "A nucleotide substitution in one of the  $\beta$ -tubulin genes of *Trichoderma viride* confers resistance to the antimetabolic drug methyl benzimidazole-2-yl-carbamate," *Mol Gen Genet* 240:73-80). The fact that *P. microspora* and *P. ultimum* have only a single copy of the beta-tubulin gene indicates that it is responsible for the sensitive or resistance properties of the organism to taxol.

#### Example 4: Isolation of mRNA and Northern analysis

Northern and PCR analysis were used to examine the expression level of tubulin mRNAs in *P. microspora* Ne32 and *P. ultimum*.

Four agar plugs of *P. ultimum* or *P. microspora* were inoculated into 40 ml of FM1 medium (5 grams soytone, 5 grams dextrose, 20 grams sucrose, and 1 gram yeast extract per liter of culture) or modified M1D (Li, et al. 1998. *Mycol Res* 102:461-464), respectively, and grown at 24°C without shaking in 250 ml Erlenmeyer flasks. Mycelia were harvested and blotted dry with Whatman paper. One gram (1 g) of mycelia was ground to powder in the presence of liquid nitrogen using mortar and pestle. The powder was transferred to a Dounce homogenizer containing 10 ml of Trizol (GibcoBRL) and homogenized. Total RNA was isolated according to the manufacturer's instructions. Total RNA was dissolved in diethylcarbonate-treated water at room temperature and stored at -80°C. Northern blotting was performed under stringent condition according to standard protocols (Sambrook et al. 1989. *Molecular Cloning: A Laboratory Manual*. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY).

Northern analysis revealed a very low level of beta-tubulin transcripts in *P. microspora* (data not shown). Therefore, total RNA from mycelia grown for 2, 5, 6, or 11 days were converted to cDNA, and used as a template in PCR reactions. Using gene-specific primers NETUB5 and NETUB6, a 413 bp beta-tubulin cDNA fragment was amplified from mycelia grown in log (2, 5 and 6 days) or stationary phase (11 days), but not from a control reaction that contained no template.

In *P. ultimum*, total RNA was isolated from mycelia grown for 2, 4, 6, 7, 8 and 10 days, and used in Northern analysis. The beta-tubulin probe hybridized to two transcripts of 1.5 and 1.6 kb, consistent with the sizes of the two cDNAs isolated. The 1.6 kb transcript was present in greater abundance.

#### Example 5: Binding of [<sup>3</sup>H]taxol to fungal cells

In animal systems, binding of [<sup>3</sup>H]taxol to intact cells has been used to characterize interactions between taxol and microtubules (Manfredi, et al. 1982. "Taxol binds to cellular microtubules," *J Cell Biol* 94:688-696). To determine whether the differential taxol sensitivity of *P. microspora* and *P. ultimum* correlates with the taxol binding properties of

their microtubules, we examined the ability of these fungal cells to specifically bind to [ $^3\text{H}$ ]taxol. The total binding of [ $^3\text{H}$ ]taxol to fungal cells consists of specific binding to microtubules and nonspecific binding to other cellular structures. The values of total and nonspecific binding were determined by binding of [ $^3\text{H}$ ]taxol to fungal cells in the absence or presence of 100-fold excess unlabeled taxol. The specific binding of [ $^3\text{H}$ ]taxol was then calculated as the difference between the amount of total and nonspecific binding.

Fresh mycelia from *P. microspora* Ne32, and *P. ultimum* were grown in 140 milliliters modified M1D media in Roux bottles at 24°C for 1-2 days. These actively growing mycelia were transferred to 50 milliliter conical tubes, and centrifuged at 7,000 rpm for 5 minutes at room temperature. Mycelia were suspended in 1 milliliter remaining M1D medium and 1 milliliter fresh M1D medium. Cells were either untreated or pretreated with the anti-mitotic drug thiabendazole to depolymerize microtubules. In pretreated cells, thiabendazole (in DMSO) was added to desired concentrations, and DMSO was adjusted to the same concentration in all samples. Samples were then incubated at room temperature for 3 hours. Subsequently, [ $^3\text{H}$ ]taxol ( $3.7 \times 10^7$  Bq/ml, Moravek) was added to desired concentrations either in the presence or absence of 100-fold excess unlabeled taxol. Samples were incubated for 2 hours at room temperature, then quenched on ice. [ $^3\text{H}$ ]taxol binding to *P. microspora* cells was performed in the presence of 0.1% (v/v) Triton X-100 to disrupt the cell membrane.

Each GFC filter (Whatman; Clifton, NJ) was weighed using an analytical balance. For *P. ultimum*, mycelia were transferred from conical tubes onto GFC filter held by a 3-piece filter funnel (Whatman). Conical tubes were washed three times with 10 milliliters of MilliQ H<sub>2</sub>O (Millipore, Inc.; Bedford, MA). Mycelia on GFC filter were washed with 120 milliliters of MilliQ H<sub>2</sub>O. For *P. microspora*, mycelia were collected by centrifugation at 5,000 rpm for 5 minutes at room temperature, and washed three times with 40 milliliters of MilliQ H<sub>2</sub>O. Mycelia were transferred onto GFC filter, and combined with residual mycelia after rinsing conical tubes with 5 milliliters of MilliQ H<sub>2</sub>O. GFC filters were dried at 80°C in an oven overnight and then weighed to obtain mycelia dry weight. Filters were counted for 5 minutes under 20 milliliters of Cytosint (Fisher Scientific; Pittsburgh, PA) in a Beckman LS3801 scintillation counter. Specific binding was calculated as the difference between [ $^3\text{H}$ ]taxol bound in the presence and absence of a 100-fold excess unlabeled taxol.

Nonspecific binding was determined as binding in the presence of 100-fold excess unlabeled taxol.

[<sup>3</sup>H]taxol was found to bind specifically to *P. ultimum* cells, and the amount of specific binding increased as a function of [<sup>3</sup>H]taxol concentration (Fig. 7A). In addition, in cells pretreated with thiabendazole to reduce the amount of assembled microtubules, the specific binding of [<sup>3</sup>H]taxol decreased in a dose-dependent manner (Fig. 7B). In fact, treatment with 1 mM of thiabendazole completely abolished the specific binding of [<sup>3</sup>H]taxol. These results indicate that taxol is able to interact with *P. ultimum* microtubules, and are consistent with the fact that this organism is sensitive to taxol.

On the other hand, initial experiments showed very low amount of specific binding of [<sup>3</sup>H]taxol to *P. microspora* (data not shown). This result could be due to inefficient interactions between taxol and *P. microspora* microtubules, or alternatively due to a membrane barrier which prevents intracellular accumulation of [<sup>3</sup>H]taxol. In animal cells, taxol crosses the cell membrane by diffusion due to its hydrophobic character (Manfredi et al. 1982. *J Cell Biol* 94:688-696). In some cases, resistance to taxol has been associated with P-glycoprotein, a membrane-located pump which causes drug efflux (Jachez et al. 1993. "Restoration of taxol sensitivity of multidrug-resistant cells by the cyclosporine SDZ PSC 833 and the cyclopeptide SDZ 280-446," *J Natl Cancer Inst* 85:478-483)). There is no information available as to whether *P. microspora* has such system. It has been shown that treatment of animal cells with nonionic detergents such as 0.1% (v/v) NP-40 or Triton X-100 disrupt the cell membrane, release most soluble proteins including unassembled tubulins, but leave assembled microtubules intact (Schliwa et al. 1981. "Stabilization of the cytoplasmic ground substance in detergent-opened cells and a structural and biochemical analysis of its composition," *Proc Natl Acad Sci USA* 78:4329-4333; Duerr et al. 1981. "Molecular analysis of cytoplasmic microtubules in situ: identification of both widespread and specific proteins," *Cell* 24:203-222; Manfredi et al. 1982. *J Cell Biol* 94:688-696). To evaluate whether a membrane barrier was responsible for the low specific binding, [<sup>3</sup>H]taxol binding to *P. microspora* cells in the presence of Triton X-100 was performed. *P. microspora* cells treated with Triton X-100 (0.1% (v/v)) showed none or very little specific binding of [<sup>3</sup>H]taxol up to 75 nM [<sup>3</sup>H]taxol (Fig. 7A). Furthermore, cells pretreated with thiabendazole also showed no specific binding of [<sup>3</sup>H]taxol in the presence of Triton X-100

(data not shown). These results indicate that taxol is unable to interact or interacts poorly with microtubules of *P. microspora*, and are consistent with the fact that this organism is resistant to taxol. In summary, the [<sup>3</sup>H]taxol binding results demonstrate that the properties of  $\beta$ -tubulin in these organisms determine their differential sensitivity to taxol.

5 Taxol stabilizes MTs by binding to beta-tubulin in assembled MTs, and its binding site has been characterized by photo cross-linking, electron crystallography, and mutagenesis. Regions between Amino Acids 1-31 and 217-231 were found to cross-link to the C-3' and C-2 group of taxol, respectively (Rao, et al. 1994. *J Biol Chem* 269:3132-3134; and Rao, et al. 1995. *J Biol Chem* 270:20235-20238). Recently, the structure of the beta-  
10 tubulin dimer was solved by electron crystallography of zinc induced sheets of tubulin dimer (Nogales, et al.1998. *Nature* 391:199-203). Modeling of taxol bound to this structure shows that the C-3' group of taxol is near Amino Acids 15-25 of beta-tubulin (near the top of helix H1), and the C-2 group is near Amino Acids 212-222 (near helix H6 and the loop between H6-H7). The identification of Amino Acids 15-25 and 217-222 in both cross-linking and  
15 electron crystallography studies indicate these regions are important for taxol binding. In addition, the electron crystallography model also shows that Leu273 of bovine beta-tubulin (located in the M-loop) contacts the taxane ring of taxol (Nogales, et al.1998. *Nature* 391:199-203). In addition, mutations at Phe270 or Ala364 in the M40 isotype of beta-tubulin result in taxol resistance in human ovarian cells (Giannakakou, et al. 1997. *J Biol*  
20 *Chem* 272:17118-17125).

Since the Amino Acids 270, 273 and 364 (marked by # in Fig. 6) do not differ among the fungal beta-tubulins listed in Fig. 6, they are not responsible for the differential taxol response among these organisms. However, comparison of Amino Acids 1-31 and 212-231 (defined here as taxol binding region I and II, respectively) from beta-tubulins of  
25 organisms that are taxol-resistant or taxol-sensitive reveal residues that are important for taxol interaction. Fig. 8 provides a comparison of the taxol binding region I and taxol binding region II amino acid sequences for pig (I, SEQ ID NO:34; II, SEQ ID NO:35), human  $\beta$ 2 (I, SEQ ID NO:36; II, SEQ ID NO:37), *Drosophila*  $\beta$ 1 (I, SEQ ID NO:38; II, SEQ ID NO:39), *Xenopus*  $\beta$ 4 (I, SEQ ID NO:40; II, SEQ ID NO:41), *Tetrahymena* (I, SEQ  
30 ID NO:42; II, SEQ ID NO:43), *Physarum*  $\beta$ 1 (I, SEQ ID NO:44; II, SEQ ID NO:45), *P. ultimum* (I, SEQ ID NO:46; II, SEQ ID NO:47), *P. cinnamomi* (I, SEQ ID NO: 48; II, SEQ

ID NO: 49) *A. klebsiana* (I, SEQ ID NO:50; II, SEQ ID NO:51), *P. microspora* (I, SEQ ID NO:52; II, SEQ ID NO:53), *A. nidulans* benA (I, SEQ ID NO:54; II, SEQ ID NO:55), and *S. cerevisiae* (I, SEQ ID NO:56; II, SEQ ID NO:57).

Beta-tubulins from taxol-sensitive organisms such as human, pig, *Drosophila*, *Xenopus*, *Tetrahymena* and *Physarum* are highly conserved in taxol binding region I and II, and are identical between Amino Acids 15-25 and 217-222 (except a conserved substitution at Amino Acid 23 in *Drosophila*  $\beta$ 1). Beta-tubulin from *P. ultimum* displays only four substitutions compared to the above sequences, none of which occurs between Amino Acids 15-25 and 217-222. This similarity is consistent with the fact that *P. ultimum*, like the animal organisms noted above, is taxol-sensitive. Also consistent with this, previous biochemical studies of animal tubulins and data of [ $^3$ H]taxol binding to *P. ultimum* demonstrated herein (Fig. 7A and 7B), show that taxol binds beta-tubulin in assembled MTs of these organisms (Kellogg, et al. 1989. *J Cell Biol* 109:2977-2991; and Manfredi, J.J. and Horwitz, S.B. 1984. *Pharmacol Ther* 25:83-125). Beta-tubulin sequences from *P. ultimum* and *A. klebsiana* are identical in taxol binding region I and II except Amino Acid 219, but *A. klebsiana* is relatively resistant to taxol ( $IC_{50} > 11.7 \mu M$ ). This reduced sensitivity is due in part to the fact that *A. klebsiana* contains an asparagine at Amino Acid 219, whereas *P. ultimum*, and six other beta-tubulins from taxol-sensitive organisms, have threonine.

Beta-tubulins from taxol-resistant organisms such as *P. microspora*, *A. nidulans* and *S. cerevisiae* are similar to each other within taxol binding region I and II, but differ from the above discussed sequences in seven positions (19, 22, 23, 25, 218, 219, and 221) within regions 15-25 and 217-222. The [ $^3$ H]taxol binding data presented herein (Fig. 7A and 7B), together with previous biochemical studies (Yoon, Y. and Oakley, B.R. 1995. *Biochem* 34:6373-6381; and Bames, et al. 1992. *Mol Biol Cell* 3:29-47), show that beta-tubulins in assembled MTs of these organisms are unable to efficiently bind taxol. These sequences contain the asparagine (or glutamine in the case of *S. cerevisiae*) at Amino Acid 219, as observed in *A. klebsiana*, a substitution that contributes in part to the reduced sensitivity to taxol in these fungi. Other substitutions, including which involve differences in charge and polarity such as changes from Lys19 to Ala, Glu22 to Gln, and Val23 to Thr, also contribute to the taxol resistant phenotype of these organisms.

These results indicate that a number of residues including threonine at Amino Acid 219 are important in the binding of beta-tubulin to taxol. In particular, Amino Acid 219 plays an important role in determining taxol binding property of beta-tubulin and, consequently, the taxol-sensitivity of cells. Beta-tubulins from taxol-sensitive species have Thr219 (threonine at Amino Acid 219), while those from taxol-resistant species have Asn219 (asparagine at Amino Acid 219) or Glu219 (glutamine at Amino Acid 219). The taxol sensitivity of *P. cinnamomi* is consistent with the presence of Thr219 in TUBB-pc (SEQ ID NO:6) and not Asn219 as previously reported by Weerakoon et al. The presence of Asn219 (asparagine at Amino Acid 219) found in *P. microspora* is consistent with the taxol resistance of this species. Using the information that the presence of threonine at Amino Acid 219 in beta-tubulins corresponds to taxol-binding and taxol-sensitivity, taxol analogs or other compounds can be designed which mimic the interaction of taxol with beta-tubulin. Further, such information can also be used to generate mutant beta-tubulins resistant to taxol by substituting the threonine for another amino acid residue at Amino Acid 219.

#### **Example 6: Sensitivity to microtubule-depolymerization drugs.**

The effect of several MT-depolymerization drugs on the growth of *P. microspora* Ne32, *P. ultimum* and *A. klebsiana* was examined. These drugs included colchicine, colcemid (a synthetic derivative of colchicine), and two benzimidazole drugs, nocodazole and thiabendazole.

Colchicine, colcemid, nocodazole, and thiabendazole were obtained from Sigma Chemical Company (St. Louis, MO). A stock solution of colchicine was prepared in water, and other stock solutions in DMSO. An agar plug (6 mm in diameter) of fresh mycelia was transferred onto PDA plates containing 1 % (v/v) DMSO in the presence or absence of an anti-microtubule agent. Fungal colonies were grown at 24°C for 24 hours in the case of *P. ultimum* or 48 hours in the case of *P. microspora* and *A. klebsiana*. The growth inhibitory effect of these anti-mitotic agents was measured by the size of colony diameters.

Biochemical and genetic evidence has shown that these drugs bind to beta-tubulin in the tubulin dimer and cause MT depolymerization (Davidse, L.C. and Flach, W. 1978.

"Interaction of thiabendazole with fungal tubulin," *Biochim Biophys Acta* 543:82-90; Jung,



M.K. and Oakley, B.R. 1990. "Identification of an amino acid substitution in the  $\beta$ -tubulin gene of *Aspergillus nidulans* that confers thiabendazole resistance and benomyl supersensitivity," *Cell Motil Cytoskeleton* 11:87-94; Manfredi, J.J. and Horwitz, S.B. 1984. *Pharmacol Ther* 25:83-125). It has been shown that many fungi are resistant to colchicine (Cameron et al. 1990. *J Biol Chem* 265:15245-15252; Kilmartin, J.V. 1981. "Purification of yeast tubulin by self-assembly *in vitro*," *Biochem* 20:3629-3633; and Davidse, L.C. and Flach, W. 1977. "Differential binding of methyl benzimidazole-2-yl-carbarnate to fungal tubulin as a mechanism of resistance to this antimitotic agent in mutant strains of *Aspergillus nidulans*," *J Cell Biol* 72:174-193), but are sensitive to nocodazole (Kilmartin, J.V. 1981. *Biochem* 20:3629-3633) and thiabendazole (Davidse, L.C. and Flach, W. 1978. *Biochim Biophys Acta* 543:82-90).

As shown in Table II, the three fungal species tested herein were resistant to colchicine and colcemid ( $IC_{50} > 100 \mu M$ ), and were sensitive to nocodazole ( $IC_{50}$  2-22  $\mu M$ ). These results are consistent with the studies noted above. In contrast, these fungi were differentially sensitive to thiabendazole. *P. microspora* was highly sensitive ( $IC_{50}$  3  $\mu M$ ), while *P. ultimum* and *A. klebsiana* were less sensitive ( $IC_{50}$  270-350  $\mu M$ ). These results demonstrate that the biochemical properties of beta-tubulin differ in these three fungi.

**Table II: Sensitivity of fungi to microtubule depolymerization drugs**

Drug	<i>P. microspora</i>	<i>P. ultimum</i>	<i>A. klebsiana</i>
colchicine	>100	>100	>100
colcemid	>100	>100	>100
nocodazole	2	22	2
thiabendazole	3	350	270

Mutations at Amino Acids 6, 165, 167, 198, 200 and 241 in beta-tubulin (marked by asterisks in Fig. 6) result in altered sensitivity to thiabendazole and other benzimidazole drugs in yeast, *N. crassa*, *A. nidulans* benA, and *Trichoderma viride* (Thomas, et al. 1985. "Isolation and characterization of mutations in the  $\beta$ -tubulin gene of *Saccharomyces cerevisiae*," *Genetics* 112:715-734; Orbach, et al. 1986. *Mol Cell Biol* 6:2452-2461; Jung, et

al. 1992. "Amino acid alterations in the  $\beta$ -tubulin gene of *Aspergillus nidulans* that confer benomyl resistance," *Cell Motil Cytoskeleton* 22:170-174; Jung, M.K. and Oakley, B.R. 1990. *Cell Motil Cytoskeleton* 17:87-94; Fugimura, et al. 1992. "A single amino-acid substitution in the beta-tubulin gene of *Neurospora* confers both cabendazim resistance and diethofencarb sensitivity," *Curr Genet* 21:399-404; and Goldman et al. 1993. *Mol Gen Genet* 240:73-80). These six residues in beta-tubulin from *P. microspora* are identical to those observed in beta-tubulin from other thiabendazole sensitive species such as *N. crassa* and *A. nidulans* benA. In contrast, beta-tubulin from *P. ultimum* and *A. klebsiana* differ at Amino Acids 165, 167 and 200. It has been previously shown that a phenylalanine-to-tyrosine change at Amino Acid 167 results in benzimidazole resistance in *N. crassa* (Orbach, et al. 1986. *Mol Cell Biol* 6:2452-2461), and the fact that both *P. ultimum* and *A. klebsiana* have a tyrosine at this position accounts for their resistance to such drugs. In summary, the differential sensitivity to thiabendazole exhibited by these three fungi is consistent with the comparison of fungal beta-tubulins shown in Fig. 6.

#### **Example 7: Production of Antibodies Capable of Distinguishing Taxol-Binding and Non-Binding Beta-tubulins**

Monoclonal or polyclonal antibodies can be raised against the following antigens: 1) native beta-tubulins extracted from *P. microspora*, *P. ultimum*, or *P. cinnamomi*; 2) beta-tubulins of *P. microspora*, *P. ultimum*, or *P. cinnamomi* produced from a heterologous system such as *E. coli*, yeast, and insect cells; and 3) synthetic peptide corresponding to the SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6, and preferably comprising at least one taxol binding region. The antibodies are used to interact with the above mentioned beta-tubulins using Elisa or Western blotting using standard protocols (Harlow, E.D. and Lane, D. 1988. *Antibodies: A Laboratory Manual*). The antibodies which could distinguish the taxol binding beta-tubulin from the taxol non-binding beta-tubulin are selected as the reagent.

A specific example is to raise polyclonal or monoclonal antibodies to synthetic peptides corresponding to SEQ ID NO:4 or SEQ ID NO:6 which comprise at least one taxol binding region, for instance containing the taxol-binding region II comprising Thr219 or in which the Thr219 is replaced by Asn219/Gln219. The ability of these antibodies to interact with beta-tubulin is examined using Elisa using standard protocols. The antibody which can binds to peptide containing Thr219 but not to peptide containing Asn/Gln 219 is selected as

the reagent which is specific for the taxol-binding site containing Thr 219. On the other hand, the antibody which specifically binds to the peptide containing Asn219/Gln 219 but not to the peptide containing Thr 219 is selected as the reagent which specifically recognizes taxol binding site devoid of Thr 219.

#### Example 8: Screening Assays to Detect Beta-Tubulin in Matter

Several assays can be used to determine if a composition of matter contains beta-tubulin capable of binding taxol. These assays are useful for screening a variety of compositions of matter, including living matter such as plants or microorganisms, or non-living matter such as plant materials or patient samples for the presence of beta-tubulin.

The first assay is performed using Northern or Southern hybridization method well known in the art (Sambrook, et al. *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1989). The total RNA, mRNA or genomic DNA are isolated from the composition of matter and separated by electrophoresis. DNA, synthetic oligonucleotide, or RNA corresponding to the coding region or a portion of beta-tubulin (e.g., derived from SEQ ID NO:1, SEQ ID NO: 3 or SEQ ID NO:5) which comprises at least one taxol binding region will be used to synthesize isotopically labeled probes. Hybridization with a probe derived from SEQ ID NO:1 will indicate beta-tubulin with high probability of taxol resistance. On the other hand, the hybridization with a probe derived from SEQ ID NO:3 or SEQ ID NO:5 will indicate beta-tubulin with a high probability of taxol sensitivity.

The second assay is to use a PCR-based assay using standard protocols (Sambrook, et al. *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1989). Both genomic DNA or cDNA converted from total RNA or mRNA are used as template in a PCR assay. Gene-specific or degenerate primers corresponding to the coding region of beta-tubulin (e.g., derived from SEQ ID NO:1, SEQ ID NO:3 or SEQ ID NO:5) which comprises at least one taxol binding region will be synthesized. Only DNA containing the appropriate primer sequences will be amplified, and all other variations will be suppressed. The amplification of PCR fragment of the predicted size using primers derived from SEQ ID NO:3 or SEQ ID NO:5 but not from primers derived from SEQ ID NO:1 will indicate high probability of taxol binding beta-tubulin. On

the other hand, the amplification of a PCR fragment of the predicted size using primers derived from SEQ ID NO:1 but not from primers derived from SEQ ID NO:3 or SEQ ID NO:5 will indicate high probability of taxol non-binding beta-tubulin. The subsequent obtaining of the beta-tubulin sequence and examination of the presence or absence of Thr219 residue will provide further determination.

The third assay is to use Elisa or Western blotting using standard protocols (Harlow, E.D. and Lane, D. 1988. *Antibodies: A Laboratory Manual*). Cell extracts of the composition of matter are prepared. Synthetic peptide, or native beta-tubulins extracted from *P. microspora*, *P. ultimum*, or *P. cinnamomi*, or produced from a heterologous system such as *E. coli*, yeast, and insect cells will be used to raise polyclonal or monoclonal antibodies. The antibodies will be used in the above mentioned Elisa or Western blotting. The antibody which recognizes the taxol binding from the non taxol binding is used in these assays.

#### **Example 9: Construction of Taxol-sensitive and Taxol-resistant Isogenic Strains**

*P. ultimum* contains a single beta-tubulin. In vitro, its beta-tubulin gene or cDNA can be altered to change the Thr219 to a different residue, for instance to Asn219 or Gln219. This altered DNA sequence is cloned into a transformation vector, and used to transform the wild-type strain *P. ultimum* using established protocols (Balance, et al. 1985. *Gene* 36:321-331). Homologous recombination between the wild-type beta-tubulin gene and the modified beta-tubulin in the vector occur. Transformed fungus are selected on media containing taxol. The taxol-resistant clones are selected and their beta-tubulin cDNA sequenced to confirm the absence of Thr 219. The taxol-resistant isogenic strain of *P. cinnamomi* is similarly constructed and used in screening assays as described in later examples. The only difference between these isogenic strains is that the taxol-sensitive strain is capable of binding to taxol due to the presence of Thr 219, and the taxol-resistant strain is incapable of binding to taxol due to the absence of Thr 219. Such taxol-resistant strains can be used in combination with the wild-type taxol-sensitive strains for screening as described in later examples.

**Example 10: Screening Assays to Detect Taxol or Taxol-like Compounds in Matter**

Several assays can be used to detect taxol or taxol-like compounds in a composition of matter. These assays are useful for screening a variety of compositions of matter, including living matter such as plants or microorganisms, or non-living matter such as plant materials, patient samples, or compound libraries for the presence of taxol or taxol-like compounds.

One screening method is to use taxol-resistant *P. microspora* in combination with the taxol-sensitive *P. ultimum* or *P. cinnamomi*. Taxol inhibits the growth of both *P. ultimum* by binding to their beta-tubulin, while taxol does not affect the growth of *P. microspora* since it does not interact with its beta-tubulin. A composition of matter which is capable of the inhibition of *P. ultimum*, but not *P. microspora* has a high probability of containing taxol-or a taxol-like compound.

An improved screening method uses taxol-sensitive and taxol-resistant isogenic strains of *P. ultimum* or *P. cinnamomi* as described in above example. The composition of matter is used to examine its effect on the growth of both the taxol-sensitive as well as the taxol-resistant strains. The inhibition of the taxol-sensitive strain but not the taxol-resistant strain indicates the presence of taxol or a taxol-like compound. On the other hand, the non-inhibition of both the taxol-sensitive and taxol-resistant strains indicates the absence of taxol or a taxol-like compound.

Composition of matter can be screened for the presence of taxol or taxol-like compounds based on their ability to promote the assembly of microtubules, as well as to stabilize assembled microtubules in conditions such as cold which otherwise cause depolymerization (Schiff, et al. 1979; Horwitz, 1981). The alpha- and beta-tubulins used in these assays can be from the following sources. 1) native microtubules consisting of beta-tubulins and alpha-tubulins extracted from *P. ultimum* or *P. cinnamomi*; 2) beta-tubulins extracted from *P. ultimum* or *P. cinnamomi* and interacted with another source of alpha-tubulin, for example, bovine alpha-tubulin; 3) all or portions of SEQ ID NO:4 or SEQ ID NO:6 produced from a heterologous system such as *E. coli*, yeast, insect cells or the like and alpha-tubulin either from *P. ultimum*, *P. cinnamomi* or another source. If the composition of matter has the ability to promote the assembly of these MTs, as well as to prevent

depolymerization of assembled MTs in conditions which otherwise cause depolymerization, the composition of matter is likely to contain taxol or a taxol-like compound. Meanwhile, these isolated compounds should be unable to promote the assembly of MTs as well as prevent the depolymerization of MTs which consist of beta-tubulin derived from *P.*

5 *microspora*.

An alternative screening method can be performed based on the competitive inhibition of [<sup>3</sup>H]taxol binding to MTs in *P. ultimum* or *P. cinnamomi* by taxol or taxol-like compounds. The specific binding of [<sup>3</sup>H]taxol to *P. ultimum* is performed as described in Example 5. The amount of [<sup>3</sup>H]taxol specifically bound to *P. ultimum* in the absence of  
10 inhibitors is considered 100%. The composition of matter is added to the assay mixture, and the amount of [<sup>3</sup>H]taxol specifically bound to *P. ultimum* in the presence of the composition of matter is measured. Reduction in the [<sup>3</sup>H]taxol specific binding indicates that the composition of matter possesses taxol-like quality. If increased concentrations of the composition of matter can completely inhibit the [<sup>3</sup>H]taxol binding, it will indicate that the  
15 compound likely binds to the same binding site in the beta-tubulin in MTs.

The screening of compositions of matter for taxol or taxol-like compounds can be performed by one of the above methods. Preferably, one of the first two methods is used for an initial screening, since they are simple to perform and easily handle large amounts of samples. The third and fourth method can be used for subsequent screening.

#### 20 **Example 11: Screening Assay to Distinguish Taxol-Sensitivity of A Patient Sample**

In this diagnostic assay, antibodies depicted in Example 7 which could distinguish taxol-binding beta-tubulin from the non-binding beta-tubulin are used. Cellular proteins are extracted from a tumor specimen from a patient sample to detect the presence of a beta-  
25 tubulin with either taxol-binding or non-binding capabilities.

For example, in a diagnostic assay to screen for tumors resistant to taxol, the taxol binding regions of taxol-sensitive and taxol-resistant beta-tubulins of the present invention (e.g., SEQ ID NO:2, SEQ ID NO:4, and SEQ ID NO:6) are used to raise monoclonal or polyclonal antibodies using standard methods well known in the art (Harlow, E.D. and Lane,  
30 D. 1988. *Antibodies: A Laboratory Manual*). For example, monoclonal antibody probes are

reacted with a patient sample, such as a tumor specimen, to detect the presence of a beta-tubulins with either taxol-binding or non-binding capabilities. Visualization of antibody-antigen binding is mediated through any means known in the art, e.g., secondary radiolabeled or fluorescent antibodies or colorimetric methods using peroxidase and/or alkaline phosphatase (Harlow, E.D. and Lane, D. 1988. *Antibodies: A Laboratory Manual*). The detection of beta-tubulins with taxol-binding capability, i.e., taxol-sensitive beta-tubulins, corresponds to a positive response to taxol therapy. Alternatively, the detection of non-binding taxol-resistant beta-tubulins and/or the absence of taxol-sensitive beta-tubulins corresponds to a diminished or lack of response to taxol therapy.

#### Example 12: Biocontrol of Taxol-sensitive Pathogenic Oomycetes Using *P. microspora* on Plants

Many oomycetes including *P. ultimum* and *P. cinnamomi* are plant pathogens which can cause crop damage and result in severe economical loss. For instance, *P. ultimum* causes root rot of beans, and *P. cinnamomi* causes root rot of Avacado (ATCC: Catalogue of Filamentous Fungi, 18th edition, 1991). Many of the oomycetes are also taxol-sensitive (Young, et al. 1992. "Antifungal properties of taxol and various analogues," *Experientia* 48:882-885). Two of these strains, *P. ultimum* and *P. cinnamomi*, contain threonine at Amino Acid 219.

The biocontrol method of the present invention involves a two-step process: 1) the taxol sensitivity of the plant pathogen is determined and 2) if the plant pathogen is taxol-sensitive, a taxol-producing *P. microspora* is applied to the infected plants and surrounding soil as a source of growth-inhibiting taxol.

The taxol sensitivity of the plant pathogen is first determined. One method of identifying taxol sensitivity is to determine the presence or absence of threonine at Amino Acid 219. If the identity of the pathogen is known, DNA and protein databases are searched to determine whether the beta-tubulin sequence has been reported, if so, the identity of Amino Acid 219 is determined from the database. If the pathogen's beta-tubulin sequence is unavailable, the cDNA sequence is isolated and analyzed to determine the identity of Amino Acid 219. The presence of threonine at Amino Acid 219 in the pathogen's beta-tubulin gene indicates sensitivity to taxol, and thus, the pathogen is designated as treatable by a taxol-

producing *P. microspora*. If Amino Acid 219 is not threonine, the taxol sensitivity would have to be determined by other means such as taxol growth inhibition. Other screening methods presented herein for determining the presence of taxol-binding beta-tubulins can also be used.

5 It has been previously reported that *P. microspora* produces taxol at 50 ug /liter (Strobel, et al. 1996. *Microbiol* 142:435-440) and secretes taxol outside of the fungal cell. At this taxol concentration, the growth of *P. ultimum* and *P. cinnamomi* is inhibited (see Fig. 1). For treatment, *P. microspora* is inoculated to the area of plants or soil infected with the taxol-sensitive pathogen. The growth of *P. microspora* results in the secretion of taxol,  
10 which consequently inhibits the growth of these taxol-sensitive organisms.

### Example 13: Use of Crystal Structures in Design of Antineoplastic or Antifungal Drugs

The three-dimensional structure of beta-tubulins are used to rationally design taxol-like compounds using methods known in the art (Ealick, et al. 1991. "Application of  
15 crystallographic and modeling methods in the design of purine nucleoside phosphorylase inhibitors," *Science* 88:11540-11544; Rossman, et al. 1991. "Application of crystallography to the design of antiviral agents," *Infectious Agents and Disease* 1:3-10). As taught by the present invention, application of the knowledge that Thr219 in the protein structure plays an important role in binding of taxol to taxol-like compounds can be critically applied to the  
20 development of drugs having taxol-like activities.



We claim:

1. A purified DNA segment encoding a beta-tubulin of the fungal species *Pestalotiopsis microspora* or a portion thereof.
2. The DNA segment of Claim 1, wherein said portion encodes at least one taxol binding site.
3. The DNA segment of Claim 2, wherein said portion encodes a protein having taxol binding site I and taxol binding site II.
4. The DNA segment of Claim 3, wherein said protein is able to interact with alpha-tubulin.
5. The DNA segment of Claim 1, wherein said DNA segment comprises at least a portion of SEQ ID NO:1.
6. The DNA segment of Claim 5, wherein said portion comprises the nucleotide sequence from nucleotide 75 through nucleotide 167 of SEQ ID NO:1.
7. The DNA segment of Claim 6, wherein at least one nucleotide in said nucleotide sequence is substituted.
8. The DNA segment of Claim 5, wherein said portion comprises the nucleotide sequence from nucleotide 708 through nucleotide 764 of SEQ ID NO:1.
9. The DNA segment of Claim 8, wherein at least one nucleotide in said nucleotide sequence is substituted.
10. The DNA segment of Claim 9, wherein nucleotide 729, nucleotide 730, nucleotide 731 or mixtures thereof are substituted.
11. The DNA segment of Claim 5, comprising the nucleotide sequence from nucleotide 75 to nucleotide 1412 of SEQ ID NO:1, said DNA segment encoding a beta-tubulin.

12. The DNA segment of Claim 11, wherein at least one nucleotide in said nucleotide sequence is substituted and wherein the taxol binding capacity of said beta-tubulin is not altered.

13. The DNA segment of Claim 11, wherein at least one nucleotide in said nucleotide sequence is substituted and wherein the taxol binding capacity of said beta-tubulin is altered.

14. An amino acid sequence comprising at least a portion of a beta-tubulin of the fungal species *Pestalotiopsis microspora*.

15. The amino acid sequence of Claim 14, wherein said portion comprises at least one taxol binding site.

16. The amino acid sequence of Claim 15, wherein said portion comprises taxol binding site I and taxol binding site II.

17. The amino acid sequence of Claim 16, wherein said portion is able to interact with alpha-tubulin.

18. The amino acid sequence of Claim 14, wherein said amino acid sequence comprises at least a portion of the beta-tubulin as depicted in SEQ ID NO:2.

19. The amino acid sequence of Claim 18, wherein said portion comprises Amino Acids 1-31 of SEQ ID NO:2.

20. The amino acid sequence of Claim 19 having at least one amino acid substitution.

21. The amino acid sequence of Claim 18, wherein said portion comprises Amino Acids 212-230 of SEQ ID NO:2.

22. The amino acid sequence of Claim 21 having at least one amino acid substitution.

23. The amino acid sequence of Claim 18, wherein said portion comprises an amino acid substitution at Amino Acid 219.

24. The amino acid sequence of Claim 18, wherein said portion consists essentially of Amino Acids 1-446 of SEQ ID NO:2 and wherein said portion behaves as a taxol-resistant beta-tubulin.

25. The amino acid sequence of Claim 24, wherein said portion contains at least one amino acid substitution that alters the taxol binding property of said portion.

26. The amino acid sequence of Claim 24, wherein said portion contains at least one amino acid substitution that does not alter the taxol binding property of said portion.

27. The amino acid sequence of Claim 14, wherein said amino acid sequence is substituted with any amino acid which perturbs the three-dimensional structure of said amino acid sequence surrounding Amino Acid 219 as numbered in SEQ ID NO:2.

28. A purified DNA segment encoding a beta-tubulin of the fungal species *Pythium ultimum* or a portion thereof.

29. The DNA segment of Claim 28, wherein said portion encodes at least one taxol binding site.

30. The DNA segment of Claim 29, wherein said portion encodes a protein having taxol binding site I and taxol binding site II.

31. The DNA segment of Claim 30, wherein said protein is able to interact with alpha-tubulin.

32. The DNA segment of Claim 28, wherein said DNA segment comprises at least a portion of SEQ ID NO:3.

33. The DNA segment of Claim 32, wherein said portion comprises the nucleotide sequence from nucleotide 92 through nucleotide 184 of SEQ ID NO:3.

34. The DNA segment of Claim 33, wherein at least one nucleotide in said nucleotide sequence is substituted.

35. The DNA segment of Claim 32, wherein said portion comprises the nucleotide sequence from nucleotide 725 through nucleotide 781 of SEQ ID NO:3

36. The DNA segment of Claim 35, wherein at least one nucleotide in said nucleotide sequence is substituted.

37. The DNA segment of Claim 35, wherein nucleotide 746, nucleotide 747, nucleotide 748 or mixtures thereof are substituted.

38. The DNA segment of Claim 32, comprising the nucleotide sequence from nucleotide 92 to nucleotide 1429 of SEQ ID NO:3, said DNA segment encoding a beta-tubulin.

39. The DNA segment of Claim 38, wherein at least one nucleotide in said nucleotide sequence is substituted and wherein the taxol binding capacity of said beta-tubulin is not altered.

40. The DNA segment of Claim 38, wherein at least one nucleotide in said nucleotide sequence is substituted and wherein the taxol binding capacity of said beta-tubulin is altered.

41. An amino acid sequence comprising at least a portion of a beta-tubulin of the fungal species *Pythium ultimum*.

42. The amino acid sequence of Claim 41, wherein said amino acid sequence comprises at least one taxol binding site.

43. The amino acid sequence of Claim 42, wherein said portion comprises taxol binding site I and taxol binding site II.

44. The amino acid sequence of Claim 43, wherein said portion is able to interact with alpha-tubulin.

45. The amino acid sequence of Claim 41, wherein said amino acid sequence comprises at least a portion of the beta-tubulin as depicted in SEQ ID NO:4.

46. The amino acid sequence of Claim 45, wherein said portion comprises Amino Acids 1-31 of SEQ ID NO:4

47. The amino acid sequence of Claim 46, having at least one amino acid substitution.
48. The amino acid sequence of Claim 45, wherein said portion comprises Amino Acids 212-230 of SEQ ID NO:4
49. The amino acid sequence of Claim 48, having at least one amino acid substitution.
50. The amino acid sequence of Claim 45, wherein said portion comprises an amino acid substitution at Amino Acid 219.
51. The amino acid sequence of Claim 45, wherein said portion consists essentially of Amino Acids 1-446 of SEQ ID NO:4 and wherein said portion behaves as a taxol-sensitive beta-tubulin.
52. The amino acid sequence of Claim 51, wherein said portion contains at least one amino acid substitution that alters the taxol binding property of said portion.
53. The amino acid sequence of Claim 51, wherein said portion contains at least one amino acid substitution that does not alter the taxol binding property of said portion.
54. The amino acid sequence of Claim 41, wherein said amino acid sequence is substituted with any amino acid which perturbs the three-dimensional structure of said amino acid sequence surrounding Amino Acid 219 as numbered in SEQ ID NO:4.
55. A purified DNA segment encoding a beta-tubulin of the fungal species *Phytophthora cinnamomi* or a portion thereof, wherein said DNA segment consists essentially of at least a portion of SEQ ID NO:5.
56. The DNA segment of Claim 55, wherein said portion comprises the nucleotide sequence from nucleotide 11 through nucleotide 103 of SEQ ID NO:5.
57. The DNA segment of Claim 56, wherein at least one nucleotide in said nucleotide sequence is substituted, providing that when nucleotide substitution changes only

one amino acid code nucleotide 80 cannot consist of adenine while nucleotide 81 is thymine and nucleotide 82 is adenine, cytosine or thymine.

58. The DNA segment of Claim 55, wherein said portion comprises the nucleotide sequence from nucleotide 644 through nucleotide 700 of SEQ ID NO:5

59. The DNA segment of Claim 58, wherein at least one nucleotide in said nucleotide sequence is substituted, providing that when nucleotide substitution changes only one amino acid code nucleotide 665 cannot be adenine while nucleotide 666 is adenine and nucleotide 667 is cytosine or thymine.

60. The DNA segment of Claim 55, comprising the nucleotide sequence from nucleotide 11 to nucleotide 1342 of SEQ ID NO:5, said DNA segment encoding a beta-tubulin.

61. The DNA segment of Claim 60, wherein at least one nucleotide in said nucleotide sequence is substituted, providing that when nucleotide substitution changes only one amino acid code nucleotide 665 cannot be adenine while nucleotide 666 is adenine and nucleotide 667 is cytosine or thymine.

62. The DNA segment of Claim 60 or 61, wherein at least one nucleotide in said nucleotide sequence is substituted, and wherein the taxol binding capacity of said beta-tubulin is not altered.

63. The DNA segment of Claim 60 or 61, wherein at least one nucleotide in said nucleotide sequence is substituted and wherein the taxol binding capacity of said beta-tubulin is altered.

64. An amino acid sequence comprising at least a portion of a beta-tubulin of the fungal species *Phytophthora cinnamomi* as depicted in SEQ ID NO:6.

65. The amino acid sequence of Claim 64, wherein said portion comprises Amino Acids 1-31 of SEQ ID NO:6.

66. The amino acid sequence of Claim 65, having at least one amino acid is substituted, providing that when only one amino acid is substituted Amino Acid 24 is not isoleucine.

67. The amino acid sequence of Claim 64, wherein said portion comprises Amino Acids 212-230 of SEQ ID NO:6.

68. The amino acid sequence of Claim 67, having at least one amino acid is substituted, providing that when only one amino acid is substituted Amino Acid 219 is not asparagine.

69. The amino acid sequence of Claim 64, wherein said portion comprises an amino acid substitution at Amino Acid 219, wherein said Amino Acid 219 is not substituted with asparagine.

70. The amino acid sequence of Claim 64, wherein said portion consists essentially of Amino Acids 1-446 of SEQ ID NO:6 and wherein said portion behaves as a taxol-sensitive beta-tubulin.

71. The amino acid sequence of Claim 70, wherein said portion contains at least one amino acid substitution, providing that when only one amino acid is substituted Amino Acid 219 is not asparagine, and wherein said amino acid substitution that alters the taxol binding property of said portion.

72. The amino acid sequence of Claim 70, wherein said portion contains at least one amino acid substitution, providing that when only one amino acid is substituted Amino Acid 219 is not asparagine, and wherein said amino acid substitution does not alter the taxol binding property of said portion.

73. The amino acid sequence of Claim 64, wherein said amino acid sequence is substituted with any amino acid which perturbs the three-dimensional structure of said amino acid sequence surrounding Amino Acid 219 and wherein when only one amino acid is substituted at Amino Acid 219 said substituted amino acid is not asparagine.

74. A vector comprising a purified DNA segment encoding a beta-tubulin of the fungal species *Pestalotiopsis microspora* or a portion thereof.

75. The vector of Claim 74, wherein said portion encodes at least one taxol binding site.

76. A vector comprising a purified DNA segment encoding a beta-tubulin of the fungal species *Pythium ultimum* or a portion thereof.

77. The vector of Claim 76, wherein said portion encodes at least one taxol binding site.

78. A vector comprising a purified DNA segment encoding a beta-tubulin of the fungal species *Phytophthora cinnamomi* wherein said DNA segment consists essentially of SEQ ID No:5 or a portion thereof.

79. The vector of Claim 78, wherein said portion encodes at least one taxol binding site.

80. A method of determining the taxol binding capacity of a beta-tubulin or beta-tubulin-like compound comprising  
providing antibodies raised against amino acid sequences comprising at least one taxol binding site of a beta-tubulin from a taxol-resistant *Pestalotiopsis microspora*, a taxol-sensitive *Pythium ultimum*, or taxol-sensitive *Phytophthora cinnamomi* as depicted in SEQ ID NO:6 to form a reagent, wherein said antibodies distinguish between taxol-binding and non-taxol-binding properties;

contacting said beta-tubulin with said reagent; and  
determining degree of binding between said antibodies in said reagent and said beta-tubulin or beta-tubulin-like compound;

whereby binding of antibodies which specifically recognize taxol-binding properties indicate taxol sensitive; whereby binding of antibodies which specifically recognize taxol-non-binding properties indicate taxol resistance.

81. The method of Claim 80, wherein said antibodies are raised against an amino acid sequence comprising at least one taxol binding site of a beta-tubulin from a taxol-resistant *Pestalotiopsis microspora*.



82. The method of Claim 81, wherein said amino acid sequence comprises at least one taxol binding site from SEQ ID NO:2

83. The method of Claim 80, wherein said antibodies are raised against an amino acid sequence comprising at least one taxol binding site of a beta-tubulin from a taxol-sensitive *Pythium ultimum*.

84. The method of Claim 81, wherein said amino acid sequence comprises at least one taxol binding site from SEQ ID NO:4

85. The method of Claim 80, wherein said antibodies are raised against an amino acid sequence comprising at least one taxol binding site of a beta-tubulin from a taxol-sensitive *Phytophthora cinnamomi* as depicted in SEQ ID NO:6.

86. The method of Claims 80, 81, 82, 83, 84 or 85, wherein said beta-tubulin or beta-tubulin-like protein is selected from the group consisting of recombinantly expressed protein, exogenously isolated protein, synthetic peptides, and cell cultures.

87. A method of screening a composition of matter for the presence of taxol or taxol-like compounds comprising

providing beta-tubulins with amino acid sequences comprising both taxol binding sites from taxol-sensitive *Pythium ultimum* or taxol-sensitive *Phytophthora cinnamomi* as depicted in SEQ ID NO:6 in addition to alpha-tubulin from any taxol-sensitive organism to form a reagent;

contacting said composition of matter with said reagent; and

determining the ability of the composition of matter to promote MT assembly or ability to prevent depolymerization of assembled MTs under depolymerizing conditions;

whereby the ability to promote microtubule assembly or prevent depolymerization indicate the possible presence of taxol or taxol-like compounds in said composition of matter.

88. A method of screening a composition of matter for the presence of taxol or taxol-like compounds comprising

providing mycelia of taxol-sensitive *Pythium ultimum* or a taxol-sensitive *Phytophthora cinnamomi* as depicted in SEQ ID NO:6;

5           contacting said composition of matter with said mycelia in the presence of said  
labeled taxol; and  
          determining degree of competitive inhibition of binding between said beta-tubulins  
and said labeled taxol by said composition of matter;  
          whereby the composition of matter is determined to possess taxol or taxol-like  
10   compounds if it is able to block taxol binding to the beta-tubulins from the taxol-sensitive  
*Pythium ultimum* or *Phytophthora cinnamomi*.

89. A method of altering the taxol binding property of a recombinantly expressed  
beta-tubulin or a portion thereof comprising

          determining the identity of the codon at Amino Acid 219 as numbered in SEQ ID  
NO:2 in the coding region of the vector; and

5           if said codon at Amino Acid 219 codes for any amino acid except threonine,  
substituting nucleotides in said codon to code for threonine at Amino Acid 219 to alter a  
non-taxol-binding beta-tubulin or portion thereof to a taxol-binding beta-tubulin or portion  
thereof or if said codon at Amino Acid 219 codes for threonine, substituting nucleotides in  
said codon to code for any amino acid except threonine at Amino Acid 219 to alter a taxol-  
10   binding beta-tubulin or portion thereof to a non-taxol-binding beta-tubulin or portion  
thereof.

90. A method of developing a taxol-sensitive fungal cell from a taxol-resistant  
fungal cell comprising

          transforming said non-taxol-sensitive fungal cell by introducing a DNA segment  
encoding taxol-binding beta-tubulin comprising threonine at Amino Acid 219 as numbered  
5   in SEQ ID NO:2;

          wherein said transformed fungal cell expresses said DNA segment under the control  
of a suitable constitutive or inducible promoter when exposed to conditions which permit  
expression.

91. A transgenic taxol-sensitive fungal cell transformed by introducing a DNA  
segment encoding taxol-binding beta-tubulin comprising threonine at Amino Acid 219 as  
numbered in SEQ ID NO:2, wherein said transformed fungal cell expresses said DNA

segment under the control of a suitable constitutive or inducible promoter when exposed to conditions which permit expression.

92. A method of developing a taxol-resistant fungal cell from a taxol-sensitive fungal cell comprising

transforming said taxol-sensitive fungal cell by introducing a DNA segment encoding non-taxol-binding beta-tubulin wherein the amino acid at Amino Acid 219 as numbered in SEQ ID NO:2 is not threonine;

wherein said transformed fungal cell over-expresses said DNA segment under the control of a suitable constitutive or inducible promoter when exposed to conditions which permit expression.

93. A transgenic taxol-sensitive fungal cell transformed by introducing a DNA segment encoding taxol-binding beta-tubulin comprising threonine at Amino Acid 219 as numbered in SEQ ID NO:2, wherein said transformed fungal cell over-expresses said DNA segment under the control of a suitable constitutive or inducible promoter when exposed to conditions which permit expression.

94. A method of screening a composition of matter for the presence of taxol or taxol-like compounds comprising

providing distinguishable taxol-resistant and taxol-sensitive fungal cells;

contacting said composition of matter with said fungal cells;

determining the growth inhibition of said fungal cells;

whereby the composition of matter is determined to possess taxol or taxol-like compounds if it is able to inhibit the growth of taxol-sensitive fungal cells but not able to inhibit the growth of taxol-resistant fungal cells.

95. The method of Claim 94, wherein said distinguishable taxol-resistant and taxol-sensitive fungal cells consists essentially of transgenic taxol-resistant and taxol-sensitive isogenic fungal cells.

96. The method of Claim 94, wherein said taxol-resistant fungal cells are derived from a fungi which is unrelated to the fungi from which the taxol-sensitive fungal cells are derived.

97. A method for controlling the growth of plant pathogens comprising determining the taxol sensitivity of said plant pathogen; and if said pathogen is determined to be taxol-sensitive, said plant and soil surrounding said plant are treated with a taxol-producing *P. microspora*.

98. The method of Claim 97, wherein the taxol sensitivity of said plant pathogen is determined by identifying Amino Acid 219, wherein the plant is designated as taxol-sensitive if Amino Acid 219 is threonine.

WO 00/56894

1/10




Fig. 1

2/10

1 CCGTCGAGCTCTACTCCAAAGAAGGCCTCTTTGTTGCTTCTCTCAGCCTCGACATCTTCTACAAACCGCCATCATCGGTGAGATTGTT  
 5 M R E I V  
 90 CACCTCCAGACCGGTCAATGCGGTAAACCAATTTGCTGCTGCTTCTGGGAAACCATCTCTGGCGAGCAGCGTCTCGACAGCAATGGAGTC  
 35 H L Q T G Q C G N Q I G A A F W Q T I S G E H G L D S N G V  
 180 TACAACGGTACTCCGAGCTCCAGCTCGAGCGCATGAGCGTCTACTTCAACGAGGCTTCGGGCAACAAGTACGTTCTCTCGTCCGCTCCTC  
 65 Y N G T S E L Q L E R M S V Y F N E A S G N K Y V P R A V L  
 270 GTCGATCTCGAGCCCGGTACCATGGATGCCGTCCGCGCGGTCTTTTCGTCAGCTCTTCCGCCCTGACAACTTCGTCTTCGGTCACTCC  
 95 V D L E P G T M D A V R A G P F G Q L F R P D N F V F G Q S  
 360 GGTGCGGAAACAACCTGGGCAAGGTCACCTACACTGAGGGTGCCGAGTCTCGACAGGTTGTCCGTGCGGAGGCGCGAG  
 125 G A G N N W A K G H Y T E G A E L V D Q V L D V V R R E A E  
 450 GCTTGGAGTGCCTCCAGGTTTCCAGATCACCCACTCCCTGGTGGTGGTACCGGTGCCGGTATGGGTACTCTGTTGATCTCCAAGATC  
 155 A C D C L Q G F Q I T H S L G G G T G A G M G T L L I S K I  
 540 CGTAGGAGTTCCCGACCGCATGATGGCCACCTTCTCCGTGCTGCCCTCCCAAGGTCTCGACACCGTCTCGAGCGCTTACACGCCC  
 185 R E E F P D R M M A T F S V V P S P K V S D T V V E P Y N A  
 630 ACCCTCTCCGTCCACCAAGTGTGAGAACTCGGACGAGACCTTCTGCAATTGACAAACGAGGCTCTCTACGACATCTGCATCGGACCCCTG  
 215 T L S V H Q L V E N S D E T F C I D N E A L Y D I C M R T L  
 720 AAGCTGTCCAAACCCCTCGTACGGTGACCTGAACCACTGGTCTCCGCCGTCTGCGGTGTCAACCACTTCTGCTTCCCTGGTTCAG  
 NETUB5  
 810 K L S N P S Y G D L N H L V S A V M S G V T T C L R F P G Q  
 245 CTGAACTCTGACCTGGCAAGCTGGCCGTCAACATGGTGCCTTCCCTCGTCTGCACTTCTTCACTGTCGGCTTGTCTCCCTGACCAAGC  
 275 L N S D L R K L A V N M V P F P R L H F F M V G F A P L T S  
 900 CGTGGCGCCCACTCTTTCCGTGCGGTCAACCGTCCCGAGTTGACCCAGCAGATGTTTCGACCCCAAGAACATGATGGTCTCCGACTTC  
 305 R G A H S F R A V T V P E L T Q Q M F D P K N M M A A S D F  
 990 CGTAACGGTCGCTACCTGACCTGCTTCCCATCTTCCGTGGTAAGTCTCCATGAAGGAGGTTCGAGGACCATGCGCAACGTCACGAAC  
 335 R N G R Y L T C S A I F R G K V S M K E V E D Q M R N V Q N  
 1080 AAGAACTCGTCTACTTCTGTCGAGTGGATCCCAACACGTCGACACCGCCCTCTGCTCCATTCCTCCCGCGGCTTAAAGATGTCGTC  
 365 K N S S Y F V E W I P N N V Q T A L C S I P P R G L K M S S  
 1170 ACTTTTCGTCGAAACTCGACTGCTATCCAGGAGCTGTTCAAGCGCATCGGCGAGCAGTTCACTGCCATGTTCCGTGCGCAAGGCTTCTCTTG  
 NETUB6  
 1260 T F V G N S T A I Q E L F K R I G E Q F T A M F R R K A F L  
 395 CATTGGTACACTGGTGAGGATGACGAGATGGAGTTCACTGAGGCGGAGTCAACATGAACGACTTGGTCAAGCAATACCAAGCATAC  
 425 H W Y T G E G M D E M E F T E A E S N M N D L V S E Y Q Q Y  
 1350 CAGGACGCTGGTTCGATGAGGAGGAGGAGTACGAGGAGGAGCCTCTGCCCCGAGGACGAGTAAACGGTCTGCTAGAGGCTACCAAG  
 446 Q D A G V D E E E E E E E E P L P E D E \*  
 1440 TTGCCAACATGTGGCGTAGGGCTGGTACGAAGGCAACTCAATGGTCTACTCTGTTTCAATTTGGCCATAACCCCTCCTCTCTTTCT  
 1530 GTCACAGCGAATAATTTTCGGTCGCTTCTCGCTTTTCAAAAGAAGATAGTTAGGTCACTCTTAATAGAAAGTGAAGGTTGGCCCTTTG  
 1620 TTAGATATACCTTTTGGGGCTGAATAAAAAAAAAAAAAAAAAAAAAA (1668)

Fig. 2

3/10

1 CTGGACGGTCAAGCAGGTACTGCCAGCCAGCAGCCGCGCAGGAGAAAGACCCGAGTTCTATTCGACGCGAAACAGACAGACATA  
 92 ATGAGAGAACTAGTTCACATCCAAAGTGGCAGTGGTAAACCAATTTGGCCCAAGTTTGGGAAGTGAATTTCTGATGAACACACGGTGTG  
 MR ELVHIQGGQCQGNQIGAKFWESI SD EHG V 30  
 182 GACCCGACGGGTAGCTACCATGGTACTCCGACCTGCAGTTGGAGCGCATCAACGTGTACTACAACGAAGTACGGGCGGTGTTACGTG  
 DPTGSYHGDSDLQLLERLIN VY YNEA TGG RY V 60  
 272 CCTCGTCCGATCTTGATGGATTTGGAGCCAGGTACCATGGACTCGGTCCGTCCGCTCCATTCGGTCAGCTTTTCCGCCCCAGATAACTTC  
 PRAILMDLEPGTMDSDSVRA GPF GQLFRP DNF 90  
 362 GTCTTCGGCCAACCCGGTGTGGTAACAACCTGGGCCAAGGTCTACTATACGGAAGGCGTGAATTCGACTCGGTCTTGGATGTGCGC  
 VFGQPGA GNNWAKGHYTEGAEL IDS VLDVA 120  
 452 CGCAAGGAAGCTGAGAGTGCATTGCCCTGCAAGGTTTCCAGATCACCCACTCCCTCGGTGGTGTACCGGTTCCGGTATGGGTACGCTT  
 RKEAESCDCLQGQFI THSLGGGTGS GM GTL 150  
 542 TTGATCTCTAAGATCCGTGAAGAATACCCAGATCGTATCATGTGCACGTACTCGGTGTCGCCATCGCCAAAGGTGTGCGATACCGTCCGTC  
 WTIL-U  
 632 LISKIRE EYPRDIRIMCTYSVCPSPKVS DTVV 180  
 722 GAACCATACAATGCCACGCTTTTCGGTCCACAGTTGGTCGAAAGCCCGATGAAGTCATGTGTTTGGATAACGAGGCTCTCTACGATATC  
 EPNATLSVHQLV ENAD EVMCLDN EALYDI 210  
 812 TGCTTCGGTACCTGAAGTTGACGACCCCAAGTACGGTGACTTGAACCACTTGGTGTGTGTGCTGCCATGTCCGTATCACGACGTGCGCTG  
 CFR TLKL TPTPT YGD LNLHLVCAAMSGIT T T C L 240  
 CGATTCCCGAGTCAATTGGACTTCGGACTTCGGTAAGCTCGCGGTGAACCTTGATCCCGTTCGCCAGCTCTCCACTCTTTCATGATTTGGTTTC  
 RFPGLNLNSDLRLRKLAVNLIPFPLR LHF FMI GF 270  
 902 GCGCCATTGACCTCCCGTGGTTCCGACGAGTACCGTGTCTTTGACCGTCCCGAATTCGACCCAGCAACAATTCGACGCGGAAGAACATGATG  
 WTIL-L  
 992 APLTSRGSQ QYRALTLTVPELTLTQQQ F DAKNM M 300  
 TCGCGCGCGATCCTCGCCACGGTCTGTTATTAACTGCTGCCTGTATGTTCCGTGGCGCATGAGCACCAAGGAAGTCGATGAACAAATG  
 CADA DPHRGRLYLTLTAACMF RGRMS TK EVD EQ M 330  
 1082 CTCACGTGCAGAACAGAACTCGTCGTACTTTGTGGAGTGGATTCAAACAACATCAAGGCCAGCGTGTGTGATATCCCAACCAAGGCT  
 LNVQ NKNS SYFVEWIPNNIKASVCDIP PK G 360  
 1172 CTGAAGATGAGTACCACCTTCGTTGGTAACTCGACTGCGATCCAGGAGATGTTCAAGCGTGTGTGCGAGAGTTTCAACGCTATGTTCCGT  
 LKMS TTFVGNSTAIQE MFKRVSE QFTAMFR 390  
 1262 CGTAAGGCTTTCTTGCACTGGTACACGGGTGAAGTATGGATGAGATGGAATTCACGGAAGCCGAGTCGAACATGAACGATTTGGTGTGCG  
 RKAFLH WYTGEGMDEMEFT'EAE S NMDLV S 420  
 1352 GAATACGACGAGTACCAAGACGCGACAGCAAGAGAGGAGTGAATTCGACGAAGATGAAGAAATGGACCAATGATGTAGACGACGCGG  
 EYQQQYQDA TAE EGE EDE EME M \* 446  
 1442 GCGATATAGCGACTCCTTTGCAGCAGCGGTGTGCGGCGTCTGAGATATTCTCCAAGTACCATACAGAACCGTGTAGTGGACTCTTTCGTAT  
 ↑  
 ↑+(A) 31  
 1532 TCAACTATTACTCCAATATTAGCGAGGTAGCTTCACTACGAGCAGCGGAGTTAGTGCCTTCCGTTCTGCTCTTACTGGAAGAGAGATTT  
 1622 TCTAAGTTTAAAAA (1650)

Fig. 3

4/10

1 CAGCGACAACATGAGAGAGCTCGTTACATCCAGGGTGGCCAGTGCGGTAACCAAGATCGGCGCAAGTTCTGGGAGGTCTCTCCGACGAG  
 PCBTUB1U  
 92 CACGGCGTGGACCCGACGGGATCTTACACGGGACTCGGACCTGACGCTGGAGCGCATCAACGTGTACTACAACGAGGCCACGGGCGGC  
 H G V D P T G S Y H G D S D L Q L E R I N Y Y N E A T G G  
 182 CGTACGTGCCCCGCGCCATCTCATGGACCTGGAGCCCGGACCATGAGACTCGGTGCGCGCGGCCCTTACGCGCCAGCTCTTCCGCGCG  
 R Y V P R A I L M D L E P G T M D S V R A G P Y G Q L F R P  
 272 GACACTTCGTGTTGCGCCAGACGGGCGCGGTAACTAGTGGCCAAAGGACATACACGGGCGCGGAGCTCATCGACTCGGTGCTC  
 D N F V F Q T G A G N N W A K G H Y T E G A E L I D S V L  
 362 GATGTCGTCGCAAGGAGCGGAGAGCTGCGACTGCCGAGGATCCAGATCAGCACTCGCTCGGTGCGGTTACCGGTTCCGGTATG  
 D V V R K E A E S C D C L Q G F Q I T H S L G G G T G S G M  
 452 GGCACGCTTCTTATCTCCAAGATCCGTGAGGAGTACCCGACCGTATCATGTGACGTACTCGGTGTGCCGTGCGCCCAAGGTGTCGAC  
 G T L L I S K I R E E Y P D R I M C T Y S V C P S P K V S D  
 542 ACGTTCGTGGAGCCCTACAACGCGACGCTGTCCGTGACACGCTTGTGAGAACCGGATGAGGTCTGCTGGATACGAGGCGCCTG  
 PCBTUB2U  
 632 TACGACATTTGCTTCCGACGCTGAAGCTCAGACCCCGACCTACGCTGAGTGAACCAACCTGTGTGCGCGCCCATGTCCGGCATCAC  
 Y D I C F R T L K L T T P T Y G D L N H L V C A A M S G I T  
 722 ACGTGCCTGCTTCCCGGCGGAGCTGAACCTCGGTCCTGCTAAGCTTGGCGTGAACCTGATCCCGTTCGCGGTCTGCACTTCTTCATG  
 T C L R F P G Q L N S D L R K L A V N L I P F P R L H F F M  
 812 ATCGGCTTCGCGCGCTGACGTGCGGTGCTCGCAGGAGTACCGTCCCTGACGGTCCCGAGCTGACCCAGCAGCAGTTCGATGCTAAG  
 I G F A P L T T S R G S Q Q Y R A L T V P E L T Q Q F D A K  
 902 AACATGATGTGCGCGCTGACCTCGCCACGCGCGCTATTTAACTCCGCGTGTATGTTCCGCGGACGTATGAGCACGAGGAGGTGAT  
 N M M C A A D P R H G R Y L T A A C M F R G R M S T K E V D  
 992 GAGCAGATGCTTAACTGACGACAAAGAACTCGTCTGCTGAGTGGATCCCAACACATCAAGCTAGCGTGTGTGACATCCCG  
 E Q M L N V Q N K N S S Y F V E W I P N N I K A S V C D I P  
 1082 CCTAAGGTCTCAAGATGAGCACCAGTTTCATCGGCAACTCCACTGCCATCCAGGAGATGTTCAAGCGTGTGTCCGAACAGTTCCAGGCT  
 P K G L K M S T T F I G N S T A I Q E M F K R V S E Q F T A  
 1172 ATGTCCGTCGTAAGGCTTCTTGCACTGTACACGGGCGAGGGTATGGATGAGATGAGTTCACGGAGGTGAGTCCAAACATGAACGAT  
 M F R R K A F L H W Y T G E G M D E M E F T E A E S N M N D  
 1262 CTTGTGCTGAGTACCAGCACTACAGGACGCGCCACCGCAGAGGAGGCGGAGTTCGACGAGGACCGAGGATGAGATGAGACGCG(1350)  
 PCBTUB4L  
 L V S E Y Q Q Y Q D A T A E E E G E F D E D E E W M R \*

Fig. 4



**5/10**

Taxol	binding	region	I
1	2	3	4

**Fig. 5**

6/10

Taxol		binding	region	I	*
<i>P. microspora</i>	1	MREIVHLQTGC	GNQIGAAFWQTISGEHGLDSNGVYNGTSELQ	LMRSMVYFNEASGNKYV	60
<i>N. crassa</i>	1		AS	N	60
<i>A. nidulans</i>	1		GS	D	60
<i>P. ultimum</i>	1	L I G	K EV D V PT S H D D	IN Y T GR	60
<i>P. cinnamomi</i>	1	L I G	K EVV D V PT S H D D	IN Y T GR	60
<i>A. klebsiana</i>	1	L I G	K EV D V PT S H D D	IN Y T - T	59
Human $\beta 2$	1	A	K EV D I PT T H D D	IN Y T G	60
<i>P. microspora</i>		PRAVLVLEPGTMDAVRAGPFGLFRPDNFVFGQSGAGNNWAKGHYTEGAELVDQVLDVVRREAE			125
<i>N. crassa</i>					125
<i>A. nidulans</i>		C	E	N V	125
<i>P. ultimum</i>	I M	S	P	I S A K	125
<i>P. cinnamomi</i>	I M	S	Y	I S L K	125
<i>A. klebsiana</i>	I M	S	Y	I S K	124
Human $\beta 2$		S S I		S K	125
**					
<i>P. microspora</i>		ACDCIQGFQITHSLGGGTGAGMGTTLLISKIREFFPDRMATEFVVPSPKVSDTVVEPNATLSVH			190
<i>N. crassa</i>	G				190
<i>A. nidulans</i>	G				190
<i>P. ultimum</i>	S	S	Y I C Y C		190
<i>P. cinnamomi</i>	S	S	Y I C Y C		190
<i>A. klebsiana</i>	S	S	Y I C Y C		189
Human $\beta 2$	S	L	Y I N		190
**					
<i>P. microspora</i>		QLVENSDETFCIDNEALYDICTMRTKLISNPSYGDNLHLVSAVMSGVTTCLRFPGQLNSDLRKLA			255
<i>N. crassa</i>				VS	255
<i>A. nidulans</i>	H				255
<i>P. ultimum</i>	A VM L	F	TT T	C A I	255
<i>P. cinnamomi</i>	A VM L	F	TT T	C A I	255
<i>A. klebsiana</i>	A VM L	F	T T	C A I L	253
Human $\beta 2$	T Y	F	TT T	T A	255

Fig. 6A

**Fig. 6B**

8/10




Fig. 7A

9/10




Fig.7B

10/10

	Region I (1-31 aa)	Region II (212-231 aa)
	*****	*****
(s) Pig	MREIVHIQAGCGNQIGAKFWEVISDEHGID	FRTLKLTTPTYGDLNHLVSA
(s) Human $\beta 2$	L	
(s) <i>Drosophila</i> $\beta 1$		L
(s) <i>Xenopus</i> $\beta 4$	L	
(s) <i>Tetrahymena</i>	I	
(s) <i>Physarum</i> $\beta 1$	G	
(s) <i>P. ultimum</i>	L G	C
(s) <i>P. cinnamomi</i>	L G	C
(r) <i>A. klebsiana</i>	L G	C
(r) <i>P. microspora</i>	L T	N
(r) <i>A. nidulans</i> benA	L T	SN S
(r) <i>S. cerevisiae</i>	I SA Y	SN S
		NQ S
		Q N S

Fig.8

## DECLARATION AND POWER OF ATTORNEY

COPY

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name, that I believe that I am the original, first and sole inventor (if only one name is listed below) or I believe that we are the original, first and joint inventors (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention, design or discovery entitled **FUNGAL BETA-TUBULIN GENES**, the specification of which (check one)

- ☐ is attached hereto; or  
☒ was filed on **March 23, 2000**, as PCT International Application Number **PCT/US00/07995**, and amended by letter to the International Preliminary Examining Authority received on **May 21, 2001**

that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above; that I do not know and do not believe that said invention, design or discovery was ever known or used in the United States of America before my invention or discovery thereof, or patented or described in any printed publication in any country before my invention or discovery thereof, or more than one year prior to this application, or in public use or on sale in the United States of America more than one year prior to this application; that said invention, design or discovery has not been patented or made the subject of an inventor's certificate issued prior to the date of this application in any country foreign to the United States of America on an application filed by me or my legal representatives or assigns; and that I acknowledge the duty to disclose information of which I am aware which is material to the examiner of this application in accordance with 37 C.F.R. § 1.56(a).

I hereby claim foreign priority benefits under 35 U.S.C. § 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application(s) for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

NUMBER	COUNTRY	DATE FILED	PRIORITY CLAIMED
--------	---------	------------	------------------

N/A

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below.

APPLICATION SERIAL NO.	DATE FILED
------------------------	------------

60/125,717

March 23, 1999

I hereby claim the benefit under 35 U.S.C. § 120 of any United States Application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States Application(s) in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose material information as defined in 37 C.F.R. § 1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

APPLICATION SERIAL NO.

DATE FILED

STATUS

N/A

I hereby appoint:

3  
Eugenia S. Hansen  
Karen L. Knezek  
Rod A. Cooper

Reg. No. 31,966  
Reg. No. 39,253  
Reg. No. 42,436

all of the firm of Sidley & Austin, my attorneys with full power of substitution and revocation, to prosecute this application and to transact all business in the United States Patent and Trademark Office connected therewith, and to file and prosecute any international patent applications filed thereon before any international authorities under the Patent Cooperation Treaty.

Send correspondence to:

Direct telephone calls to:

Sidley Austin Brown & Wood  
717 N. Harwood  
Suite 3400  
Dallas, TX 75201-6507

Eugenia S. Hansen  
at (214) 981-3300  
Atty. Docket No. **10365/07304**

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under § 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.



## DECLARATION AND POWER OF ATTORNEY

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name, that I believe that I am the original, first and sole inventor (if only one name is listed below) or I believe that we are the original, first and joint inventors (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention, design or discovery entitled **FUNGAL BETA-TUBULIN GENES**, the specification of which (check one)

- ( ) is attached hereto; or  
(X) was filed on **March 23, 2000**, as PCT International Application Number **PCT/US00/07995**, and amended by letter to the International Preliminary Examining Authority received on **May 21, 2001**

that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above; that I do not know and do not believe that said invention, design or discovery was ever known or used in the United States of America before my invention or discovery thereof, or patented or described in any printed publication in any country before my invention or discovery thereof, or more than one year prior to this application, or in public use or on sale in the United States of America more than one year prior to this application; that said invention, design or discovery has not been patented or made the subject of an inventor's certificate issued prior to the date of this application in any country foreign to the United States of America on an application filed by me or my legal representatives or assigns; and that I acknowledge the duty to disclose information of which I am aware which is material to the examiner of this application in accordance with 37 C.F.R. § 1.56(a).

I hereby claim foreign priority benefits under 35 U.S.C. § 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application(s) for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

NUMBER	COUNTRY	DATE FILED	PRIORITY CLAIMED
--------	---------	------------	------------------

N/A

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below.

APPLICATION SERIAL NO.	DATE FILED
------------------------	------------

60/125,717

March 23, 1999

I hereby claim the benefit under 35 U.S.C. § 120 of any United States Application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States Application(s) in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose material information as defined in 37 C.F.R. § 1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

**APPLICATION SERIAL NO.**

**DATE FILED**

**STATUS**

N/A

I hereby appoint:

3 Eugenia S. Hansen

Reg. No. 31,966

Karen L. Knezek

Reg. No. 39,253

Rod A. Cooper

Reg. No. 42,436

all of the firm of Sidley & Austin, my attorneys with full power of substitution and revocation, to prosecute this application and to transact all business in the United States Patent and Trademark Office connected therewith, and to file and prosecute any international patent applications filed thereon before any international authorities under the Patent Cooperation Treaty.

Send correspondence to:

Direct telephone calls to:

Sidley Austin Brown & Wood

Eugenia S. Hansen

717 N. Harwood

at (214) 981-3300

Suite 3400

Atty. Docket No. **10365/07304**

Dallas, TX 75201-6507

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under § 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Full name of sole or joint inventor: Rajinder S. Sidhu

Inventor's signature: Rajinder S. Sidhu

Date: 10-26-01

Residence (City, County, State): Dallas, Dallas County, Texas TX

Citizenship: United States of America

Post Office Address: 7521 Danfield Court, Dallas, Texas 75252

Full name of sole or joint inventor: Arthur P. Bollon

Inventor's signature: Arthur P. Bollon

Date: October 12, 2001

Residence (City, County, State): Dallas, Dallas County, Texas TX

Citizenship: United States of America

Post Office Address: 13227 Cedar Lane, Dallas, Texas 75234

Full name of sole or joint inventor: Jing-Hong Mu

Inventor's signature: Jing-Hong Mu

Date: Oct. 12, 2001

Residence (City, County, State): Dallas, Dallas County, Texas TX

Citizenship: China

Post Office Address: 534 Newberry Drive, Richardson, Texas 75080

Full name of sole or joint inventor: **Rajinder S. Sidhu**

Inventor's signature: Rajinder Singh Sidhu

Date: 10-26-01

Residence (City, County, State): **Dallas, Dallas County, Texas** TX

Citizenship: **United States of America**

Post Office Address: **7521 Danfield Court, Dallas, Texas 75252**

Full name of sole or joint inventor: **Arthur P. Bollon**

Inventor's signature: Arthur P. Bollon

Date: October 12, 2001

Residence (City, County, State): **Dallas, Dallas County, Texas** TX

Citizenship: **United States of America**

Post Office Address: **13227 Cedar Lane, Dallas, Texas 75234**

Full name of sole or joint inventor: **Jing-Hong Mu**

Inventor's signature: Jing-Hong Mu

Date: Oct. 12, 2001

Residence (City, County, State): **Dallas, Dallas County, Texas** TX

Citizenship: **China**

Post Office Address: **534 Newberry Drive, Richardson, Texas 75080**

28 NOV 2001

2

Applicant or Patentee: **Rajinder S. Sidhu, et al.**  
Serial or Patent No.: **To be assigned**  
International Appln. No.: **PCT/US00/07995**  
International Filing Date: **March 23, 2000**  
For: **FUNGAL BETA-TUBULIN GENES**

**VERIFIED STATEMENT (DECLARATION)****CLAIMING SMALL ENTITY STATUS****(37 C.F.R. §§ 1.9(f) AND 1.27(C)) SMALL BUSINESS CONCERN**

I hereby declare that I am an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF ORGANIZATION: **Cytoclonal Pharmaceuticals, Inc.**  
ADDRESS OF ORGANIZATION: **2110 Research Row, Suite 621, Dallas, Texas 75235**

I hereby declare that the above-identified small business concern qualifies as a small business concern as defined in 13 C.F.R. § 121.12, and reproduced in 37 C.F.R. § 1.9(d), for purposes of paying reduced fees under §§ 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a fulltime, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contracts or law have been conveyed to and remain with the small business concern identified above with regard to the invention, entitled **FUNGAL BETA-TUBULIN GENES** by inventor **Rajinder S. Sidhu, et al.**

described in:

- ☐ the specification filed herewith.
- ☒ International Application No. **PCT/US00/07995**, filed **March 23, 2000** and amended by letter to the International Preliminary Examining Authority received on **May 21, 2001**.
- ☐ patent no. , issued .

If the rights held by the above-identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below\* and no rights to the invention are held by any person, other than the inventor, who could not qualify as an independent inventor under 37 C.F.R. § 1.9(c) if that person made the invention or by any

RECEIVED 2002

COPY

Applicant or Patentee: **Rajinder S. Sidhu, et al.**  
Serial or Patent No.: **To be assigned**  
International Appln. No.: **PCT/US00/07995**  
International Filing Date: **March 23, 2000**  
For: **FUNGAL BETA-TUBULIN GENES**

**VERIFIED STATEMENT (DECLARATION)****CLAIMING SMALL ENTITY STATUS****(37 C.F.R. §§ 1.9(f) AND 1.27(C)) SMALL BUSINESS CONCERN**

I hereby declare that I am an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF ORGANIZATION: **Cytoclonal Pharmaceuticals, Inc.**  
ADDRESS OF ORGANIZATION: **2110 Research Row, Suite 621, Dallas, Texas 75235**

I hereby declare that the above-identified small business concern qualifies as a small business concern as defined in 13 C.F.R. § 121.12, and reproduced in 37 C.F.R. § 1.9(d), for purposes of paying reduced fees under §§ 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a fulltime, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contracts or law have been conveyed to and remain with the small business concern identified above with regard to the invention, entitled **FUNGAL BETA-TUBULIN GENES** by inventor **Rajinder S. Sidhu, et al.**

described in:

- ☐ the specification filed herewith.
- ☒ International Application No. **PCT/US00/07995**, filed **March 23, 2000** and amended by letter to the International Preliminary Examining Authority received on **May 21, 2001**.
- ☐ patent no. , issued .

If the rights held by the above-identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below\* and no rights to the invention are held by any person, other than the inventor, who could not qualify as an independent inventor under 37 C.F.R. § 1.9(c) if that person made the invention or by any

concern which would not qualify as a small business concern under 37 C.F.R. § 1.9(d), or a nonprofit organization under 37 C.F.R. § 1.9(e).

Each person, concern or organization having any rights in the invention is listed below:

- (X) no such person, concern or organization  
( ) persons, concerns or organizations listed below\*

\*NOTE: Separate verified statements are required from each named person, concern, or organization having rights to the invention averring to their status as small entities. (37 C.F.R. § 1.27)

NAME:

ADDRESS:

( ) individual ( ) small business concern ( ) nonprofit organization

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 C.F.R. § 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under § 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING: Robert J. Rousseau

TITLE IN ORGANIZATION: Vice President of Business Development and Licensing,  
Cytoclonal Pharmaceuticals, Inc.

ADDRESS OF PERSON SIGNING: 2110 Research Row, Suite 621, Dallas, Texas  
75235

SIGNATURE: 

DATE: 10/10/01

concern which would not qualify as a small business concern under 37 C.F.R. § 1.9(d), or a nonprofit organization under 37 C.F.R. § 1.9(e).

Each person, concern or organization having any rights in the invention is listed below:

- (X) no such person, concern or organization  
( ) persons, concerns or organizations listed below\*

\*NOTE: Separate verified statements are required from each named person, concern, or organization having rights to the invention averring to their status as small entities. (37 C.F.R. § 1.27)

NAME:

ADDRESS:

( ) individual ( ) small business concern ( ) nonprofit organization

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 C.F.R. § 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under § 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING: Robert J. Rousseau

TITLE IN ORGANIZATION: Vice President of Business Development and Licensing,  
Cytoclonal Pharmaceuticals, Inc.

ADDRESS OF PERSON SIGNING: 2110 Research Row, Suite 621, Dallas, Texas  
75235

SIGNATURE: 

DATE: 10/10/01



## SEQUENCE LISTING

<110> Sidhu, Rajinder S.  
 Bollon, Arthur P.  
 Mu, Jing-Hong  
 Cytoclonal Pharmaceuticals, Inc.

<120> Fungal Beta-Tubulin Genes

<130> 10365/07302

<140>

<141>

<160> 57

<170> PatentIn Ver. 2.1

<210> 1

<211> 1668

<212> DNA

<213> Pestalotiopsis microspora

<220>

<221> CDS

<222> (75)..(1412)

<400> 1

ccgtcgagct ctactccaaa gaaggcctct ttgttgcttc ctctcagcct cgacatcttc 60

tacaaaccgc	catc	atg	cgt	gag	att	gtt	cac	ctc	cag	acc	ggt	caa	tgc	110
		Met	Arg	Glu	Ile	Val	His	Leu	Gln	Thr	Gly	Gln	Cys	
		1				5					10			

ggt aac caa att ggt gct gcc ttc tgg caa acc atc tct ggc gag cac	158
Gly Asn Gln Ile Gly Ala Ala Phe Trp Gln Thr Ile Ser Gly Glu His	
15 20 25	

ggt ctc gac agc aat gga gtc tac aac ggt acc tcc gag ctc cag ctc	206
Gly Leu Asp Ser Asn Gly Val Tyr Asn Gly Thr Ser Glu Leu Gln Leu	
30 35 40	

gag cgc atg agc gtc tac ttc aac gag gct tcc ggc aac aag tac gtt	254
Glu Arg Met Ser Val Tyr Phe Asn Glu Ala Ser Gly Asn Lys Tyr Val	
45 50 55 60	

cct cgt gcc gtc ctc gtc gat ctc gag ccc ggt acc atg gat gcc gtc	302
Pro Arg Ala Val Leu Val Asp Leu Glu Pro Gly Thr Met Asp Ala Val	
65 70 75	

cgc gcc ggt cct ttc ggt cag ctc ttc cgc cct gac aac ttc gtc ttc	350
Arg Ala Gly Pro Phe Gly Gln Leu Phe Arg Pro Asp Asn Phe Val Phe	
80 85 90	

ggt cag tcc ggt gcc gga aac aac tgg gcc aag ggt cac tac act gag 398  
 Gly Gln Ser Gly Ala Gly Asn Asn Trp Ala Lys Gly His Tyr Thr Glu  
 95 100 105

ggt gcc gag ctc gtc gac cag gtc ctc gac gtt gtc cgt cgc gag gcc 446  
 Gly Ala Glu Leu Val Asp Gln Val Leu Asp Val Val Arg Arg Glu Ala  
 110 115 120

gag gct tgc gac tgc ctc cag ggt ttc cag atc acc cac tcc ctg ggt 494  
 Glu Ala Cys Asp Cys Leu Gln Gly Phe Gln Ile Thr His Ser Leu Gly  
 125 130 135 140

ggt ggt acc ggt gcc ggt atg ggt act ctg ttg atc tcc aag atc cgt 542  
 Gly Gly Thr Gly Ala Gly Met Gly Thr Leu Leu Ile Ser Lys Ile Arg  
 145 150 155

gag gag ttc ccc gac cgc atg atg gcc acc ttc tcc gtc gtg ccc tcc 590  
 Glu Glu Phe Pro Asp Arg Met Met Ala Thr Phe Ser Val Val Pro Ser  
 160 165 170

ccc aag gtc tcc gac acc gtc gtc gag ccc tac aac gcc acc ctc tcc 638  
 Pro Lys Val Ser Asp Thr Val Val Glu Pro Tyr Asn Ala Thr Leu Ser  
 175 180 185

gtc cac cag ctg gtc gag aac tcg gac gag acc ttc tgc att gac aac 686  
 Val His Gln Leu Val Glu Asn Ser Asp Glu Thr Phe Cys Ile Asp Asn  
 190 195 200

gag gct ctc tac gac atc tgc atg cgc acc ctg aag ctg tcc aac ccc 734  
 Glu Ala Leu Tyr Asp Ile Cys Met Arg Thr Leu Lys Leu Ser Asn Pro  
 205 210 215 220

tcg tac ggt gac ctg aac cac ctg gtc tcc gcc gtc atg tcg ggt gtc 782  
 Ser Tyr Gly Asp Leu Asn His Leu Val Ser Ala Val Met Ser Gly Val  
 225 230 235

acc act tgc ttg cgt ttc cct ggt cag ctg aac tct gac ctg cgc aag 830  
 Thr Thr Cys Leu Arg Phe Pro Gly Gln Leu Asn Ser Asp Leu Arg Lys  
 240 245 250

ctg gcc gtc aac atg gtg ccc ttc cct cgt ctg cac ttc ttc atg gtc 878  
 Leu Ala Val Asn Met Val Pro Phe Pro Arg Leu His Phe Phe Met Val  
 255 260 265

ggc ttt gct ccc ctg acc agc cgt ggc gcc cac tct ttc cgt gcc gtc 926  
 Gly Phe Ala Pro Leu Thr Ser Arg Gly Ala His Ser Phe Arg Ala Val  
 270 275 280

acc gtc ccc gag ttg acc cag cag atg ttc gac ccc aag aac atg atg 974  
 Thr Val Pro Glu Leu Thr Gln Gln Met Phe Asp Pro Lys Asn Met Met  
 285 290 295 300

gct gct tcc gac ttc cgt aac ggt cgc tac ctg acc tgc tct gcc atc 1022  
 Ala Ala Ser Asp Phe Arg Asn Gly Arg Tyr Leu Thr Cys Ser Ala Ile  
 305 310 315

ttc cgt ggt aag gtc tcc atg aag gag gtc gag gac cag atg cgc aac 1070  
 Phe Arg Gly Lys Val Ser Met Lys Glu Val Glu Asp Gln Met Arg Asn  
 320 325 330  
  
 gtc cag aac aag aac tcg tcc tac ttc gtc gag tgg atc ccc aac aac 1118  
 Val Gln Asn Lys Asn Ser Ser Tyr Phe Val Glu Trp Ile Pro Asn Asn  
 335 340 345  
  
 gtg cag acc gcc ctc tgc tcc att cct ccc cgc ggc ctt aag atg tcg 1166  
 Val Gln Thr Ala Leu Cys Ser Ile Pro Pro Arg Gly Leu Lys Met Ser  
 350 355 360  
  
 tcc act ttc gtc gga aac tcg act gct atc cag gag ctg ttc aag cgc 1214  
 Ser Thr Phe Val Gly Asn Ser Thr Ala Ile Gln Glu Leu Phe Lys Arg  
 365 370 375 380  
  
 atc ggc gag cag ttc act gcc atg ttc cgt cgc aag gct ttc ttg cat 1262  
 Ile Gly Glu Gln Phe Thr Ala Met Phe Arg Arg Lys Ala Phe Leu His  
 385 390 395  
  
 tgg tac act ggt gag ggt atg gac gag atg gag ttc act gag gcc gag 1310  
 Trp Tyr Thr Gly Glu Gly Met Asp Glu Met Glu Phe Thr Glu Ala Glu  
 400 405 410  
  
 tcc aac atg aac gac ttg gtc agc gaa tac cag cag tac cag gac gct 1358  
 Ser Asn Met Asn Asp Leu Val Ser Glu Tyr Gln Gln Tyr Gln Asp Ala  
 415 420 425  
  
 ggt gtc gat gag gag gag gag gag tac gag gag gag cct ctg ccc gag 1406  
 Gly Val Asp Glu Glu Glu Glu Glu Tyr Glu Glu Glu Pro Leu Pro Glu  
 430 435 440  
  
 gac gag taaacggctc gctagaggct accaaagtgtg ccaacatgtg gcgtagggt 1462  
 Asp Glu  
 445  
  
 ggctgacgaa ggcaacttca atggtctact ctgtttcatt ttggcctaata acccctcctc 1522  
 cttttctgtc acagcgaata attttcggtc gcctttctcg cttttcaaaa gaagataggt 1582  
 taggtcactc ctaatagaag tgaagggtgg ccctttgtta gatatacctt ttggggctga 1642  
 ataaaaaaaa aaaaaaaaaa aaaaaa 1668

&lt;210&gt; 2

&lt;211&gt; 446

&lt;212&gt; PRT

&lt;213&gt; Pestalotiopsis microspora

&lt;400&gt; 2

Met Arg Glu Ile Val His Leu Gln Thr Gly Gln Cys Gly Asn Gln Ile  
 1 5 10 15

Gly Ala Ala Phe Trp Gln Thr Ile Ser Gly Glu His Gly Leu Asp Ser  
 20 25 30  
 Asn Gly Val Tyr Asn Gly Thr Ser Glu Leu Gln Leu Glu Arg Met Ser  
 35 40 45  
 Val Tyr Phe Asn Glu Ala Ser Gly Asn Lys Tyr Val Pro Arg Ala Val  
 50 55 60  
 Leu Val Asp Leu Glu Pro Gly Thr Met Asp Ala Val Arg Ala Gly Pro  
 65 70 75 80  
 Phe Gly Gln Leu Phe Arg Pro Asp Asn Phe Val Phe Gly Gln Ser Gly  
 85 90 95  
 Ala Gly Asn Asn Trp Ala Lys Gly His Tyr Thr Glu Gly Ala Glu Leu  
 100 105 110  
 Val Asp Gln Val Leu Asp Val Val Arg Arg Glu Ala Glu Ala Cys Asp  
 115 120 125  
 Cys Leu Gln Gly Phe Gln Ile Thr His Ser Leu Gly Gly Gly Thr Gly  
 130 135 140  
 Ala Gly Met Gly Thr Leu Leu Ile Ser Lys Ile Arg Glu Glu Phe Pro  
 145 150 155 160  
 Asp Arg Met Met Ala Thr Phe Ser Val Val Pro Ser Pro Lys Val Ser  
 165 170 175  
 Asp Thr Val Val Glu Pro Tyr Asn Ala Thr Leu Ser Val His Gln Leu  
 180 185 190  
 Val Glu Asn Ser Asp Glu Thr Phe Cys Ile Asp Asn Glu Ala Leu Tyr  
 195 200 205  
 Asp Ile Cys Met Arg Thr Leu Lys Leu Ser Asn Pro Ser Tyr Gly Asp  
 210 215 220  
 Leu Asn His Leu Val Ser Ala Val Met Ser Gly Val Thr Thr Cys Leu  
 225 230 235 240  
 Arg Phe Pro Gly Gln Leu Asn Ser Asp Leu Arg Lys Leu Ala Val Asn  
 245 250 255  
 Met Val Pro Phe Pro Arg Leu His Phe Phe Met Val Gly Phe Ala Pro  
 260 265 270  
 Leu Thr Ser Arg Gly Ala His Ser Phe Arg Ala Val Thr Val Pro Glu  
 275 280 285  
 Leu Thr Gln Gln Met Phe Asp Pro Lys Asn Met Met Ala Ala Ser Asp  
 290 295 300

PCT/US00/07995  
 WO 00/56894

Phe Arg Asn Gly Arg Tyr Leu Thr Cys Ser Ala Ile Phe Arg Gly Lys  
305 310 315 320

Val Ser Met Lys Glu Val Glu Asp Gln Met Arg Asn Val Gln Asn Lys  
325 330 335

Asn Ser Ser Tyr Phe Val Glu Trp Ile Pro Asn Asn Val Gln Thr Ala  
340 345 350

Leu Cys Ser Ile Pro Pro Arg Gly Leu Lys Met Ser Ser Thr Phe Val  
355 360 365

Gly Asn Ser Thr Ala Ile Gln Glu Leu Phe Lys Arg Ile Gly Glu Gln  
370 375 380

Phe Thr Ala Met Phe Arg Arg Lys Ala Phe Leu His Trp Tyr Thr Gly  
385 390 395 400

Glu Gly Met Asp Glu Met Glu Phe Thr Glu Ala Glu Ser Asn Met Asn  
405 410 415

Asp Leu Val Ser Glu Tyr Gln Gln Tyr Gln Asp Ala Gly Val Asp Glu  
420 425 430

Glu Glu Glu Glu Tyr Glu Glu Glu Pro Leu Pro Glu Asp Glu  
435 440 445

<210> 3

<211> 1650

<212> DNA

<213> Pythium ultimum

<220>

<221> CDS

<222> (92)..(1429)

<400> 3

ctgggacggt caaagcacgg tactgccagc caccgagccg ccgccgcagg agaagcaccc 60

gagttcattc gcagcgaaac agacagacat a atg aga gaa cta gtt cac atc 112  
Met Arg Glu Leu Val His Ile  
1 5

caa ggt ggc cag tgc ggt aac caa att ggc gcc aag ttt tgg gaa gtg 160  
Gln Gly Gly Gln Cys Gly Asn Gln Ile Gly Ala Lys Phe Trp Glu Val  
10 15 20

att tct gat gaa cac ggt gtg gac ccg acg ggt agc tac cat ggt gac 208  
Ile Ser Asp Glu His Gly Val Asp Pro Thr Gly Ser Tyr His Gly Asp  
25 30 35

tcc gac ctg cag ttg gag cgc atc aac gtg tac tac aac gaa gct acg 256  
 Ser Asp Leu Gln Leu Glu Arg Ile Asn Val Tyr Tyr Asn Glu Ala Thr  
 40 45 50 55

ggc ggt cgt tac gtg cct cgt gcg atc ttg atg gat ttg gag cca ggt 304  
 Gly Gly Arg Tyr Val Pro Arg Ala Ile Leu Met Asp Leu Glu Pro Gly  
 60 65 70

acc atg gac tcg gtc cgt gcc ggt cca ttc ggt cag ctt ttc cgc cca 352  
 Thr Met Asp Ser Val Arg Ala Gly Pro Phe Gly Gln Leu Phe Arg Pro  
 75 80 85

gat aac ttc gtc ttc ggc caa ccc ggt gct ggt aac aac tgg gcc aag 400  
 Asp Asn Phe Val Phe Gly Gln Pro Gly Ala Gly Asn Asn Trp Ala Lys  
 90 95 100

ggt cac tat acg gaa ggc gct gaa ttg atc gac tcg gtc ttg gat gtc 448  
 Gly His Tyr Thr Glu Gly Ala Glu Leu Ile Asp Ser Val Leu Asp Val  
 105 110 115

gcc cgc aag gaa gct gag agc tgc gat tgc ctg caa ggt ttc cag atc 496  
 Ala Arg Lys Glu Ala Glu Ser Cys Asp Cys Leu Gln Gly Phe Gln Ile  
 120 125 130 135

acc cac tcc ctc ggt ggt ggt acc ggt tcc ggt atg ggt acg ctt ttg 544  
 Thr His Ser Leu Gly Gly Gly Thr Gly Ser Gly Met Gly Thr Leu Leu  
 140 145 150

atc tct aag atc cgt gaa gaa tac cca gat cgt atc atg tgc acg tac 592  
 Ile Ser Lys Ile Arg Glu Glu Tyr Pro Asp Arg Ile Met Cys Thr Tyr  
 155 160 165

tcg gtg tgc cca tcg cca aag gtg tcg gat acc gtc gtc gaa cca tac 640  
 Ser Val Cys Pro Ser Pro Lys Val Ser Asp Thr Val Val Glu Pro Tyr  
 170 175 180

aat gcc acg ctt tcg gtc cac cag ttg gtc gaa aac gcc gat gaa gtc 688  
 Asn Ala Thr Leu Ser Val His Gln Leu Val Glu Asn Ala Asp Glu Val  
 185 190 195

atg tgt ttg gat aac gag gct ctc tac gat atc tgc ttc cgt acc ctg 736  
 Met Cys Leu Asp Asn Glu Ala Leu Tyr Asp Ile Cys Phe Arg Thr Leu  
 200 205 210 215

aag ttg acg acc cca acg tac ggt gac ttg aac cac ttg gtg tgt gct 784  
 Lys Leu Thr Thr Pro Thr Tyr Gly Asp Leu Asn His Leu Val Cys Ala  
 220 225 230

gcc atg tcc ggt atc acg acg tgc ctg cga ttc cca ggt caa ttg aat 832  
 Ala Met Ser Gly Ile Thr Thr Cys Leu Arg Phe Pro Gly Gln Leu Asn  
 235 240 245

tcg gac ttg cgt aag ctc gcg gtg aac ttg atc ccg ttc cca cgt ctc 880  
 Ser Asp Leu Arg Lys Leu Ala Val Asn Leu Ile Pro Phe Pro Arg Leu  
 250 255 260

Patent 600,466

cac ttc ttc atg att ggt ttc gcg cca ttg acc tcc cgt ggt tcg cag 928  
 His Phe Phe Met Ile Gly Phe Ala Pro Leu Thr Ser Arg Gly Ser Gln  
 265 270 275

cag tac cgt gct ttg acc gtc cca gaa ttg acc cag caa caa ttc gac 976  
 Gln Tyr Arg Ala Leu Thr Val Pro Glu Leu Thr Gln Gln Gln Phe Asp  
 280 285 290 295

gcg aag aac atg atg tgc gcc gcc gat cct cgc cac ggt cgt tat tta 1024  
 Ala Lys Asn Met Met Cys Ala Ala Asp Pro Arg His Gly Arg Tyr Leu  
 300 305 310

act gct gcc tgt atg ttc cgt gcc cgc atg agc acc aag gaa gtc gat 1072  
 Thr Ala Ala Cys Met Phe Arg Gly Arg Met Ser Thr Lys Glu Val Asp  
 315 320 325

gaa caa atg ctc aac gtg cag aac aag aac tcg tcg tac ttt gtg gag 1120  
 Glu Gln Met Leu Asn Val Gln Asn Lys Asn Ser Ser Tyr Phe Val Glu  
 330 335 340

tgg att cca aac aac atc aag gcc agc gtg tgt gat atc cca cca aag 1168  
 Trp Ile Pro Asn Asn Ile Lys Ala Ser Val Cys Asp Ile Pro Pro Lys  
 345 350 355

ggt ctg aag atg agt acc acc ttc gtt ggt aac tcg act gcg atc cag 1216  
 Gly Leu Lys Met Ser Thr Thr Phe Val Gly Asn Ser Thr Ala Ile Gln  
 360 365 370 375

gag atg ttc aag cgt gtg tcg gag cag ttc acg gcc atg ttc cgt cgt 1264  
 Glu Met Phe Lys Arg Val Ser Glu Gln Phe Thr Ala Met Phe Arg Arg  
 380 385 390

aag gct ttc ttg cac tgg tac acg ggt gaa ggt atg gat gag atg gaa 1312  
 Lys Ala Phe Leu His Trp Tyr Thr Gly Glu Gly Met Asp Glu Met Glu  
 395 400 405

ttc acg gaa gcc gag tcg aac atg aac gat ttg gtg tcg gaa tac cag 1360  
 Phe Thr Glu Ala Glu Ser Asn Met Asn Asp Leu Val Ser Glu Tyr Gln  
 410 415 420

cag tac caa gac gcg aca gca gaa gag gaa ggt gaa ttc gac gaa gat 1408  
 Gln Tyr Gln Asp Ala Thr Ala Glu Glu Glu Gly Glu Phe Asp Glu Asp  
 425 430 435

gaa gaa atg gac gaa atg atg tagacgacgc gggcgatata gcgactcctt 1459  
 Glu Glu Met Asp Glu Met Met  
 440 445

tgcagcagcg gttgtggcgg cgctcgagata ttctccaagt accatacaga acgtgtagtg 1519

gactcttcgt attcaactat tactccaata ttagcgaggt agcttcacta cgagcagggc 1579

agttagtcgc ttccgttctg ctccactagg aagagagaga tttctaagtt ttaaaaaaaaa 1639

aaaaaaaaa a 1650

<210> 4  
 <211> 446  
 <212> PRT  
 <213> Pythium ultimum

<400> 4

Met	Arg	Glu	Leu	Val	His	Ile	Gln	Gly	Gly	Gln	Cys	Gly	Asn	Gln	Ile
1				5					10					15	
Gly	Ala	Lys	Phe	Trp	Glu	Val	Ile	Ser	Asp	Glu	His	Gly	Val	Asp	Pro
		20						25					30		
Thr	Gly	Ser	Tyr	His	Gly	Asp	Ser	Asp	Leu	Gln	Leu	Glu	Arg	Ile	Asn
		35					40					45			
Val	Tyr	Tyr	Asn	Glu	Ala	Thr	Gly	Gly	Arg	Tyr	Val	Pro	Arg	Ala	Ile
	50					55					60				
Leu	Met	Asp	Leu	Glu	Pro	Gly	Thr	Met	Asp	Ser	Val	Arg	Ala	Gly	Pro
65					70					75					80
Phe	Gly	Gln	Leu	Phe	Arg	Pro	Asp	Asn	Phe	Val	Phe	Gly	Gln	Pro	Gly
			85						90					95	
Ala	Gly	Asn	Asn	Trp	Ala	Lys	Gly	His	Tyr	Thr	Glu	Gly	Ala	Glu	Leu
			100					105					110		
Ile	Asp	Ser	Val	Leu	Asp	Val	Ala	Arg	Lys	Glu	Ala	Glu	Ser	Cys	Asp
		115					120					125			
Cys	Leu	Gln	Gly	Phe	Gln	Ile	Thr	His	Ser	Leu	Gly	Gly	Gly	Thr	Gly
	130					135					140				
Ser	Gly	Met	Gly	Thr	Leu	Leu	Ile	Ser	Lys	Ile	Arg	Glu	Glu	Tyr	Pro
145					150					155					160
Asp	Arg	Ile	Met	Cys	Thr	Tyr	Ser	Val	Cys	Pro	Ser	Pro	Lys	Val	Ser
			165						170					175	
Asp	Thr	Val	Val	Glu	Pro	Tyr	Asn	Ala	Thr	Leu	Ser	Val	His	Gln	Leu
		180						185					190		
Val	Glu	Asn	Ala	Asp	Glu	Val	Met	Cys	Leu	Asp	Asn	Glu	Ala	Leu	Tyr
		195					200					205			
Asp	Ile	Cys	Phe	Arg	Thr	Leu	Lys	Leu	Thr	Thr	Pro	Thr	Tyr	Gly	Asp
	210					215					220				
Leu	Asn	His	Leu	Val	Cys	Ala	Ala	Met	Ser	Gly	Ile	Thr	Thr	Cys	Leu
225					230					235					240
Arg	Phe	Pro	Gly	Gln	Leu	Asn	Ser	Asp	Leu	Arg	Lys	Leu	Ala	Val	Asn
				245					250					255	



Leu Ile Pro Phe Pro Arg Leu His Phe Phe Met Ile Gly Phe Ala Pro  
 260 265 270  
 Leu Thr Ser Arg Gly Ser Gln Gln Tyr Arg Ala Leu Thr Val Pro Glu  
 275 280 285  
 Leu Thr Gln Gln Gln Phe Asp Ala Lys Asn Met Met Cys Ala Ala Asp  
 290 295 300  
 Pro Arg His Gly Arg Tyr Leu Thr Ala Ala Cys Met Phe Arg Gly Arg  
 305 310 315 320  
 Met Ser Thr Lys Glu Val Asp Glu Gln Met Leu Asn Val Gln Asn Lys  
 325 330 335  
 Asn Ser Ser Tyr Phe Val Glu Trp Ile Pro Asn Asn Ile Lys Ala Ser  
 340 345 350  
 Val Cys Asp Ile Pro Pro Lys Gly Leu Lys Met Ser Thr Thr Phe Val  
 355 360 365  
 Gly Asn Ser Thr Ala Ile Gln Glu Met Phe Lys Arg Val Ser Glu Gln  
 370 375 380  
 Phe Thr Ala Met Phe Arg Arg Lys Ala Phe Leu His Trp Tyr Thr Gly  
 385 390 395 400  
 Glu Gly Met Asp Glu Met Glu Phe Thr Glu Ala Glu Ser Asn Met Asn  
 405 410 415  
 Asp Leu Val Ser Glu Tyr Gln Gln Tyr Gln Asp Ala Thr Ala Glu Glu  
 420 425 430  
 Glu Gly Glu Phe Asp Glu Asp Glu Glu Met Asp Glu Met Met  
 435 440 445

&lt;210&gt; 5

&lt;211&gt; 1350

&lt;212&gt; DNA

<213> *Phytophthora cinnamomi*

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (11)..(1342)

&lt;400&gt; 5

cagcgacaac atg aga gag ctc gtt cac atc cag ggt ggc cag tgc ggt 49  
 Met Arg Glu Leu Val His Ile Gln Gly Gly Gln Cys Gly  
 1 5 10

aac cag atc ggc gcc aag ttc tgg gag gtc gtc tcc gac gag cac ggc 97  
 Asn Gln Ile Gly Ala Lys Phe Trp Glu Val Val Ser Asp Glu His Gly  
 15 20 25

Patent 2504555

gtg gac ccg acg gga tcc tac cac ggc gac tcg gac ctg cag ctg gag	145
Val Asp Pro Thr Gly Ser Tyr His Gly Asp Ser Asp Leu Gln Leu Glu	
30 35 40 45	
cgc atc aac gtg tac tac aac gag gcc acg ggc ggc cgc tac gtg ccc	193
Arg Ile Asn Val Tyr Tyr Asn Glu Ala Thr Gly Gly Arg Tyr Val Pro	
50 55 60	
cgc gcc atc ctc atg gac ctg gag ccc ggc acc atg gac tcg gtg cgc	241
Arg Ala Ile Leu Met Asp Leu Glu Pro Gly Thr Met Asp Ser Val Arg	
65 70 75	
gcc ggc ccc tac ggc cag ctc ttc cgc ccg gac aac ttc gtg ttc ggc	289
Ala Gly Pro Tyr Gly Gln Leu Phe Arg Pro Asp Asn Phe Val Phe Gly	
80 85 90	
cag acg ggc gcc ggt aac aac tgg gcc aag gga cac tac acg gag ggc	337
Gln Thr Gly Ala Gly Asn Asn Trp Ala Lys Gly His Tyr Thr Glu Gly	
95 100 105	
gcc gag ctc atc gac tcg gtg ctc gat gtc gtc cgc aag gag gcg gag	385
Ala Glu Leu Ile Asp Ser Val Leu Asp Val Val Arg Lys Glu Ala Glu	
110 115 120 125	
agc tgc gac tgc ctg cag gga ttc cag atc acg cac tcg ctc ggt ggc	433
Ser Cys Asp Cys Leu Gln Gly Phe Gln Ile Thr His Ser Leu Gly Gly	
130 135 140	
ggt acc ggt tcc ggt atg ggc acg ctt ctt atc tcc aag atc cgt gag	481
Gly Thr Gly Ser Gly Met Gly Thr Leu Leu Ile Ser Lys Ile Arg Glu	
145 150 155	
gag tac ccg gac cgt atc atg tgc acg tac tcg gtg tgc ccg tcg ccc	529
Glu Tyr Pro Asp Arg Ile Met Cys Thr Tyr Ser Val Cys Pro Ser Pro	
160 165 170	
aag gtg tcg gac acg gtc gtg gag ccc tac aac gcg acg ctg tcc gtg	577
Lys Val Ser Asp Thr Val Val Glu Pro Tyr Asn Ala Thr Leu Ser Val	
175 180 185	
cac cag ctt gtc gag aac gcc gat gag gtc atg tgc ctg gat aac gag	625
His Gln Leu Val Glu Asn Ala Asp Glu Val Met Cys Leu Asp Asn Glu	
190 195 200 205	
gcc ctg tac gac att tgc ttc cgc acg ctg aag ctc acg acc ccc acc	673
Ala Leu Tyr Asp Ile Cys Phe Arg Thr Leu Lys Leu Thr Thr Pro Thr	
210 215 220	
tac ggt gac ctg aac cac ctg gtg tgc gcc gcc atg tcc ggc atc acc	721
Tyr Gly Asp Leu Asn His Leu Val Cys Ala Ala Met Ser Gly Ile Thr	
225 230 235	
acg tgc ctg cgt ttc ccc ggc cag ctg aac tcg gac ctg cgt aag ctt	769
Thr Cys Leu Arg Phe Pro Gly Gln Leu Asn Ser Asp Leu Arg Lys Leu	
240 245 250	

gcc gtg aac ctg atc ccg ttc ccg cgt ctg cac ttc ttc atg atc ggc	817
Ala Val Asn Leu Ile Pro Phe Pro Arg Leu His Phe Phe Met Ile Gly	
255 260 265	
ttc gcc ccg ctg acg tcg cgt ggc tcg cag cag tac cgt gcc ctg acg	865
Phe Ala Pro Leu Thr Ser Arg Gly Ser Gln Gln Tyr Arg Ala Leu Thr	
270 275 280 285	
gtg ccc gag ctg acc cag cag cag ttc gat gct aag aac atg atg tgc	913
Val Pro Glu Leu Thr Gln Gln Gln Phe Asp Ala Lys Asn Met Met Cys	
290 295 300	
gcc gct gac cct cgc cac ggc cgc tat tta act gcc gcg tgt atg ttc	961
Ala Ala Asp Pro Arg His Gly Arg Tyr Leu Thr Ala Ala Cys Met Phe	
305 310 315	
cgc gga cgt atg agc acg aag gag gtc gat gag cag atg ctt aac gtg	1009
Arg Gly Arg Met Ser Thr Lys Glu Val Asp Glu Gln Met Leu Asn Val	
320 325 330	
cag aac aag aac tcg tcg tac ttc gtc gag tgg atc ccc aac aac atc	1057
Gln Asn Lys Asn Ser Ser Tyr Phe Val Glu Trp Ile Pro Asn Asn Ile	
335 340 345	
aag gct agc gtg tgt gac atc ccg cct aag ggt ctc aag atg agc acc	1105
Lys Ala Ser Val Cys Asp Ile Pro Pro Lys Gly Leu Lys Met Ser Thr	
350 355 360 365	
acg ttc atc ggc aac tcc act gcc atc cag gag atg ttc aag cgt gtg	1153
Thr Phe Ile Gly Asn Ser Thr Ala Ile Gln Glu Met Phe Lys Arg Val	
370 375 380	
tcc gaa cag ttc acg gct atg ttc cgt cgt aag gct ttc ttg cac tgt	1201
Ser Glu Gln Phe Thr Ala Met Phe Arg Arg Lys Ala Phe Leu His Cys	
385 390 395	
aca cgg ggc gag ggt atg gat gag atg gag ttc acg gag gct gag tcc	1249
Thr Arg Gly Glu Gly Met Asp Glu Met Glu Phe Thr Glu Ala Glu Ser	
400 405 410	
aac atg aac gat ctt gtg tct gag tac cag cag tac cag gac gcc acc	1297
Asn Met Asn Asp Leu Val Ser Glu Tyr Gln Gln Tyr Gln Asp Ala Thr	
415 420 425	
gca gag gag gag ggc gag ttc gac gag gac gag gaa tgg atg aga	1342
Ala Glu Glu Glu Gly Glu Phe Asp Glu Asp Glu Glu Trp Met Arg	
430 435 440	
tagacgcg	1350

<210> 6  
 <211> 444  
 <212> PRT  
 <213> Phytophthora cinnamomi

<400> 6

Met	Arg	Glu	Leu	Val	His	Ile	Gln	Gly	Gly	Gln	Cys	Gly	Asn	Gln	Ile
1				5				10					15		
Gly	Ala	Lys	Phe	Trp	Glu	Val	Val	Ser	Asp	Glu	His	Gly	Val	Asp	Pro
			20					25					30		
Thr	Gly	Ser	Tyr	His	Gly	Asp	Ser	Asp	Leu	Gln	Leu	Glu	Arg	Ile	Asn
		35					40					45			
Val	Tyr	Tyr	Asn	Glu	Ala	Thr	Gly	Gly	Arg	Tyr	Val	Pro	Arg	Ala	Ile
	50					55					60				
Leu	Met	Asp	Leu	Glu	Pro	Gly	Thr	Met	Asp	Ser	Val	Arg	Ala	Gly	Pro
65					70				75						80
Tyr	Gly	Gln	Leu	Phe	Arg	Pro	Asp	Asn	Phe	Val	Phe	Gly	Gln	Thr	Gly
				85					90					95	
Ala	Gly	Asn	Asn	Trp	Ala	Lys	Gly	His	Tyr	Thr	Glu	Gly	Ala	Glu	Leu
			100					105					110		
Ile	Asp	Ser	Val	Leu	Asp	Val	Val	Arg	Lys	Glu	Ala	Glu	Ser	Cys	Asp
		115					120					125			
Cys	Leu	Gln	Gly	Phe	Gln	Ile	Thr	His	Ser	Leu	Gly	Gly	Gly	Thr	Gly
	130					135					140				
Ser	Gly	Met	Gly	Thr	Leu	Leu	Ile	Ser	Lys	Ile	Arg	Glu	Glu	Tyr	Pro
145					150					155					160
Asp	Arg	Ile	Met	Cys	Thr	Tyr	Ser	Val	Cys	Pro	Ser	Pro	Lys	Val	Ser
				165					170					175	
Asp	Thr	Val	Val	Glu	Pro	Tyr	Asn	Ala	Thr	Leu	Ser	Val	His	Gln	Leu
			180					185					190		
Val	Glu	Asn	Ala	Asp	Glu	Val	Met	Cys	Leu	Asp	Asn	Glu	Ala	Leu	Tyr
		195					200					205			
Asp	Ile	Cys	Phe	Arg	Thr	Leu	Lys	Leu	Thr	Thr	Pro	Thr	Tyr	Gly	Asp
	210					215					220				
Leu	Asn	His	Leu	Val	Cys	Ala	Ala	Met	Ser	Gly	Ile	Thr	Thr	Cys	Leu
225					230					235					240
Arg	Phe	Pro	Gly	Gln	Leu	Asn	Ser	Asp	Leu	Arg	Lys	Leu	Ala	Val	Asn
				245					250					255	

Glu Gly Glu Phe Asp Glu Asp Glu Glu Trp Met Arg  
435 440

25

<213> Pestalotiopsis microspora

<220>  
<223> motif conserved in P. ultimum

<400> 8  
Trp Ala Lys Gly His Tyr Thr Glu  
1 5

<210> 9  
<211> 25  
<212> DNA  
<213> Artificial Sequence

<220>  
<221> modified\_base  
<222> (14)  
<223> i

<220>  
<223> Description of Artificial Sequence:reverse primer

<400> 9  
cgaagaartg rarncgrrgg aargg

25

<210> 10  
<211> 8  
<212> PRT  
<213> Pestalotiopsis microspora

<220>  
<223> motif conserved in P. ultimum

<400> 10  
Pro Phe Pro Arg Leu His Phe Phe  
1 5

<210> 11  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:forward primer

<400> 11  
cgagccytac aacgcyacyc t

21

<210> 12  
<211> 7  
<212> PRT  
<213> Pestalotiopsis microspora

<220>

<223> motif conserved in *P. ultimum*

<400> 12

Glu Pro Tyr Asn Ala Thr Leu

1

5

<210> 13

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:reverse primer

<400> 13

ctcgttcacg ttrswctcrg cctc

24

<210> 14

<211> 8

<212> PRT

<213> Pestalotiopsis microspora

<220>

<223> motif conserved in *P. ultimum*

<400> 14

Glu Ala Glu Ser Asn Met Asn Asp

1

5

<210> 15

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:forward primer

<400> 15

gggtgtcacc acttgcttgc gttt

24

<210> 16

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:reverse primer

<400> 16

tcgagtttcc gacgaaagtg gacga

25

<210> 17  
<211> 26  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:forward primer

<400> 17  
ctatcatgtg cacgtactcg gtgtgc

26

<210> 18  
<211> 26  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:reverse primer

<400> 18  
ctgggacggt caaagcacgg tactgc

26

<210> 19  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:forward primer

<400> 19  
cagcgacaac atgagagagc tcg

23

<210> 20  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:forward primer

<400> 20  
cgatgaggtc atgtgcctgg ataa

24

<210> 21  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:reverse primer



&lt;400&gt; 21

aaacggaggc acgtggtgat g

21

&lt;210&gt; 22

&lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:reverse primer

&lt;400&gt; 22

cgcgtctatc tcattccattc ctcg

24

&lt;210&gt; 23

&lt;211&gt; 444

&lt;212&gt; PRT

&lt;213&gt; Phytophthora cinnamomi

&lt;400&gt; 23

Met	Arg	Glu	Leu	Val	His	Ile	Gln	Gly	Gly	Gln	Cys	Gly	Asn	Gln	Ile
1				5				10					15		

Gly	Ala	Lys	Phe	Trp	Glu	Val	Ile	Ser	Asp	Glu	His	Gly	Val	Asp	Pro
	20							25				30			

Thr	Gly	Ser	Tyr	His	Gly	Asp	Ser	Asp	Leu	Gln	Leu	Glu	Arg	Ile	Asn
	35					40					45				

Val	Tyr	Tyr	Asn	Glu	Ala	Thr	Gly	Gly	Arg	Tyr	Val	Pro	Arg	Ala	Ile
50						55					60				

Leu	Met	Asp	Leu	Glu	Pro	Gly	Thr	Met	Asp	Ser	Val	Arg	Ala	Gly	Pro
65					70				75					80	

Tyr	Gly	Gln	Leu	Phe	Arg	Pro	Asp	Asn	Phe	Val	Phe	Gly	Gln	Thr	Gly
			85					90					95		

Ala	Gly	Asn	Asn	Trp	Ala	Lys	Gly	His	Tyr	Thr	Glu	Gly	Ala	Glu	Leu
		100						105					110		

Ile	Asp	Ser	Val	Leu	Asp	Val	Val	Arg	Lys	Glu	Ala	Glu	Ser	Cys	Asp
	115					120						125			

Cys	Leu	Gln	Gly	Phe	Gln	Ile	Thr	His	Ser	Leu	Gly	Gly	Gly	Thr	Gly
130					135						140				

Ser	Gly	Met	Gly	Thr	Leu	Leu	Ile	Ser	Lys	Ile	Arg	Glu	Glu	Tyr	Pro
145					150					155				160	

Asp	Arg	Ile	Met	Cys	Thr	Tyr	Ser	Val	Cys	Pro	Ser	Pro	Lys	Val	Ser
			165						170					175	

Asp Thr Val Val Glu Pro Tyr Asn Ala Thr Leu Ser Val His Gln Leu  
 180 185 190  
 Val Glu Asn Ala Asp Glu Val Met Cys Leu Asp Asn Glu Ala Leu Tyr  
 195 200 205  
 Asp Ile Cys Phe Arg Thr Leu Lys Leu Thr Asn Pro Thr Tyr Gly Asp  
 210 215 220  
 Leu Asn His Leu Val Cys Ala Ala Met Ser Gly Ile Thr Thr Cys Leu  
 225 230 235 240  
 Arg Phe Pro Gly Gln Leu Asn Ser Val Leu Lys Leu Phe Ala Val Asn  
 245 250 255  
 Leu Ile Pro Phe Pro Arg Leu His Phe Phe Met Ile Gly Phe Ala Pro  
 260 265 270  
 Leu Thr Ser Arg Gly Ser Gln Gln Tyr Arg Ala Leu Thr Val Pro Glu  
 275 280 285  
 Leu Thr Gln Gln Gln Phe Asp Ala Lys Asn Met Met Cys Ala Ala Asp  
 290 295 300  
 Pro Arg His Gly Arg Tyr Leu Thr Ala Ala Cys Met Phe Arg Gly Arg  
 305 310 315 320  
 Met Ser Thr Lys Glu Val Asp Glu Gln Met Leu Asn Val Gln Asn Lys  
 325 330 335  
 Asn Ser Ser Tyr Phe Val Glu Trp Ile Pro Asn Asn Ile Lys Ala Ser  
 340 345 350  
 Val Cys Asp Ile Pro Pro Gln Gly Leu Lys Met Ser Thr Thr Phe Ile  
 355 360 365  
 Gly Asn Ser Thr Ala Ile Gln Glu Met Phe Lys Arg Val Ser Glu Gln  
 370 375 380  
 Phe Thr Ala Met Phe Arg Arg Lys Ala Phe Leu His Trp Tyr Thr Gly  
 385 390 395 400  
 Glu Gly Met Asp Glu Met Glu Phe Thr Glu Ala Glu Ser Asn Met Asn  
 405 410 415  
 Asp Leu Val Ser Glu Tyr Gln Gln Tyr Gln Asp Gly Thr Ala Glu Glu  
 420 425 430  
 Glu Gly Glu Phe Asp Glu Asp Glu Glu Trp Met Arg  
 435 440

<400> 24																
Met	Arg	Glu	Ile	Val	His	Leu	Gln	Ala	Gly	Gln	Cys	Gly	Asn	Gln	Ile	
1				5					10					15		
Gly	Lys	Ala	Phe	Trp	Glu	Val	Ile	Ser	Asp	Glu	His	Gly	Ile	Asp	Pro	
			20					25					30			
Thr	Gly	Thr	Tyr	His	Gly	Asp	Ser	Asp	Leu	Gln	Leu	Glu	Arg	Ile	Asn	
		35					40					45				
Val	Tyr	Tyr	Asn	Glu	Ala	Thr	Gly	Gly	Lys	Tyr	Val	Pro	Arg	Ala	Val	
	50					55					60					
Leu	Val	Asp	Leu	Glu	Pro	Gly	Thr	Met	Asp	Ser	Val	Arg	Ser	Gly	Pro	
65					70					75					80	
Phe	Gly	Gln	Ile	Phe	Arg	Pro	Asp	Asn	Phe	Val	Phe	Gly	Gln	Ser	Gly	
				85					90					95		
Ala	Gly	Asn	Asn	Trp	Ala	Lys	Gly	His	Tyr	Thr	Glu	Gly	Ala	Glu	Leu	
			100					105					110			
Val	Asp	Ser	Val	Leu	Asp	Val	Val	Arg	Lys	Glu	Ala	Glu	Ser	Cys	Asp	
		115					120					125				
Cys	Leu	Gln	Gly	Phe	Gln	Leu	Thr	His	Ser	Leu	Gly	Gly	Gly	Thr	Gly	
	130					135					140					
Ser	Gly	Met	Gly	Thr	Leu	Leu	Ile	Ser	Lys	Ile	Arg	Glu	Glu	Tyr	Pro	
145					150					155					160	
Asp	Arg	Ile	Met	Asn	Thr	Phe	Ser	Val	Val	Pro	Ser	Pro	Lys	Val	Ser	
				165					170					175		
Asp	Thr	Val	Val	Glu	Pro	Tyr	Asn	Ala	Thr	Leu	Ser	Val	His	Gln	Leu	
			180					185					190			
Val	Glu	Asn	Thr	Asp	Glu	Thr	Tyr	Cys	Ile	Asp	Asn	Glu	Ala	Leu	Tyr	
		195					200					205				
Asp	Ile	Cys	Phe	Arg	Thr	Leu	Lys	Leu	Thr	Thr	Pro	Thr	Tyr	Gly	Asp	
	210					215					220					
Leu	Asn	His	Leu	Val	Ser	Ala	Thr	Met	Ser	Gly	Val	Thr	Thr	Cys	Leu	
225					230					235					240	
Arg	Phe	Pro	Gly	Gln	Leu	Asn	Ala	Asp	Leu	Arg	Lys	Leu	Ala	Val	Asn	
				245					250					255		

Met Val Pro Phe Pro Arg Leu His Phe Phe Met Pro Gly Phe Ala Pro  
 260 265 270

Leu Thr Ser Arg Gly Ser Gln Gln Tyr Arg Ala Leu Thr Val Pro Glu  
 275 280 285

Leu Thr Gln Gln Met Phe Asp Ala Lys Asn Met Met Ala Ala Cys Asp  
 290 295 300

Pro Arg His Gly Arg Tyr Leu Thr Val Ala Ala Val Phe Arg Gly Arg  
 305 310 315 320

Met Ser Met Lys Glu Val Asp Glu Gln Met Leu Asn Val Gln Asn Lys  
 325 330 335

Asn Ser Ser Tyr Phe Val Glu Trp Ile Pro Asn Asn Val Lys Thr Ala  
 340 345 350

Val Cys Asp Ile Pro Pro Arg Gly Leu Lys Met Ser Ala Thr Phe Ile  
 355 360 365

Gly Asn Ser Thr Ala Ile Gln Glu Leu Phe Lys Arg Ile Ser Glu Gln  
 370 375 380

Phe Thr Ala Met Phe Arg Arg Lys Ala Phe Leu His Trp Tyr Thr Gly  
 385 390 395 400

Glu Gly Met Asp Glu Met Glu Phe Thr Glu Ala Glu Ser Asn Met Asn  
 405 410 415

Asp Leu Val Ser Glu Tyr Gln Gln Tyr Gln Asp Ala Thr Ala Glu Glu  
 420 425 430

Glu Gly Glu Phe Glu Glu Glu Ala Glu Glu Glu Val Ala  
 435 440 445

&lt;210&gt; 25

&lt;211&gt; 447

&lt;212&gt; PRT

&lt;213&gt; Neurospora crassa

&lt;400&gt; 25

Met Arg Glu Ile Val His Leu Gln Thr Gly Gln Cys Gly Asn Gln Ile  
 1 5 10 15

Gly Ala Ala Phe Trp Gln Thr Ile Ser Gly Glu His Gly Leu Asp Ala  
 20 25 30

Ser Gly Val Tyr Asn Gly Thr Ser Glu Leu Gln Leu Glu Arg Met Asn  
 35 40 45

Val Tyr Phe Asn Glu Ala Ser Gly Asn Lys Tyr Val Pro Arg Ala Val  
 50 55 60

Leu 65	Val	Asp	Leu	Glu	Pro 70	Gly	Thr	Met	Asp	Ala 75	Val	Arg	Ala	Gly	Pro 80
Phe	Gly	Gln	Leu	Phe 85	Arg	Pro	Asp	Asn	Phe 90	Val	Phe	Gly	Gln	Ser 95	Gly
Ala	Gly	Asn	Asn 100	Trp	Ala	Lys	Gly	His 105	Tyr	Thr	Glu	Gly	Ala 110	Glu	Leu
Val	Asp	Gln 115	Val	Leu	Asp	Val	Val 120	Arg	Arg	Glu	Ala	Glu 125	Gly	Cys	Asp
Cys 130	Leu	Gln	Gly	Phe	Gln	Ile 135	Thr	His	Ser	Leu	Gly 140	Gly	Gly	Thr	Gly
Ala 145	Gly	Met	Gly	Thr	Leu 150	Leu	Ile	Ser	Lys	Ile 155	Arg	Glu	Glu	Phe	Pro 160
Asp	Arg	Met	Met	Ala 165	Thr	Phe	Ser	Val	Val 170	Pro	Ser	Pro	Lys	Val 175	Ser
Asp	Thr	Val 180	Val	Glu	Pro	Tyr	Asn	Ala 185	Thr	Leu	Ser	Val	His 190	Gln	Leu
Val	Glu	Asn 195	Ser	Asp	Glu	Thr	Phe 200	Cys	Ile	Asp	Asn	Glu 205	Ala	Leu	Tyr
Asp 210	Ile	Cys	Met	Arg	Thr	Leu 215	Lys	Leu	Ser	Asn	Pro 220	Ser	Tyr	Gly	Asp
Leu 225	Asn	His	Leu	Val	Ser 230	Ala	Val	Met	Ser	Gly 235	Val	Thr	Val	Ser	Leu 240
Arg	Phe	Pro	Gly	Gln 245	Leu	Asn	Ser	Asp	Leu 250	Arg	Lys	Leu	Ala	Val 255	Asn
Met	Val	Pro	Phe 260	Pro	Arg	Leu	His	Phe 265	Phe	Met	Val	Gly	Phe 270	Ala	Pro
Leu	Thr	Ser 275	Arg	Gly	Ala	His	His 280	Phe	Arg	Ala	Val	Ser 285	Val	Pro	Glu
Leu 290	Thr	Gln	Gln	Met	Phe	Asp 295	Pro	Lys	Asn	Met	Met 300	Ala	Ala	Ser	Asp
Phe 305	Arg	Asn	Gly	Arg	Tyr 310	Leu	Thr	Cys	Ser	Ala 315	Ile	Phe	Arg	Gly	Lys 320
Val	Ser	Met	Lys	Glu 325	Val	Glu	Asp	Gln	Met 330	Arg	Asn	Val	Gln	Asn 335	Lys
Asn	Ser	Ser	Tyr 340	Phe	Val	Glu	Trp	Ile 345	Pro	Asn	Asn	Val	Gln 350	Thr	Ala

Ala Gly Met Gly Thr Leu Leu Ile Ser Lys Ile Arg Glu Glu Phe Pro  
145 150 155 160

Asp Arg Met Met Ala Thr Phe Ser Val Val Pro Ser Pro Lys Val Ser  
 165 170 175  
 Asp Thr Val Val Glu Pro Tyr Asn Ala Thr Leu Ser Val His Gln Leu  
 180 185 190  
 Val Glu His Ser Asp Glu Thr Phe Cys Ile Asp Asn Glu Ala Leu Tyr  
 195 200 205  
 Asp Ile Cys Met Arg Thr Leu Lys Leu Ser Asn Pro Ser Tyr Gly Asp  
 210 215 220  
 Leu Asn His Leu Val Ser Ala Val Met Ser Gly Val Thr Thr Cys Leu  
 225 230 235 240  
 Arg Phe Pro Gly Gln Leu Asn Ser Asp Leu Arg Lys Trp Ala Val Asn  
 245 250 255  
 Met Val Pro Phe Pro Arg Leu His Phe Phe Met Val Gly Phe Ala Pro  
 260 265 270  
 Leu Thr Ser Arg Gly Ala Tyr Ser Phe Arg Ala Val Ser Val Pro Glu  
 275 280 285  
 Leu Thr Gln Gln Met Phe Asp Pro Lys Asn Met Met Ala Ala Ser Asp  
 290 295 300  
 Phe Arg Asn Gly Arg Tyr Leu Thr Cys Ser Ala Ile Phe Arg Gly Lys  
 305 310 315 320  
 Val Ser Met Lys Glu Val Glu Asp Gln Met Arg Asn Ile Gln Ser Lys  
 325 330 335  
 Asn Gln Ser Tyr Phe Val Glu Trp Ile Pro Asn Asn Ile Gln Ser Ala  
 340 345 350  
 Leu Cys Ser Ile Pro Pro Arg Gly Leu Lys Met Ser Ser Thr Phe Ile  
 355 360 365  
 Gly Asn Ser Thr Ser Ile Gln Glu Leu Phe Lys Arg Val Gly Asp Gln  
 370 375 380  
 Phe Thr Ala Met Phe Arg Arg Lys Ala Phe Leu His Trp Tyr Thr Gly  
 385 390 395 400  
 Glu Gly Met Asp Glu Met Glu Phe Thr Glu Ala Glu Ser Asn Met Asn  
 405 410 415  
 Asp Leu Val Ser Glu Tyr Gln Gln Tyr Gln Asp Ala Ser Ile Ser Glu  
 420 425 430  
 Gly Glu Glu Glu Tyr Ala Glu Glu Glu Ile Met Glu Gly Glu Glu  
 435 440 445

<210> 27  
 <211> 444  
 <212> PRT  
 <213> Achlya klebsiana

<400> 27

Met Arg Glu Leu Val His Ile Gln Gly Gly Gln Cys Gly Asn Gln Ile  
 1 5 10 15

Gly Ala Lys Phe Trp Glu Val Ile Ser Asp Glu His Gly Val Asp Pro  
 20 25 30

Thr Gly Ser Tyr His Gly Asp Ser Asp Leu Gln Leu Glu Arg Ile Asn  
 35 40 45

Val Tyr Tyr Asn Glu Ala Thr Gly Thr Tyr Val Pro Arg Ala Ile Leu  
 50 55 60

Met Asp Leu Glu Pro Gly Thr Met Asp Ser Val Arg Ala Gly Pro Tyr  
 65 70 75 80

Gly Gln Leu Phe Arg Pro Asp Asn Phe Val Phe Gly Gln Thr Gly Ala  
 85 90 95

Gly Asn Asn Trp Ala Lys Gly His Tyr Thr Glu Gly Ala Glu Leu Ile  
 100 105 110

Asp Ser Val Leu Asp Val Val Arg Lys Glu Ala Glu Ser Cys Asp Cys  
 115 120 125

Leu Gln Gly Phe Gln Ile Thr His Ser Leu Gly Gly Gly Thr Gly Ser  
 130 135 140

Gly Met Gly Thr Leu Leu Ile Ser Lys Ile Arg Glu Glu Tyr Pro Asp  
 145 150 155 160

Arg Ile Met Cys Thr Tyr Ser Val Cys Pro Ser Pro Lys Val Ser Asp  
 165 170 175

Thr Val Val Glu Pro Tyr Asn Ala Thr Leu Ser Val His Gln Leu Val  
 180 185 190

Glu Asn Ala Asp Glu Val Met Cys Leu Asp Asn Glu Ala Leu Tyr Asp  
 195 200 205

Ile Cys Phe Arg Thr Leu Lys Leu Thr Asn Pro Thr Tyr Gly Asp Leu  
 210 215 220

Asn His Leu Val Cys Ala Ala Met Ser Gly Ile Thr Thr Leu Leu Arg  
 225 230 235 240

Phe Pro Gly Gln Leu Asn Ser Val Leu Lys Leu Ala Val Asn Leu Ile  
 245 250 255



```
<210> 29
<211> 15
<212> PRT
<213> Pestalotiopsis microspora
```

&lt;220&gt;

&lt;223&gt; motif conserved in P. ultimum, H. sapiens, N. crassa, A. nidulans, and A. klebsiana

&lt;400&gt; 29

Ala Val Leu Val Asp Leu Glu Pro Gly Thr Met Asp Ser Val Arg  
1 5 10 15

&lt;210&gt; 30

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Pestalotiopsis microspora

&lt;220&gt;

&lt;223&gt; motif conserved in P. ultimum, H. sapiens, N. crassa, A. nidulans, and A. klebsiana

&lt;400&gt; 30

Gly Gly Gly Thr Gly Ser Gly  
1 5

&lt;210&gt; 31

&lt;211&gt; 4

&lt;212&gt; PRT

&lt;213&gt; Pestalotiopsis microspora

&lt;220&gt;

&lt;223&gt; motif conserved in P. ultimum, H. sapiens, N. crassa, A. nidulans, and A. klebsiana

&lt;400&gt; 31

Asp Asn Glu Ala  
1

&lt;210&gt; 32

&lt;211&gt; 4

&lt;212&gt; PRT

&lt;213&gt; Pestalotiopsis microspora

&lt;220&gt;

&lt;223&gt; motif conserved in P. ultimum, H. sapiens, N. crassa, A. nidulans and A. klebsiana

&lt;400&gt; 32

Met Arg Glu Ile  
1

&lt;210&gt; 33

&lt;211&gt; 4

&lt;212&gt; PRT

&lt;213&gt; Pestalotiopsis microspora

&lt;220&gt;

<223> motif conserved in P. ultimum, H. sapiens, N.  
crassa, A. nidulans, and A. klebsiana

&lt;400&gt; 33

Met Arg Glu Leu  
1

&lt;210&gt; 34

&lt;211&gt; 31

&lt;212&gt; PRT

&lt;213&gt; Sus scrofa

&lt;400&gt; 34

Met Arg Glu Ile Val His Ile Gln Ala Gly Gln Cys Gly Asn Gln Ile  
1 5 10 15Gly Ala Lys Phe Trp Glu Val Ile Ser Asp Glu His Gly Ile Asp  
20 25 30

&lt;210&gt; 35

&lt;211&gt; 20

&lt;212&gt; PRT

&lt;213&gt; Sus scrofa

&lt;400&gt; 35

Phe Arg Thr Leu Lys Leu Thr Thr Pro Thr Tyr Gly Asp Leu Asn His  
1 5 10 15Leu Val Ser Ala  
20

&lt;210&gt; 36

&lt;211&gt; 31

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 36

Met Arg Glu Ile Val His Leu Gln Ala Gly Gln Cys Gly Asn Gln Ile  
1 5 10 15Gly Ala Lys Phe Trp Glu Val Ile Ser Asp Glu His Gly Ile Asp  
20 25 30

&lt;210&gt; 37

&lt;211&gt; 20

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 37

Phe Arg Thr Leu Lys Leu Thr Thr Pro Thr Tyr Gly Asp Leu Asn His  
1 5 10 15

Leu Val Ser Ala  
20

&lt;210&gt; 38

&lt;211&gt; 31

&lt;212&gt; PRT

&lt;213&gt; Drosophila melanogaster

&lt;400&gt; 38

Met Arg Glu Ile Val His Ile Gln Ala Gly Gln Cys Gly Asn Gln Ile  
1 5 10 15

Gly Ala Lys Phe Trp Glu Ile Ile Ser Asp Glu His Gly Ile Asp  
20 25 30

&lt;210&gt; 39

&lt;211&gt; 20

&lt;212&gt; PRT

&lt;213&gt; Drosophila melanogaster

&lt;400&gt; 39

Phe Arg Thr Leu Lys Leu Thr Thr Pro Thr Tyr Gly Asp Leu Asn His  
1 5 10 15

Leu Val Ser Leu  
20

&lt;210&gt; 40

&lt;211&gt; 31

&lt;212&gt; PRT

&lt;213&gt; Xenopus laevis

&lt;400&gt; 40

Met Arg Glu Ile Val His Leu Gln Ala Gly Gln Cys Gly Asn Gln Ile  
1 5 10 15

Gly Ala Lys Phe Trp Glu Val Ile Ser Asp Glu His Gly Ile Asp  
20 25 30

&lt;210&gt; 41

&lt;211&gt; 20

&lt;212&gt; PRT

&lt;213&gt; Xenopus laevis

&lt;400&gt; 41

Phe Arg Thr Leu Lys Leu Thr Thr Pro Thr Tyr Gly Asp Leu Asn His  
1 5 10 15

Leu Val Ser Ala  
20

<210> 42  
<211> 31  
<212> PRT  
<213> Tetrahymena thermophila

<400> 42  
Met Arg Glu Ile Val His Ile Gln Gly Gly Gln Cys Gly Asn Gln Ile  
1 5 10 15

Gly Ala Lys Phe Trp Glu Val Ile Ser Asp Glu His Gly Ile Asp  
20 25 30

<210> 43  
<211> 20  
<212> PRT  
<213> Tetrahymena thermophila

<400> 43  
Phe Arg Thr Leu Lys Leu Thr Thr Pro Thr Tyr Gly Asp Leu Asn His  
1 5 10 15

Leu Val Ser Ala  
20

<210> 44  
<211> 31  
<212> PRT  
<213> Physarum polycephalum

<400> 44

Met Arg Glu Ile Val His Ile Gln Ala Gly Gln Cys Gly Asn Gln Ile  
1 5 10 15

Gly Ala Lys Phe Trp Glu Val Ile Ser Asp Glu His Gly Ile Asp  
20 25 30

<210> 45  
<211> 20  
<212> PRT  
<213> Physarum polycephalum

<400> 45  
Phe Arg Thr Leu Lys Leu Thr Thr Pro Thr Tyr Gly Asp Leu Asn His  
1 5 10 15

Leu Val Ser Ala  
20

<210> 46  
<211> 31  
<212> PRT  
<213> Pythium ultimum

<400> 46  
Met Arg Glu Leu Val His Ile Gln Gly Gly Gln Cys Gly Asn Gln Ile  
1 5 10 15  
Gly Ala Lys Phe Trp Glu Val Ile Ser Asp Glu His Gly Val Asp  
20 25 30

<210> 47  
<211> 20  
<212> PRT  
<213> Pythium ultimum

<400> 47  
Phe Arg Thr Leu Lys Leu Thr Thr Pro Thr Tyr Gly Asp Leu Asn His  
1 5 10 15  
Leu Val Cys Ala  
20

<210> 48  
<211> 31  
<212> PRT  
<213> Phytophthora cinnamomi

<400> 48  
Met Arg Glu Leu Val His Ile Gln Gly Gly Gln Cys Gly Asn Gln Ile  
1 5 10 15  
Gly Ala Lys Phe Trp Glu Val Val Ser Asp Glu His Gly Val Asp  
20 25 30

<210> 49  
<211> 20  
<212> PRT  
<213> Phytophthora cinnamomi

<400> 49  
Phe Arg Thr Leu Lys Leu Thr Thr Pro Thr Tyr Gly Asp Leu Asn His  
1 5 10 15  
Leu Val Cys Ala  
20

<210> 50  
<211> 31  
<212> PRT  
<213> Achlya klebsiana

Publ. No. WO/99/05689

&lt;400&gt; 50

Met Arg Glu Leu Val His Ile Gln Gly Gly Gln Cys Gly Asn Gln Ile  
1 5 10 15

Gly Ala Lys Phe Trp Glu Val Ile Ser Asp Glu His Gly Val Asp  
20 25 30

&lt;210&gt; 51

&lt;211&gt; 20

&lt;212&gt; PRT

<213> *Achlya klebsiana*

&lt;400&gt; 51

Phe Arg Thr Leu Lys Leu Thr Asn Pro Thr Tyr Gly Asp Leu Asn His  
1 5 10 15

Leu Val Cys Ala  
20

&lt;210&gt; 52

&lt;211&gt; 31

&lt;212&gt; PRT

<213> *Pestalotiopsis microspora*

&lt;400&gt; 52

Met Arg Glu Ile Val His Leu Gln Thr Gly Gln Cys Gly Asn Gln Ile  
1 5 10 15

Gly Ala Ala Phe Trp Gln Thr Ile Ser Gly Glu His Gly Leu Asp  
20 25 30

&lt;210&gt; 53

&lt;211&gt; 20

&lt;212&gt; PRT

<213> *Pestalotiopsis microspora*

&lt;400&gt; 53

Met Arg Thr Leu Lys Leu Ser Asn Pro Ser Tyr Gly Asp Leu Asn His  
1 5 10 15

Leu Val Ser Ala  
20

&lt;210&gt; 54

&lt;211&gt; 31

&lt;212&gt; PRT

<213> *Aspergillus nidulans*

&lt;400&gt; 54

Met Arg Glu Ile Val His Leu Gln Thr Gly Gln Cys Gly Asn Gln Ile  
1 5 10 15

Gly Ala Ala Phe Trp Gln Thr Ile Ser Gly Glu His Gly Leu Asp  
20 25 30

&lt;210&gt; 55

&lt;211&gt; 20

&lt;212&gt; PRT

<213> *Aspergillus nidulans*

&lt;400&gt; 55

Met Arg Thr Leu Lys Leu Ser Asn Pro Ser Tyr Gly Asp Leu Asn His  
1 5 10 15

Leu Val Ser Ala  
20

&lt;210&gt; 56

&lt;211&gt; 31

&lt;212&gt; PRT

<213> *Saccharomyces cerevisiae*

&lt;400&gt; 56

Met Arg Glu Ile Ile His Ile Ser Ala Gly Gln Tyr Gly Asn Gln Ile  
1 5 10 15

Gly Ala Ala Phe Trp Glu Thr Ile Cys Gly Glu His Gly Leu Asp  
20 25 30

&lt;210&gt; 57

&lt;211&gt; 20

&lt;212&gt; PRT

<213> *Saccharomyces cerevisiae*

&lt;400&gt; 57

Gln Arg Thr Leu Lys Leu Asn Gln Pro Ser Tyr Gly Asp Leu Asn Asn  
1 5 10 15

Leu Val Ser Ser  
20

T00001 35025550



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Rajinder S. Sidhu, et al.

For:

**FUNGAL BETA-TUBULIN GENES**

Application Serial No.

Unassigned

Filing Date:

Concurrently herewith

International

Application No.:

PCT/US00/07995

International

Filing Date:

23 March 2000


Assistant Commissioner for Patents

Box PCT

Washington, D.C. 20231

EXPRESS MAIL NO. EL794555629US DATE OF DEPOSIT 19 September 2001  
I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Box PCT, Washington, D.C. 20231 on  
19 September 2001  
(Date of Deposit)

Derrick Gordon  
Name of Depositor



Signature


Date of Signature: 19 September 2001

Dear Sir:

**STATEMENT UNDER WIPO STANDARD ST.25**

This statement is being filed pursuant to the WIPO Standard ST.25 and pursuant to Administrative Instructions, Section 208. Applicants are filing concurrently herewith a Sequence Listing in paper copy and computer readable form. The Sequence Listing has been amended to delete the corporate applicant CYTOCLONAL PHARMACEUTICS, INC. from the applicant list, and the Attorney Docket No. has been amended to reflect the Attorney Docket No. for the national stage application. The undersigned hereby states that the sequence information recorded in computer readable form is identical to the written Sequence Listing furnished in the international patent application as filed and that the Sequence Listing does not go beyond the international application. The undersigned hereby states that the Sequence Listing in paper copy filed concurrently herewith and the sequence listing in computer readable form are the same.

Respectfully submitted,

By: 

Karen L. Knezek  
Registration No. 39,253

KLK\ld

19 September 2001

Sidley Austin Brown &amp; Wood

717 N. Harwood, Suite 3400

Dallas, Texas 75201-6507

(214) 981-3300

## SEQUENCE LISTING

<110> Sidhu, Rajinder S.  
Bollon, Arthur P.  
Mu, Jing-Hong

<120> Fungal Beta-Tubulin Genes

<130> 10365/07304

<140>

<141>

<160> 57

<170> PatentIn Ver. 2.1

<210> 1

<211> 1668

<212> DNA

<213> Pestalotiopsis microspora

<220>

<221> CDS

<222> (75)..(1412)

<400> 1

ccgtcgcagct ctactccaaa gaaggcctct ttgttgcttc ctctcagcct cgacatcttc 60

tacaaaccgc catc atg cgt gag att gtt cac ctc cag acc ggt caa tgc 110  
Met Arg Glu Ile Val His Leu Gln Thr Gly Gln Cys  
1 5 10

ggt aac caa att ggt gct gcc ttc tgg caa acc atc tct ggc gag cac 158  
Gly Asn Gln Ile Gly Ala Ala Phe Trp Gln Thr Ile Ser Gly Glu His  
15 20 25

ggt ctc gac agc aat gga gtc tac aac ggt acc tcc gag ctc cag ctc 206  
Gly Leu Asp Ser Asn Gly Val Tyr Asn Gly Thr Ser Glu Leu Gln Leu  
30 35 40

gag cgc atg agc gtc tac ttc aac gag gct tcc ggc aac aag tac gtt 254  
Glu Arg Met Ser Val Tyr Phe Asn Glu Ala Ser Gly Asn Lys Tyr Val  
45 50 55 60

cct cgt gcc gtc ctc gtc gat ctc gag ccc ggt acc atg gat gcc gtc 302  
Pro Arg Ala Val Leu Val Asp Leu Glu Pro Gly Thr Met Asp Ala Val  
65 70 75

cgc gcc ggt cct ttc ggt cag ctc ttc cgc cct gac aac ttc gtc ttc 350  
Arg Ala Gly Pro Phe Gly Gln Leu Phe Arg Pro Asp Asn Phe Val Phe  
80 85 90

ggt cag tcc ggt gcc gga aac aac tgg gcc aag ggt cac tac act gag 398  
Gly Gln Ser Gly Ala Gly Asn Asn Trp Ala Lys Gly His Tyr Thr Glu  
95 100 105

10365/07304

ggt gcc gag ctc gtc gac cag gtc ctc gac gtt gtc cgt cgc gag gcc	446
Gly Ala Glu Leu Val Asp Gln Val Leu Asp Val Val Arg Arg Glu Ala	
110 115 120	
gag gct tgc gac tgc ctc cag ggt ttc cag atc acc cac tcc ctg ggt	494
Glu Ala Cys Asp Cys Leu Gln Gly Phe Gln Ile Thr His Ser Leu Gly	
125 130 135 140	
ggt ggt acc ggt gcc ggt atg ggt act ctg ttg atc tcc aag atc cgt	542
Gly Gly Thr Gly Ala Gly Met Gly Thr Leu Leu Ile Ser Lys Ile Arg	
145 150 155	
gag gag ttc ccc gac cgc atg atg gcc acc ttc tcc gtc gtg ccc tcc	590
Glu Glu Phe Pro Asp Arg Met Met Ala Thr Phe Ser Val Val Pro Ser	
160 165 170	
ccc aag gtc tcc gac acc gtc gtc gag ccc tac aac gcc acc ctc tcc	638
Pro Lys Val Ser Asp Thr Val Glu Pro Tyr Asn Ala Thr Leu Ser	
175 180 185	
gtc cac cag ctg gtc gag aac tcg gac gag acc ttc tgc att gac aac	686
Val His Gln Leu Val Glu Asn Ser Asp Glu Thr Phe Cys Ile Asp Asn	
190 195 200	
gag gct ctc tac gac atc tgc atg cgc acc ctg aag ctg tcc aac ccc	734
Glu Ala Leu Tyr Asp Ile Cys Met Arg Thr Leu Lys Leu Ser Asn Pro	
205 210 215 220	
tcg tac ggt gac ctg aac cac ctg gtc tcc gcc gtc atg tcg ggt gtc	782
Ser Tyr Gly Asp Leu Asn His Leu Val Ser Ala Val Met Ser Gly Val	
225 230 235	
acc act tgc ttg cgt ttc cct ggt cag ctg aac tct gac ctg cgc aag	830
Thr Thr Cys Leu Arg Phe Pro Gly Gln Leu Asn Ser Asp Leu Arg Lys	
240 245 250	
ctg gcc gtc aac atg gtg ccc ttc cct cgt ctg cac ttc ttc atg gtc	878
Leu Ala Val Asn Met Val Pro Phe Pro Arg Leu His Phe Phe Met Val	
255 260 265	
ggc ttt gct ccc ctg acc agc cgt ggc gcc cac tct ttc cgt gcc gtc	926
Gly Phe Ala Pro Leu Thr Ser Arg Gly Ala His Ser Phe Arg Ala Val	
270 275 280	
acc gtc ccc gag ttg acc cag cag atg ttc gac ccc aag aac atg atg	974
Thr Val Pro Glu Leu Thr Gln Gln Met Phe Asp Pro Lys Asn Met Met	
285 290 295 300	
gct gct tcc gac ttc cgt aac ggt cgc tac ctg acc tgc tct gcc atc	1022
Ala Ala Ser Asp Phe Arg Asn Gly Arg Tyr Leu Thr Cys Ser Ala Ile	
305 310 315	
ttc cgt ggt aag gtc tcc atg aag gag gtc gag gac cag atg cgc aac	1070
Phe Arg Gly Lys Val Ser Met Lys Glu Val Glu Asp Gln Met Arg Asn	
320 325 330	

gtc cag aac aag aac tcg tcc tac ttc gtc gag tgg atc ccc aac aac 1118  
 Val Gln Asn Lys Asn Ser Ser Tyr Phe Val Glu Trp Ile Pro Asn Asn  
 335 340 345  
 gtg cag acc gcc ctc tgc tcc att cct ccc cgc ggc ctt aag atg tcg 1166  
 Val Gln Thr Ala Leu Cys Ser Ile Pro Pro Arg Gly Leu Lys Met Ser  
 350 355 360  
 tcc act ttc gtc gga aac tcg act gct atc cag gag ctg ttc aag cgc 1214  
 Ser Thr Phe Val Gly Asn Ser Thr Ala Ile Gln Glu Leu Phe Lys Arg  
 365 370 375 380  
 atc ggc gag cag ttc act gcc atg ttc cgt cgc aag gct ttc ttg cat 1262  
 Ile Gly Glu Gln Phe Thr Ala Met Phe Arg Arg Lys Ala Phe Leu His  
 385 390 395  
 tgg tac act ggt gag ggt atg gac gag atg gag ttc act gag gcc gag 1310  
 Trp Tyr Thr Gly Glu Gly Met Asp Glu Met Glu Phe Thr Glu Ala Glu  
 400 405 410  
 tcc aac atg aac gac ttg gtc agc gaa tac cag cag tac cag gac gct 1358  
 Ser Asn Met Asn Asp Leu Val Ser Glu Tyr Gln Gln Tyr Gln Asp Ala  
 415 420 425  
 ggt gtc gat gag gag gag gag gag tac gag gag gag cct ctg ccc gag 1406  
 Gly Val Asp Glu Glu Glu Glu Glu Tyr Glu Glu Pro Leu Pro Glu  
 430 435 440  
 gac gag taaacggctc gctagaggct accaaagttg ccaacatgtg gcgtagggct 1462  
 Asp Glu  
 445  
 ggctgacgaa ggcaacttca atggtctact ctgtttcatt ttggcctaata acccctcctc 1522  
 cttttctgtc acagcgaata attttcggtc gcctttctcg cttttcaaaa gaagataggt 1582  
 taggtcactc ctaatagaag tgaagggtgg ccctttgtta gatatacctt ttgggggctga 1642  
 ataaaaaaaa aaaaaaaaaa aaaaaa 1668

&lt;210&gt; 2

&lt;211&gt; 446

&lt;212&gt; PRT

&lt;213&gt; Pestalotiopsis microspora

&lt;400&gt; 2

Met Arg Glu Ile Val His Leu Gln Thr Gly Gln Cys Gly Asn Gln Ile  
 1 5 10 15

Gly Ala Ala Phe Trp Gln Thr Ile Ser Gly Glu His Gly Leu Asp Ser  
 20 25 30

Asn Gly Val Tyr Asn Gly Thr Ser Glu Leu Gln Leu Glu Arg Met Ser  
 35 40 45

Val Tyr Phe Asn Glu Ala Ser Gly Asn Lys Tyr Val Pro Arg Ala Val  
 50 55 60  
 Leu Val Asp Leu Glu Pro Gly Thr Met Asp Ala Val Arg Ala Gly Pro  
 65 70 75 80  
 Phe Gly Gln Leu Phe Arg Pro Asp Asn Phe Val Phe Gly Gln Ser Gly  
 85 90 95  
 Ala Gly Asn Asn Trp Ala Lys Gly His Tyr Thr Glu Gly Ala Glu Leu  
 100 105 110  
 Val Asp Gln Val Leu Asp Val Val Arg Arg Glu Ala Glu Ala Cys Asp  
 115 120 125  
 Cys Leu Gln Gly Phe Gln Ile Thr His Ser Leu Gly Gly Gly Thr Gly  
 130 135 140  
 Ala Gly Met Gly Thr Leu Leu Ile Ser Lys Ile Arg Glu Glu Phe Pro  
 145 150 155 160  
 Asp Arg Met Met Ala Thr Phe Ser Val Val Pro Ser Pro Lys Val Ser  
 165 170 175  
 Asp Thr Val Val Glu Pro Tyr Asn Ala Thr Leu Ser Val His Gln Leu  
 180 185 190  
 Val Glu Asn Ser Asp Glu Thr Phe Cys Ile Asp Asn Glu Ala Leu Tyr  
 195 200 205  
 Asp Ile Cys Met Arg Thr Leu Lys Leu Ser Asn Pro Ser Tyr Gly Asp  
 210 215 220  
 Leu Asn His Leu Val Ser Ala Val Met Ser Gly Val Thr Thr Cys Leu  
 225 230 235 240  
 Arg Phe Pro Gly Gln Leu Asn Ser Asp Leu Arg Lys Leu Ala Val Asn  
 245 250 255  
 Met Val Pro Phe Pro Arg Leu His Phe Phe Met Val Gly Phe Ala Pro  
 260 265 270  
 Leu Thr Ser Arg Gly Ala His Ser Phe Arg Ala Val Thr Val Pro Glu  
 275 280 285  
 Leu Thr Gln Gln Met Phe Asp Pro Lys Asn Met Met Ala Ala Ser Asp  
 290 295 300  
 Phe Arg Asn Gly Arg Tyr Leu Thr Cys Ser Ala Ile Phe Arg Gly Lys  
 305 310 315 320  
 Val Ser Met Lys Glu Val Glu Asp Gln Met Arg Asn Val Gln Asn Lys  
 325 330 335  
 Asn Ser Ser Tyr Phe Val Glu Trp Ile Pro Asn Asn Val Gln Thr Ala  
 340 345 350

10365/07304  
 4  
 Val Tyr Phe Asn Glu Ala Ser Gly Asn Lys Tyr Val Pro Arg Ala Val  
 50 55 60  
 Leu Val Asp Leu Glu Pro Gly Thr Met Asp Ala Val Arg Ala Gly Pro  
 65 70 75 80  
 Phe Gly Gln Leu Phe Arg Pro Asp Asn Phe Val Phe Gly Gln Ser Gly  
 85 90 95  
 Ala Gly Asn Asn Trp Ala Lys Gly His Tyr Thr Glu Gly Ala Glu Leu  
 100 105 110  
 Val Asp Gln Val Leu Asp Val Val Arg Arg Glu Ala Glu Ala Cys Asp  
 115 120 125  
 Cys Leu Gln Gly Phe Gln Ile Thr His Ser Leu Gly Gly Gly Thr Gly  
 130 135 140  
 Ala Gly Met Gly Thr Leu Leu Ile Ser Lys Ile Arg Glu Glu Phe Pro  
 145 150 155 160  
 Asp Arg Met Met Ala Thr Phe Ser Val Val Pro Ser Pro Lys Val Ser  
 165 170 175  
 Asp Thr Val Val Glu Pro Tyr Asn Ala Thr Leu Ser Val His Gln Leu  
 180 185 190  
 Val Glu Asn Ser Asp Glu Thr Phe Cys Ile Asp Asn Glu Ala Leu Tyr  
 195 200 205  
 Asp Ile Cys Met Arg Thr Leu Lys Leu Ser Asn Pro Ser Tyr Gly Asp  
 210 215 220  
 Leu Asn His Leu Val Ser Ala Val Met Ser Gly Val Thr Thr Cys Leu  
 225 230 235 240  
 Arg Phe Pro Gly Gln Leu Asn Ser Asp Leu Arg Lys Leu Ala Val Asn  
 245 250 255  
 Met Val Pro Phe Pro Arg Leu His Phe Phe Met Val Gly Phe Ala Pro  
 260 265 270  
 Leu Thr Ser Arg Gly Ala His Ser Phe Arg Ala Val Thr Val Pro Glu  
 275 280 285  
 Leu Thr Gln Gln Met Phe Asp Pro Lys Asn Met Met Ala Ala Ser Asp  
 290 295 300  
 Phe Arg Asn Gly Arg Tyr Leu Thr Cys Ser Ala Ile Phe Arg Gly Lys  
 305 310 315 320  
 Val Ser Met Lys Glu Val Glu Asp Gln Met Arg Asn Val Gln Asn Lys  
 325 330 335  
 Asn Ser Ser Tyr Phe Val Glu Trp Ile Pro Asn Asn Val Gln Thr Ala  
 340 345 350

Leu Cys Ser Ile Pro Pro Arg Gly Leu Lys Met Ser Ser Thr Phe Val  
355 360 365

Gly Asn Ser Thr Ala Ile Gln Glu Leu Phe Lys Arg Ile Gly Glu Gln  
370 375 380

Phe Thr Ala Met Phe Arg Arg Lys Ala Phe Leu His Trp Tyr Thr Gly  
385 390 395 400

Glu Gly Met Asp Glu Met Glu Phe Thr Glu Ala Glu Ser Asn Met Asn  
405 410 415

Asp Leu Val Ser Glu Tyr Gln Gln Tyr Gln Asp Ala Gly Val Asp Glu  
420 425 430

Glu Glu Glu Glu Tyr Glu Glu Glu Pro Leu Pro Glu Asp Glu  
435 440 445

<210> 3

<211> 1650

<212> DNA

<213> Pythium ultimum

<220>

<221> CDS

<222> (92)..(1429)

<400> 3

ctgggacggt caaagcacgg tactgccagc caccgagccg ccgccgcagg agaagcacc 60

gagttcattc gcagcgaaac agacagacat a atg aga gaa cta gtt cac atc 112  
Met Arg Glu Leu Val His Ile  
1 5

caa ggt ggc cag tgc ggt aac caa att ggc gcc aag ttt tgg gaa gtg 160  
Gln Gly Gly Gln Cys Gly Asn Gln Ile Gly Ala Lys Phe Trp Glu Val  
10 15 20

att tct gat gaa cac ggt gtg gac ccg acg ggt agc tac cat ggt gac 208  
Ile Ser Asp Glu His Gly Val Asp Pro Thr Gly Ser Tyr His Gly Asp  
25 30 35

tcc gac ctg cag ttg gag cgc atc aac gtg tac tac aac gaa gct acg 256  
Ser Asp Leu Gln Leu Glu Arg Ile Asn Val Tyr Tyr Asn Glu Ala Thr  
40 45 50 55

ggc ggt cgt tac gtg cct cgt gcg atc ttg atg gat ttg gag cca ggt 304  
Gly Gly Arg Tyr Val Pro Arg Ala Ile Leu Met Asp Leu Glu Pro Gly  
60 65 70

acc atg gac tcg gtc cgt gcc ggt cca ttc ggt cag ctt ttc cgc cca 352  
Thr Met Asp Ser Val Arg Ala Gly Pro Phe Gly Gln Leu Phe Arg Pro  
75 80 85

10365/07304

gat aac ttc gtc ttc ggc caa ccc ggt gct ggt aac aac tgg gcc aag 400  
Asp Asn Phe Val Phe Gly Gln Pro Gly Ala Gly Asn Asn Trp Ala Lys  
90 95 100

ggt cac tat acg gaa ggc gct gaa ttg atc gac tcg gtc ttg gat gtc 448  
Gly His Tyr Thr Glu Gly Ala Glu Leu Ile Asp Ser Val Leu Asp Val  
105 110 115

gcc cgc aag gaa gct gag agc tgc gat tgc ctg caa ggt ttc cag atc 496  
Ala Arg Lys Glu Ala Glu Ser Cys Asp Cys Leu Gln Gly Phe Gln Ile  
120 125 130 135

acc cac tcc ctc ggt ggt ggt acc ggt tcc ggt atg ggt acg ctt ttg 544  
Thr His Ser Leu Gly Gly Gly Thr Gly Ser Gly Met Gly Thr Leu Leu  
140 145 150

atc tct aag atc cgt gaa gaa tac cca gat cgt atc atg tgc acg tac 592  
Ile Ser Lys Ile Arg Glu Tyr Pro Asp Arg Ile Met Cys Thr Tyr  
155 160 165

tcg gtg tgc cca tcc cca aag gtg tcc gat acc gtc gtc gaa cca tac 640  
Ser Val Cys Pro Ser Pro Lys Val Ser Asp Thr Val Val Glu Pro Tyr  
170 175 180

aat gcc acg ctt tcc gtc cac cag ttg gtc gaa aac gcc gat gaa gtc 688  
Asn Ala Thr Leu Ser Val His Gln Leu Val Glu Asn Ala Asp Glu Val  
185 190 195

atg tgt ttg gat aac gag gct ctc tac gat atc tgc ttc cgt acc ctg 736  
Met Cys Leu Asp Asn Glu Ala Leu Tyr Asp Ile Cys Phe Arg Thr Leu  
200 205 210 215

aag ttg acg acc cca acg tac ggt gac ttg aac cac ttg gtg tgt gct 784  
Lys Leu Thr Thr Pro Thr Tyr Gly Asp Leu Asn His Leu Val Cys Ala  
220 225 230

gcc atg tcc ggt atc acg acg tgc ctg cga ttc cca ggt caa ttg aat 832  
Ala Met Ser Gly Ile Thr Thr Cys Leu Arg Phe Pro Gly Gln Leu Asn  
235 240 245

tcg gac ttg cgt aag ctc gcg gtg aac ttg atc ccg ttc cca cgt ctc 880  
Ser Asp Leu Arg Lys Leu Ala Val Asn Leu Ile Pro Phe Pro Arg Leu  
250 255 260

cac ttc ttc atg att ggt ttc gcg cca ttg acc tcc cgt ggt tcc cag 928  
His Phe Phe Met Ile Gly Phe Ala Pro Leu Thr Ser Arg Gly Ser Gln  
265 270 275

cag tac cgt gct ttg acc gtc cca gaa ttg acc cag caa caa ttc gac 976  
Gln Tyr Arg Ala Leu Thr Val Pro Glu Leu Thr Gln Gln Gln Phe Asp  
280 285 290 295

gcg aag aac atg atg tgc gcc gcc gat cct cgc cac ggt cgt tat tta 1024  
Ala Lys Asn Met Met Cys Ala Ala Asp Pro Arg His Gly Arg Tyr Leu  
300 305 310

act gct gcc tgt atg ttc cgt ggc cgc atg agc acc aag gaa gtc gat 1072  
 Thr Ala Ala Cys Met Phe Arg Gly Arg Met Ser Thr Lys Glu Val Asp  
 315 320 325

gaa caa atg ctc aac gtg cag aac aag aac tcg tcg tac ttt gtg gag 1120  
 Glu Gln Met Leu Asn Val Gln Asn Lys Asn Ser Ser Tyr Phe Val Glu  
 330 335 340

tgg att cca aac aac atc aag gcc agc gtg tgt gat atc cca cca aag 1168  
 Trp Ile Pro Asn Asn Ile Lys Ala Ser Val Cys Asp Ile Pro Pro Lys  
 345 350 355

ggt ctg aag atg agt acc acc ttc gtt ggt aac tcg act gcg atc cag 1216  
 Gly Leu Lys Met Ser Thr Thr Phe Val Gly Asn Ser Thr Ala Ile Gln  
 360 365 370 375

gag atg ttc aag cgt gtg tcg gag cag ttc acg gcc atg ttc cgt cgt 1264  
 Glu Met Phe Lys Arg Val Ser Glu Gln Phe Thr Ala Met Phe Arg Arg  
 380 385 390

aag gct ttc ttg cac tgg tac acg ggt gaa ggt atg gat gag atg gaa 1312  
 Lys Ala Phe Leu His Trp Tyr Thr Gly Glu Gly Met Asp Glu Met Glu  
 395 400 405

ttc acg gaa gcc gag tcg aac atg aac gat ttg gtg tcg gaa tac cag 1360  
 Phe Thr Glu Ala Glu Ser Asn Met Asn Asp Leu Val Ser Glu Tyr Gln  
 410 415 420

cag tac caa gac gcg aca gca gaa gag gaa ggt gaa ttc gac gaa gat 1408  
 Gln Tyr Gln Asp Ala Thr Ala Glu Glu Glu Gly Glu Phe Asp Glu Asp  
 425 430 435

gaa gaa atg gac gaa atg atg tagacgacgc gggcgatata gcgactcctt 1459  
 Glu Glu Met Asp Glu Met Met  
 440 445

tgcagcagcg gttgtggcgg cgtcgagata ttctccaagt accatacaga acgtgtagtg 1519

gactcttcgt attcaactat tactccaata ttagcgaggt agcttcacta cgagcaggcg 1579

agttagtgcg ttccgttctg ctctactgg aagagagaga tttctaagtt ttaaaaaaaaa 1639

aaaaaaaaa a 1650

&lt;210&gt; 4

&lt;211&gt; 446

&lt;212&gt; PRT

&lt;213&gt; Pythium ultimum

&lt;400&gt; 4

Met Arg Glu Leu Val His Ile Gln Gly Gly Gln Cys Gly Asn Gln Ile  
 1 5 10 15

Gly Ala Lys Phe Trp Glu Val Ile Ser Asp Glu His Gly Val Asp Pro  
 20 25 30



Thr Gly Ser Tyr His Gly Asp Ser Asp Leu Gln Leu Glu Arg Ile Asn  
 35 40 45  
 Val Tyr Tyr Asn Glu Ala Thr Gly Gly Arg Tyr Val Pro Arg Ala Ile  
 50 55 60  
 Leu Met Asp Leu Glu Pro Gly Thr Met Asp Ser Val Arg Ala Gly Pro  
 65 70 75 80  
 Phe Gly Gln Leu Phe Arg Pro Asp Asn Phe Val Phe Gly Gln Pro Gly  
 85 90 95  
 Ala Gly Asn Asn Trp Ala Lys Gly His Tyr Thr Glu Gly Ala Glu Leu  
 100 105 110  
 Ile Asp Ser Val Leu Asp Val Ala Arg Lys Glu Ala Glu Ser Cys Asp  
 115 120 125  
 Cys Leu Gln Gly Phe Gln Ile Thr His Ser Leu Gly Gly Gly Thr Gly  
 130 135 140  
 Ser Gly Met Gly Thr Leu Leu Ile Ser Lys Ile Arg Glu Glu Tyr Pro  
 145 150 155 160  
 Asp Arg Ile Met Cys Thr Tyr Ser Val Cys Pro Ser Pro Lys Val Ser  
 165 170 175  
 Asp Thr Val Val Glu Pro Tyr Asn Ala Thr Leu Ser Val His Gln Leu  
 180 185 190  
 Val Glu Asn Ala Asp Glu Val Met Cys Leu Asp Asn Glu Ala Leu Tyr  
 195 200 205  
 Asp Ile Cys Phe Arg Thr Leu Lys Leu Thr Thr Pro Thr Tyr Gly Asp  
 210 215 220  
 Leu Asn His Leu Val Cys Ala Ala Met Ser Gly Ile Thr Thr Cys Leu  
 225 230 235 240  
 Arg Phe Pro Gly Gln Leu Asn Ser Asp Leu Arg Lys Leu Ala Val Asn  
 245 250 255  
 Leu Ile Pro Phe Pro Arg Leu His Phe Phe Met Ile Gly Phe Ala Pro  
 260 265 270  
 Leu Thr Ser Arg Gly Ser Gln Gln Tyr Arg Ala Leu Thr Val Pro Glu  
 275 280 285  
 Leu Thr Gln Gln Gln Phe Asp Ala Lys Asn Met Met Cys Ala Ala Asp  
 290 295 300  
 Pro Arg His Gly Arg Tyr Leu Thr Ala Ala Cys Met Phe Arg Gly Arg  
 305 310 315 320  
 Met Ser Thr Lys Glu Val Asp Glu Gln Met Leu Asn Val Gln Asn Lys  
 325 330 335

Asn Ser Ser Tyr Phe Val Glu Trp Ile Pro Asn Asn Ile Lys Ala Ser  
340 345 350

Val Cys Asp Ile Pro Pro Lys Gly Leu Lys Met Ser Thr Thr Phe Val  
355 360 365

Gly Asn Ser Thr Ala Ile Gln Glu Met Phe Lys Arg Val Ser Glu Gln  
370 375 380

Phe Thr Ala Met Phe Arg Arg Lys Ala Phe Leu His Trp Tyr Thr Gly  
385 390 395 400

Glu Gly Met Asp Glu Met Glu Phe Thr Glu Ala Glu Ser Asn Met Asn  
405 410 415

Asp Leu Val Ser Glu Tyr Gln Gln Tyr Gln Asp Ala Thr Ala Glu Glu  
420 425 430

Glu Gly Glu Phe Asp Glu Asp Glu Glu Met Asp Glu Met Met  
435 440 445

<210> 5

<211> 1350

<212> DNA

<213> *Phytophthora cinnamomi*

<220>

<221> CDS

<222> (11)..(1342)

<400> 5

cagcgacaac atg aga gag ctc gtt cac atc cag ggt ggc cag tgc ggt 49  
Met Arg Glu Leu Val His Ile Gln Gly Gly Gln Cys Gly  
1 5 10

aac cag atc ggc gcc aag ttc tgg gag gtc gtc tcc gac gag cac ggc 97  
Asn Gln Ile Gly Ala Lys Phe Trp Glu Val Val Ser Asp Glu His Gly  
15 20 25

gtg gac ccg acg gga tcc tac cac ggc gac tcg gac ctg cag ctg gag 145  
Val Asp Pro Thr Gly Ser Tyr His Gly Asp Ser Asp Leu Gln Leu Glu  
30 35 40 45

cgc atc aac gtg tac tac aac gag gcc acg ggc ggc cgc tac gtg ccc 193  
Arg Ile Asn Val Tyr Tyr Asn Glu Ala Thr Gly Gly Arg Tyr Val Pro  
50 55 60

cgc gcc atc ctc atg gac ctg gag ccc ggc acc atg gac tcg gtg cgc 241  
Arg Ala Ile Leu Met Asp Leu Glu Pro Gly Thr Met Asp Ser Val Arg  
65 70 75

gcc gcc ccc tac gcc cag ctc ttc cgc ccg gac aac ttc gtg ttc gcc 289  
Ala Gly Pro Tyr Gly Gln Leu Phe Arg Pro Asp Asn Phe Val Phe Gly  
80 85 90

Phytophthora cinnamomi

cag	acg	ggc	gcc	ggg	aac	aac	tgg	gcc	aag	gga	cac	tac	acg	gag	ggc	337
Gln	Thr	Gly	Ala	Gly	Asn	Asn	Trp	Ala	Lys	Gly	His	Tyr	Thr	Glu	Gly	
95100105																
gcc	gag	ctc	atc	gac	tcg	gtg	ctc	gat	gtc	gtc	cgc	aag	gag	gcg	gag	385
Ala	Glu	Leu	Ile	Asp	Ser	Val	Leu	Asp	Val	Val	Arg	Lys	Glu	Ala	Glu	
110115120125																
agc	tgc	gac	tgc	ctg	cag	gga	ttc	cag	atc	acg	cac	tcg	ctc	ggt	ggc	433
Ser	Cys	Asp	Cys	Leu	Gln	Gly	Phe	Gln	Ile	Thr	His	Ser	Leu	Gly	Gly	
130135140																
ggt	acc	ggt	tcc	ggg	atg	ggc	acg	ctt	ctt	atc	tcc	aag	atc	cgt	gag	481
Gly	Thr	Gly	Ser	Gly	Met	Gly	Thr	Leu	Leu	Ile	Ser	Lys	Ile	Arg	Glu	
145150155																
gag	tac	cgc	gac	cgt	atc	atg	tgc	acg	tac	tgc	gtg	tgc	cgc	tgc	ccc	529
Glu	Tyr	Pro	Asp	Arg	Ile	Met	Cys	Thr	Tyr	Ser	Val	Cys	Pro	Ser	Pro	
160165170																
aag	gtg	tgc	gac	acg	gtc	gtg	gag	ccc	tac	aac	gcg	acg	ctg	tcc	gtg	577
Lys	Val	Ser	Asp	Thr	Val	Val	Glu	Pro	Tyr	Asn	Ala	Thr	Leu	Ser	Val	
175180185																
cac	cag	ctt	gtc	gag	aac	gcc	gat	gag	gtc	atg	tgc	ctg	gat	aac	gag	625
His	Gln	Leu	Val	Glu	Asn	Ala	Asp	Glu	Val	Met	Cys	Leu	Asp	Asn	Glu	
190195200205																
gcc	ctg	tac	gac	att	tgc	ttc	cgc	acg	ctg	aag	ctc	acg	acc	ccc	acc	673
Ala	Leu	Tyr	Asp	Ile	Cys	Phe	Arg	Thr	Leu	Lys	Leu	Thr	Thr	Pro	Thr	
210215220																
tac	ggt	gac	ctg	aac	cac	ctg	gtg	tgc	gcc	gcc	atg	tcc	ggc	atc	acc	721
Tyr	Gly	Asp	Leu	Asn	His	Leu	Val	Cys	Ala	Ala	Met	Ser	Gly	Ile	Thr	
225230235																
acg	tgc	ctg	cgt	ttc	ccc	ggc	cag	ctg	aac	tgc	gac	ctg	cgt	aag	ctt	769
Thr	Cys	Leu	Arg	Phe	Pro	Gly	Gln	Leu	Asn	Ser	Asp	Leu	Arg	Lys	Leu	
240245250																
gcc	gtg	aac	ctg	atc	ccg	ttc	ccg	cgt	ctg	cac	ttc	ttc	atg	atc	ggc	817
Ala	Val	Asn	Leu	Ile	Pro	Phe	Pro	Arg	Leu	His	Phe	Phe	Met	Ile	Gly	
255260265																
ttc	gcc	cgc	ctg	acg	tcg	cgt	ggc	tcg	cag	cag	tac	cgt	gcc	ctg	acg	865
Phe	Ala	Pro	Leu	Thr	Ser	Arg	Gly	Ser	Gln	Gln	Tyr	Arg	Ala	Leu	Thr	
270275280285																
gtg	ccc	gag	ctg	acc	cag	cag	cag	ttc	gat	gct	aag	aac	atg	atg	tgc	913
Val	Pro	Glu	Leu	Thr	Gln	Gln	Gln	Phe	Asp	Ala	Lys	Asn	Met	Met	Cys	
290295300																
gcc	gct	gac	cct	cgc	cac	ggc	cgc	tat	tta	act	gcc	gcg	tgt	atg	ttc	961
Ala	Ala	Asp	Pro	Arg	His	Gly	Arg	Tyr	Leu	Thr	Ala	Ala	Cys	Met	Phe	
305310315																

cgc gga cgt atg agc acg aag gag gtc gat gag cag atg ctt aac gtg 1009  
 Arg Gly Arg Met Ser Thr Lys Glu Val Asp Glu Gln Met Leu Asn Val  
 320 325 330

cag aac aag aac tcg tcg tac ttc gtc gag tgg atc ccc aac aac atc 1057  
 Gln Asn Lys Asn Ser Ser Tyr Phe Val Glu Trp Ile Pro Asn Asn Ile  
 335 340 345

aag gct agc gtg tgt gac atc ccg cct aag ggt ctc aag atg agc acc 1105  
 Lys Ala Ser Val Cys Asp Ile Pro Pro Lys Gly Leu Lys Met Ser Thr  
 350 355 360 365

acg ttc atc ggc aac tcc act gcc atc cag gag atg ttc aag cgt gtg 1153  
 Thr Phe Ile Gly Asn Ser Thr Ala Ile Gln Glu Met Phe Lys Arg Val  
 370 375 380

tcc gaa cag ttc acg gct atg ttc cgt cgt aag gct ttc ttg cac tgt 1201  
 Ser Glu Gln Phe Thr Ala Met Phe Arg Arg Lys Ala Phe Leu His Cys  
 385 390 395

aca cgg ggc gag ggt atg gat gag atg gag ttc acg gag gct gag tcc 1249  
 Thr Arg Gly Glu Gly Met Asp Glu Met Glu Phe Thr Glu Ala Glu Ser  
 400 405 410

aac atg aac gat ctt gtg tct gag tac cag cag tac cag gac gcc acc 1297  
 Asn Met Asn Asp Leu Val Ser Glu Tyr Gln Gln Tyr Gln Asp Ala Thr  
 415 420 425

gca gag gag gag ggc gag ttc gac gag gac gag gaa tgg atg aga 1342  
 Ala Glu Glu Glu Gly Glu Phe Asp Glu Asp Glu Glu Trp Met Arg  
 430 435 440

tagacgcg 1350

&lt;210&gt; 6

&lt;211&gt; 444

&lt;212&gt; PRT

<213> *Phytophthora cinnamomi*

&lt;400&gt; 6

Met Arg Glu Leu Val His Ile Gln Gly Gly Gln Cys Gly Asn Gln Ile  
 1 5 10 15

Gly Ala Lys Phe Trp Glu Val Val Ser Asp Glu His Gly Val Asp Pro  
 20 25 30

Thr Gly Ser Tyr His Gly Asp Ser Asp Leu Gln Leu Glu Arg Ile Asn  
 35 40 45

Val Tyr Tyr Asn Glu Ala Thr Gly Gly Arg Tyr Val Pro Arg Ala Ile  
 50 55 60

Leu Met Asp Leu Glu Pro Gly Thr Met Asp Ser Val Arg Ala Gly Pro  
 65 70 75 80

## 12

Tyr Gly Gln Leu Phe Arg Pro Asp Asn Phe Val Phe Gly Gln Thr Gly  
 85 90 95  
 Ala Gly Asn Asn Trp Ala Lys Gly His Tyr Thr Glu Gly Ala Glu Leu  
 100 105 110  
 Ile Asp Ser Val Leu Asp Val Val Arg Lys Glu Ala Glu Ser Cys Asp  
 115 120 125  
 Cys Leu Gln Gly Phe Gln Ile Thr His Ser Leu Gly Gly Gly Thr Gly  
 130 135 140  
 Ser Gly Met Gly Thr Leu Leu Ile Ser Lys Ile Arg Glu Glu Tyr Pro  
 145 150 155 160  
 Asp Arg Ile Met Cys Thr Tyr Ser Val Cys Pro Ser Pro Lys Val Ser  
 165 170 175  
 Asp Thr Val Val Glu Pro Tyr Asn Ala Thr Leu Ser Val His Gln Leu  
 180 185 190  
 Val Glu Asn Ala Asp Glu Val Met Cys Leu Asp Asn Glu Ala Leu Tyr  
 195 200 205  
 Asp Ile Cys Phe Arg Thr Leu Lys Leu Thr Thr Pro Thr Tyr Gly Asp  
 210 215 220  
 Leu Asn His Leu Val Cys Ala Ala Met Ser Gly Ile Thr Thr Cys Leu  
 225 230 235 240  
 Arg Phe Pro Gly Gln Leu Asn Ser Asp Leu Arg Lys Leu Ala Val Asn  
 245 250 255  
 Leu Ile Pro Phe Pro Arg Leu His Phe Phe Met Ile Gly Phe Ala Pro  
 260 265 270  
 Leu Thr Ser Arg Gly Ser Gln Gln Tyr Arg Ala Leu Thr Val Pro Glu  
 275 280 285  
 Leu Thr Gln Gln Gln Phe Asp Ala Lys Asn Met Met Cys Ala Ala Asp  
 290 295 300  
 Pro Arg His Gly Arg Tyr Leu Thr Ala Ala Cys Met Phe Arg Gly Arg  
 305 310 315 320  
 Met Ser Thr Lys Glu Val Asp Glu Gln Met Leu Asn Val Gln Asn Lys  
 325 330 335  
 Asn Ser Ser Tyr Phe Val Glu Trp Ile Pro Asn Asn Ile Lys Ala Ser  
 340 345 350  
 Val Cys Asp Ile Pro Pro Lys Gly Leu Lys Met Ser Thr Thr Phe Ile  
 355 360 365  
 Gly Asn Ser Thr Ala Ile Gln Glu Met Phe Lys Arg Val Ser Glu Gln  
 370 375 380

## 13

Phe Thr Ala Met Phe Arg Arg Lys Ala Phe Leu His Cys Thr Arg Gly  
 385 390 395 400  
 Glu Gly Met Asp Glu Met Glu Phe Thr Glu Ala Glu Ser Asn Met Asn  
 405 410 415  
 Asp Leu Val Ser Glu Tyr Gln Gln Tyr Gln Asp Ala Thr Ala Glu Glu  
 420 425 430  
 Glu Gly Glu Phe Asp Glu Asp Glu Glu Trp Met Arg  
 435 440

<210> 7  
 <211> 25  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:forward  
 degenerate primer

<400> 7  
 ctgggcyaag ggycaytaca cygag

25

<210> 8  
 <211> 8  
 <212> PRT  
 <213> Pestalotiopsis microspora

<220>  
 <223> motif conserved in P. ultimum

<400> 8  
 Trp Ala Lys Gly His Tyr Thr Glu  
 1 5

<210> 9  
 <211> 25  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <221> modified\_base  
 <222> (14)  
 <223> i

<220>  
 <223> Description of Artificial Sequence:reverse primer

<400> 9  
 cgaagaartg rarncgrggg aargg

25

<210> 10  
<211> 8  
<212> PRT  
<213> Pestalotiopsis microspora

<220>  
<223> motif conserved in P. ultimum

<400> 10  
Pro Phe Pro Arg Leu His Phe Phe  
1 5

<210> 11  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:forward primer

<400> 11  
cgagccytac aacgcyacyc t

21

<210> 12  
<211> 7  
<212> PRT  
<213> Pestalotiopsis microspora

<220>  
<223> motif conserved in P. ultimum

<400> 12  
Glu Pro Tyr Asn Ala Thr Leu  
1 5

<210> 13  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:reverse primer

<400> 13  
ctcgttcatg ttrswctcrg cctc

24

<210> 14  
<211> 8  
<212> PRT  
<213> Pestalotiopsis microspora

<220>  
<223> motif conserved in P. ultimum

<400> 14

Glu Ala Glu Ser Asn Met Asn Asp

1

5

<210> 15

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:forward primer

<400> 15

gggtgtcacc acttgcttgc gttt

24

<210> 16

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:reverse primer

<400> 16

tcgagtttcc gacgaaagtg gacga

25

<210> 17

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:forward primer

<400> 17

ctatcatgtg cacgtactcg gtgtgc

26

<210> 18

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:reverse primer

<400> 18

ctgggacggt caaagcacgg tactgc

26

<210> 19

<211> 23

<212> DNA



<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:forward primer

<400> 19

cagcgacaac atgagagagc tcg

23

<210> 20

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:forward primer

<400> 20

cgatgaggtc atgtgcctgg ataa

24

<210> 21

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:reverse primer

<400> 21

aaacggaggc acgtggtgat g

21

<210> 22

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:reverse primer

<400> 22

cgcgtctatc tcatccattc ctcg

24

<210> 23

<211> 444

<212> PRT

<213> Phytophthora cinnamomi

<400> 23

Met Arg Glu Leu Val His Ile Gln Gly Gly Gln Cys Gly Asn Gln Ile  
1 5 10 15

Gly Ala Lys Phe Trp Glu Val Ile Ser Asp Glu His Gly Val Asp Pro  
20 25 30

Thr Gly Ser Tyr His Gly Asp Ser Asp Leu Gln Leu Glu Arg Ile Asn  
 35 40 45  
 Val Tyr Tyr Asn Glu Ala Thr Gly Gly Arg Tyr Val Pro Arg Ala Ile  
 50 55 60  
 Leu Met Asp Leu Glu Pro Gly Thr Met Asp Ser Val Arg Ala Gly Pro  
 65 70 75 80  
 Tyr Gly Gln Leu Phe Arg Pro Asp Asn Phe Val Phe Gly Gln Thr Gly  
 85 90 95  
 Ala Gly Asn Asn Trp Ala Lys Gly His Tyr Thr Glu Gly Ala Glu Leu  
 100 105 110  
 Ile Asp Ser Val Leu Asp Val Val Arg Lys Glu Ala Glu Ser Cys Asp  
 115 120 125  
 Cys Leu Gln Gly Phe Gln Ile Thr His Ser Leu Gly Gly Gly Thr Gly  
 130 135 140  
 Ser Gly Met Gly Thr Leu Leu Ile Ser Lys Ile Arg Glu Glu Tyr Pro  
 145 150 155 160  
 Asp Arg Ile Met Cys Thr Tyr Ser Val Cys Pro Ser Pro Lys Val Ser  
 165 170 175  
 Asp Thr Val Val Glu Pro Tyr Asn Ala Thr Leu Ser Val His Gln Leu  
 180 185 190  
 Val Glu Asn Ala Asp Glu Val Met Cys Leu Asp Asn Glu Ala Leu Tyr  
 195 200 205  
 Asp Ile Cys Phe Arg Thr Leu Lys Leu Thr Asn Pro Thr Tyr Gly Asp  
 210 215 220  
 Leu Asn His Leu Val Cys Ala Ala Met Ser Gly Ile Thr Thr Cys Leu  
 225 230 235 240  
 Arg Phe Pro Gly Gln Leu Asn Ser Val Leu Lys Leu Phe Ala Val Asn  
 245 250 255  
 Leu Ile Pro Phe Pro Arg Leu His Phe Phe Met Ile Gly Phe Ala Pro  
 260 265 270  
 Leu Thr Ser Arg Gly Ser Gln Gln Tyr Arg Ala Leu Thr Val Pro Glu  
 275 280 285  
 Leu Thr Gln Gln Gln Phe Asp Ala Lys Asn Met Met Cys Ala Ala Asp  
 290 295 300  
 Pro Arg His Gly Arg Tyr Leu Thr Ala Ala Cys Met Phe Arg Gly Arg  
 305 310 315 320  
 Met Ser Thr Lys Glu Val Asp Glu Gln Met Leu Asn Val Gln Asn Lys  
 325 330 335

Asn Ser Ser Tyr Phe Val Glu Trp Ile Pro Asn Asn Ile Lys Ala Ser  
340 345 350

Val Cys Asp Ile Pro Pro Gln Gly Leu Lys Met Ser Thr Thr Phe Ile  
355 360 365

Gly Asn Ser Thr Ala Ile Gln Glu Met Phe Lys Arg Val Ser Glu Gln  
370 375 380

Phe Thr Ala Met Phe Arg Arg Lys Ala Phe Leu His Trp Tyr Thr Gly  
385 390 395 400

Glu Gly Met Asp Glu Met Glu Phe Thr Glu Ala Glu Ser Asn Met Asn  
405 410 415

Asp Leu Val Ser Glu Tyr Gln Gln Tyr Gln Asp Gly Thr Ala Glu Glu  
420 425 430

Glu Gly Glu Phe Asp Glu Asp Glu Glu Trp Met Arg  
435 440

<210> 24

<211> 445

<212> PRT

<213> Homo sapiens

<400> 24

Met Arg Glu Ile Val His Leu Gln Ala Gly Gln Cys Gly Asn Gln Ile  
1 5 10 15

Gly Lys Ala Phe Trp Glu Val Ile Ser Asp Glu His Gly Ile Asp Pro  
20 25 30

Thr Gly Thr Tyr His Gly Asp Ser Asp Leu Gln Leu Glu Arg Ile Asn  
35 40 45

Val Tyr Tyr Asn Glu Ala Thr Gly Gly Lys Tyr Val Pro Arg Ala Val  
50 55 60

Leu Val Asp Leu Glu Pro Gly Thr Met Asp Ser Val Arg Ser Gly Pro  
65 70 75 80

Phe Gly Gln Ile Phe Arg Pro Asp Asn Phe Val Phe Gly Gln Ser Gly  
85 90 95

Ala Gly Asn Asn Trp Ala Lys Gly His Tyr Thr Glu Gly Ala Glu Leu  
100 105 110

Val Asp Ser Val Leu Asp Val Val Arg Lys Glu Ala Glu Ser Cys Asp  
115 120 125

Cys Leu Gln Gly Phe Gln Leu Thr His Ser Leu Gly Gly Gly Thr Gly  
130 135 140

Ser Gly Met Gly Thr Leu Leu Ile Ser Lys Ile Arg Glu Glu Tyr Pro  
145 150 155 160

Asp Arg Ile Met Asn Thr Phe Ser Val Val Pro Ser Pro Lys Val Ser  
 165 170 175  
 Asp Thr Val Val Glu Pro Tyr Asn Ala Thr Leu Ser Val His Gln Leu  
 180 185 190  
 Val Glu Asn Thr Asp Glu Thr Tyr Cys Ile Asp Asn Glu Ala Leu Tyr  
 195 200 205  
 Asp Ile Cys Phe Arg Thr Leu Lys Leu Thr Thr Pro Thr Tyr Gly Asp  
 210 215 220  
 Leu Asn His Leu Val Ser Ala Thr Met Ser Gly Val Thr Thr Cys Leu  
 225 230 235 240  
 Arg Phe Pro Gly Gln Leu Asn Ala Asp Leu Arg Lys Leu Ala Val Asn  
 245 250 255  
 Met Val Pro Phe Pro Arg Leu His Phe Phe Met Pro Gly Phe Ala Pro  
 260 265 270  
 Leu Thr Ser Arg Gly Ser Gln Gln Tyr Arg Ala Leu Thr Val Pro Glu  
 275 280 285  
 Leu Thr Gln Gln Met Phe Asp Ala Lys Asn Met Met Ala Ala Cys Asp  
 290 295 300  
 Pro Arg His Gly Arg Tyr Leu Thr Val Ala Ala Val Phe Arg Gly Arg  
 305 310 315 320  
 Met Ser Met Lys Glu Val Asp Glu Gln Met Leu Asn Val Gln Asn Lys  
 325 330 335  
 Asn Ser Ser Tyr Phe Val Glu Trp Ile Pro Asn Asn Val Lys Thr Ala  
 340 345 350  
 Val Cys Asp Ile Pro Pro Arg Gly Leu Lys Met Ser Ala Thr Phe Ile  
 355 360 365  
 Gly Asn Ser Thr Ala Ile Gln Glu Leu Phe Lys Arg Ile Ser Glu Gln  
 370 375 380  
 Phe Thr Ala Met Phe Arg Arg Lys Ala Phe Leu His Trp Tyr Thr Gly  
 385 390 395 400  
 Glu Gly Met Asp Glu Met Glu Phe Thr Glu Ala Glu Ser Asn Met Asn  
 405 410 415  
 Asp Leu Val Ser Glu Tyr Gln Gln Tyr Gln Asp Ala Thr Ala Glu Glu  
 420 425 430  
 Glu Gly Glu Phe Glu Glu Glu Ala Glu Glu Glu Val Ala  
 435 440 445

&lt;210&gt; 25

&lt;211&gt; 447

&lt;212&gt; PRT

&lt;213&gt; Neurospora crassa

&lt;400&gt; 25

Met Arg Glu Ile Val His Leu Gln Thr Gly Gln Cys Gly Asn Gln Ile  
 1 5 10 15

Gly Ala Ala Phe Trp Gln Thr Ile Ser Gly Glu His Gly Leu Asp Ala  
 20 25 30

Ser Gly Val Tyr Asn Gly Thr Ser Glu Leu Gln Leu Glu Arg Met Asn  
 35 40 45

Val Tyr Phe Asn Glu Ala Ser Gly Asn Lys Tyr Val Pro Arg Ala Val  
 50 55 60

Leu Val Asp Leu Glu Pro Gly Thr Met Asp Ala Val Arg Ala Gly Pro  
 65 70 75 80

Phe Gly Gln Leu Phe Arg Pro Asp Asn Phe Val Phe Gly Gln Ser Gly  
 85 90 95

Ala Gly Asn Asn Trp Ala Lys Gly His Tyr Thr Glu Gly Ala Glu Leu  
 100 105 110

Val Asp Gln Val Leu Asp Val Val Arg Arg Glu Ala Glu Gly Cys Asp  
 115 120 125

Cys Leu Gln Gly Phe Gln Ile Thr His Ser Leu Gly Gly Gly Thr Gly  
 130 135 140

Ala Gly Met Gly Thr Leu Leu Ile Ser Lys Ile Arg Glu Glu Phe Pro  
 145 150 155 160

Asp Arg Met Met Ala Thr Phe Ser Val Val Pro Ser Pro Lys Val Ser  
 165 170 175

Asp Thr Val Val Glu Pro Tyr Asn Ala Thr Leu Ser Val His Gln Leu  
 180 185 190

Val Glu Asn Ser Asp Glu Thr Phe Cys Ile Asp Asn Glu Ala Leu Tyr  
 195 200 205

Asp Ile Cys Met Arg Thr Leu Lys Leu Ser Asn Pro Ser Tyr Gly Asp  
 210 215 220

Leu Asn His Leu Val Ser Ala Val Met Ser Gly Val Thr Val Ser Leu  
 225 230 235 240

Arg Phe Pro Gly Gln Leu Asn Ser Asp Leu Arg Lys Leu Ala Val Asn  
 245 250 255

Met Val Pro Phe Pro Arg Leu His Phe Phe Met Val Gly Phe Ala Pro  
 260 265 270

10365/07304

Leu Thr Ser Arg Gly Ala His His Phe Arg Ala Val Ser Val Pro Glu  
275 280 285

Leu Thr Gln Gln Met Phe Asp Pro Lys Asn Met Met Ala Ala Ser Asp  
290 295 300

Phe Arg Asn Gly Arg Tyr Leu Thr Cys Ser Ala Ile Phe Arg Gly Lys  
305 310 315 320

Val Ser Met Lys Glu Val Glu Asp Gln Met Arg Asn Val Gln Asn Lys  
325 330 335

Asn Ser Ser Tyr Phe Val Glu Trp Ile Pro Asn Asn Val Gln Thr Ala  
340 345 350

Leu Cys Ser Ile Pro Pro Arg Gly Leu Lys Met Ser Ser Thr Phe Val  
355 360 365

Gly Asn Ser Thr Ala Ile Gln Glu Leu Phe Lys Arg Ile Gly Glu Gln  
370 375 380

Phe Thr Ala Met Phe Arg Arg Lys Ala Phe Leu His Trp Tyr Thr Gly  
385 390 395 400

Glu Gly Met Asp Glu Met Glu Phe Thr Glu Ala Glu Ser Asn Met Asn  
405 410 415

Asp Leu Val Ser Glu Tyr Gln Gln Tyr Gln Asp Ala Gly Val Asp Glu  
420 425 430

Glu Glu Glu Glu Tyr Glu Glu Glu Ala Pro Leu Glu Gly Glu Glu  
435 440 445

<210> 26

<211> 447

<212> PRT

<213> Aspergillus nidulans

<400> 26

Met Arg Glu Ile Val His Leu Gln Thr Gly Gln Cys Gly Asn Gln Ile  
1 5 10 15

Gly Ala Ala Phe Trp Gln Thr Ile Ser Gly Glu His Gly Leu Asp Gly  
20 25 30

Ser Gly Val Tyr Asn Gly Thr Ser Asp Leu Gln Leu Glu Arg Met Asn  
35 40 45

Val Tyr Phe Asn Glu Ala Ser Gly Asn Lys Tyr Val Pro Arg Ala Val  
50 55 60

Leu Val Asp Leu Glu Pro Gly Thr Met Asp Cys Val Arg Ala Gly Pro  
65 70 75 80

Phe Gly Glu Leu Phe Arg Pro Asp Asn Phe Val Phe Gly Gln Ser Gly  
85 90 95

10365/07304

Ala Gly Asn Asn Trp Ala Lys Gly His Tyr Thr Glu Gly Ala Glu Leu  
 100 105 110  
 Val Asp Asn Val Val Asp Val Val Arg Arg Glu Ala Glu Gly Cys Asp  
 115 120 125  
 Cys Leu Gln Gly Phe Gln Ile Thr His Ser Leu Gly Gly Gly Thr Gly  
 130 135 140  
 Ala Gly Met Gly Thr Leu Leu Ile Ser Lys Ile Arg Glu Glu Phe Pro  
 145 150 155 160  
 Asp Arg Met Met Ala Thr Phe Ser Val Val Pro Ser Pro Lys Val Ser  
 165 170 175  
 Asp Thr Val Val Glu Pro Tyr Asn Ala Thr Leu Ser Val His Gln Leu  
 180 185 190  
 Val Glu His Ser Asp Glu Thr Phe Cys Ile Asp Asn Glu Ala Leu Tyr  
 195 200 205  
 Asp Ile Cys Met Arg Thr Leu Lys Leu Ser Asn Pro Ser Tyr Gly Asp  
 210 215 220  
 Leu Asn His Leu Val Ser Ala Val Met Ser Gly Val Thr Thr Cys Leu  
 225 230 235 240  
 Arg Phe Pro Gly Gln Leu Asn Ser Asp Leu Arg Lys Trp Ala Val Asn  
 245 250 255  
 Met Val Pro Phe Pro Arg Leu His Phe Phe Met Val Gly Phe Ala Pro  
 260 265 270  
 Leu Thr Ser Arg Gly Ala Tyr Ser Phe Arg Ala Val Ser Val Pro Glu  
 275 280 285  
 Leu Thr Gln Gln Met Phe Asp Pro Lys Asn Met Met Ala Ala Ser Asp  
 290 295 300  
 Phe Arg Asn Gly Arg Tyr Leu Thr Cys Ser Ala Ile Phe Arg Gly Lys  
 305 310 315 320  
 Val Ser Met Lys Glu Val Glu Asp Gln Met Arg Asn Ile Gln Ser Lys  
 325 330 335  
 Asn Gln Ser Tyr Phe Val Glu Trp Ile Pro Asn Asn Ile Gln Ser Ala  
 340 345 350  
 Leu Cys Ser Ile Pro Pro Arg Gly Leu Lys Met Ser Ser Thr Phe Ile  
 355 360 365  
 Gly Asn Ser Thr Ser Ile Gln Glu Leu Phe Lys Arg Val Gly Asp Gln  
 370 375 380  
 Phe Thr Ala Met Phe Arg Arg Lys Ala Phe Leu His Trp Tyr Thr Gly  
 385 390 395 400

Glu Gly Met Asp Glu Met Glu Phe Thr Glu Ala Glu Ser Asn Met Asn  
 405 410 415

Asp Leu Val Ser Glu Tyr Gln Gln Tyr Gln Asp Ala Ser Ile Ser Glu  
 420 425 430

Gly Glu Glu Glu Tyr Ala Glu Glu Glu Ile Met Glu Gly Glu Glu  
 435 440 445

<210> 27

<211> 444

<212> PRT

<213> Achlya klebsiana

<400> 27

Met Arg Glu Leu Val His Ile Gln Gly Gly Gln Cys Gly Asn Gln Ile  
 1 5 10 15

Gly Ala Lys Phe Trp Glu Val Ile Ser Asp Glu His Gly Val Asp Pro  
 20 25 30

Thr Gly Ser Tyr His Gly Asp Ser Asp Leu Gln Leu Glu Arg Ile Asn  
 35 40 45

Val Tyr Tyr Asn Glu Ala Thr Gly Thr Tyr Val Pro Arg Ala Ile Leu  
 50 55 60

Met Asp Leu Glu Pro Gly Thr Met Asp Ser Val Arg Ala Gly Pro Tyr  
 65 70 75 80

Gly Gln Leu Phe Arg Pro Asp Asn Phe Val Phe Gly Gln Thr Gly Ala  
 85 90 95

Gly Asn Asn Trp Ala Lys Gly His Tyr Thr Glu Gly Ala Glu Leu Ile  
 100 105 110

Asp Ser Val Leu Asp Val Val Arg Lys Glu Ala Glu Ser Cys Asp Cys  
 115 120 125

Leu Gln Gly Phe Gln Ile Thr His Ser Leu Gly Gly Gly Thr Gly Ser  
 130 135 140

Gly Met Gly Thr Leu Leu Ile Ser Lys Ile Arg Glu Glu Tyr Pro Asp  
 145 150 155 160

Arg Ile Met Cys Thr Tyr Ser Val Cys Pro Ser Pro Lys Val Ser Asp  
 165 170 175

Thr Val Val Glu Pro Tyr Asn Ala Thr Leu Ser Val His Gln Leu Val  
 180 185 190

Glu Asn Ala Asp Glu Val Met Cys Leu Asp Asn Glu Ala Leu Tyr Asp  
 195 200 205

Ile Cys Phe Arg Thr Leu Lys Leu Thr Asn Pro Thr Tyr Gly Asp Leu  
 210 215 220



## 24

Asn His Leu Val Cys Ala Ala Met Ser Gly Ile Thr Thr Leu Leu Arg  
 225 230 235 240  
 Phe Pro Gly Gln Leu Asn Ser Val Leu Lys Leu Ala Val Asn Leu Ile  
 245 250 255  
 Pro Phe Pro Arg Leu His Phe Phe Met Ile Gly Phe Ala Pro Leu Thr  
 260 265 270  
 Ser Arg Gly Ser Gln Gln Tyr Arg Ala Leu Thr Val Pro Glu Leu Thr  
 275 280 285  
 Gln Gln Gln Phe Asp Ala Lys Asn Met Met Cys Ala Ala Asp Pro Arg  
 290 295 300  
 His Gly Arg Tyr Leu Thr Ala Ala Cys Met Phe Arg Gly Arg Met Ser  
 305 310 315 320  
 Thr Lys Glu Val Asp Glu Gln Met Leu Asn Val Gln Asn Lys Asn Ser  
 325 330 335  
 Ser Tyr Phe Val Glu Trp Ile Pro Asn Asn Ile Lys Ala Ser Val Cys  
 340 345 350  
 Asp Ile Pro Pro Lys Gly Leu Lys Met Ser Thr Thr Phe Ile Gly Asn  
 355 360 365  
 Ser Thr Ala Ile Gln Glu Met Phe Lys Arg Val Ser Glu Gln Phe Thr  
 370 375 380  
 Ala Met Phe Arg Arg Lys Ala Phe Leu His Trp Tyr Thr Gly Glu Gly  
 385 390 395 400  
 Met Asp Glu Met Glu Phe Thr Glu Ala Glu Ser Asn Met Asn Asp Leu  
 405 410 415  
 Val Ser Glu Tyr Gln Gln Tyr Gln Asp Ala Thr Ala Glu Glu Glu Gly  
 420 425 430  
 Glu Phe Asp Glu Asp Glu Glu Met Asp Glu Met Met  
 435 440

&lt;210&gt; 28

&lt;211&gt; 15

&lt;212&gt; PRT

&lt;213&gt; Pestalotiopsis microspora

&lt;220&gt;

 <223> motif conserved in *P. ultimum*, *H. sapiens*, *N. crassa*, *A. nidulans*, and *A. klebsiana*

&lt;400&gt; 28

Ala	Ile	Leu	Val	Asp	Leu	Glu	Pro	Gly	Thr	Met	Asp	Ser	Val	Arg
1				5					10					15

<210> 29  
<211> 15  
<212> PRT  
<213> Pestalotiopsis microspora

<220>  
<223> motif conserved in P. ultimum, H. sapiens, N.  
crassa, A. nidulans, and A. klebsiana

<400> 29  
Ala Val Leu Val Asp Leu Glu Pro Gly Thr Met Asp Ser Val Arg  
1 5 10 15

<210> 30  
<211> 7  
<212> PRT  
<213> Pestalotiopsis microspora

<220>  
<223> motif conserved in P. ultimum, H. sapiens, N.  
crassa, A. nidulans, and A. klebsiana

<400> 30  
Gly Gly Gly Thr Gly Ser Gly  
1 5

<210> 31  
<211> 4  
<212> PRT  
<213> Pestalotiopsis microspora

<220>  
<223> motif conserved in P. ultimum, H. sapiens, N.  
crassa, A. nidulans, and A. klebsiana

<400> 31  
Asp Asn Glu Ala  
1

<210> 32  
<211> 4  
<212> PRT  
<213> Pestalotiopsis microspora

<220>  
<223> motif conserved in P. ultimum, H. sapiens, N.  
crassa, A. nidulans and A. klebsiana

<400> 32  
Met Arg Glu Ile  
1

<210> 33  
 <211> 4  
 <212> PRT  
 <213> Pestalotiopsis microspora

<220>  
 <223> motif conserved in P. ultimum, H. sapiens, N.  
 crassa, A. nidulans, and A. klebsiana

<400> 33  
 Met Arg Glu Leu  
 1

<210> 34  
 <211> 31  
 <212> PRT  
 <213> Sus scrofa

<400> 34  
 Met Arg Glu Ile Val His Ile Gln Ala Gly Gln Cys Gly Asn Gln Ile  
 1 5 10 15

Gly Ala Lys Phe Trp Glu Val Ile Ser Asp Glu His Gly Ile Asp  
 20 25 30

<210> 35  
 <211> 20  
 <212> PRT  
 <213> Sus scrofa

<400> 35  
 Phe Arg Thr Leu Lys Leu Thr Thr Pro Thr Tyr Gly Asp Leu Asn His  
 1 5 10 15

Leu Val Ser Ala  
 20

<210> 36  
 <211> 31  
 <212> PRT  
 <213> Homo sapiens

<400> 36  
 Met Arg Glu Ile Val His Leu Gln Ala Gly Gln Cys Gly Asn Gln Ile  
 1 5 10 15

Gly Ala Lys Phe Trp Glu Val Ile Ser Asp Glu His Gly Ile Asp  
 20 25 30

<210> 37  
 <211> 20  
 <212> PRT  
 <213> Homo sapiens

&lt;400&gt; 37

Phe Arg Thr Leu Lys Leu Thr Thr Pro Thr Tyr Gly Asp Leu Asn His  
 1 5 10 15

Leu Val Ser Ala  
 20

&lt;210&gt; 38

&lt;211&gt; 31

&lt;212&gt; PRT

&lt;213&gt; Drosophila melanogaster

&lt;400&gt; 38

Met Arg Glu Ile Val His Ile Gln Ala Gly Gln Cys Gly Asn Gln Ile  
 1 5 10 15

Gly Ala Lys Phe Trp Glu Ile Ile Ser Asp Glu His Gly Ile Asp  
 20 25 30

&lt;210&gt; 39

&lt;211&gt; 20

&lt;212&gt; PRT

&lt;213&gt; Drosophila melanogaster

&lt;400&gt; 39

Phe Arg Thr Leu Lys Leu Thr Thr Pro Thr Tyr Gly Asp Leu Asn His  
 1 5 10 15

Leu Val Ser Leu  
 20

&lt;210&gt; 40

&lt;211&gt; 31

&lt;212&gt; PRT

&lt;213&gt; Xenopus laevis

&lt;400&gt; 40

Met Arg Glu Ile Val His Leu Gln Ala Gly Gln Cys Gly Asn Gln Ile  
 1 5 10 15

Gly Ala Lys Phe Trp Glu Val Ile Ser Asp Glu His Gly Ile Asp  
 20 25 30

&lt;210&gt; 41

&lt;211&gt; 20

&lt;212&gt; PRT

&lt;213&gt; Xenopus laevis

&lt;400&gt; 41

Phe Arg Thr Leu Lys Leu Thr Thr Pro Thr Tyr Gly Asp Leu Asn His  
 1 5 10 15

Leu Val Ser Ala  
20

<210> 42  
<211> 31  
<212> PRT  
<213> Tetrahymena thermophila

<400> 42  
Met Arg Glu Ile Val His Ile Gln Gly Gly Gln Cys Gly Asn Gln Ile  
1 5 10 15

Gly Ala Lys Phe Trp Glu Val Ile Ser Asp Glu His Gly Ile Asp  
20 25 30

<210> 43  
<211> 20  
<212> PRT  
<213> Tetrahymena thermophila

<400> 43  
Phe Arg Thr Leu Lys Leu Thr Thr Pro Thr Tyr Gly Asp Leu Asn His  
1 5 10 15

Leu Val Ser Ala  
20

<210> 44  
<211> 31  
<212> PRT  
<213> Physarum polycephalum

<400> 44  
Met Arg Glu Ile Val His Ile Gln Ala Gly Gln Cys Gly Asn Gln Ile  
1 5 10 15

Gly Ala Lys Phe Trp Glu Val Ile Ser Asp Glu His Gly Ile Asp  
20 25 30

<210> 45  
<211> 20  
<212> PRT  
<213> Physarum polycephalum

<400> 45  
Phe Arg Thr Leu Lys Leu Thr Thr Pro Thr Tyr Gly Asp Leu Asn His  
1 5 10 15

Leu Val Ser Ala  
20

<210> 46  
 <211> 31  
 <212> PRT  
 <213> Pythium ultimum

<400> 46  
 Met Arg Glu Leu Val His Ile Gln Gly Gly Gln Cys Gly Asn Gln Ile  
           1                  5                  10                  15  
 Gly Ala Lys Phe Trp Glu Val Ile Ser Asp Glu His Gly Val Asp  
                   20                  25                  30

<210> 47  
 <211> 20  
 <212> PRT  
 <213> Pythium ultimum

<400> 47  
 Phe Arg Thr Leu Lys Leu Thr Thr Pro Thr Tyr Gly Asp Leu Asn His  
           1                  5                  10                  15  
 Leu Val Cys Ala  
                   20

<210> 48  
 <211> 31  
 <212> PRT  
 <213> Phytophthora cinnamomi

<400> 48  
 Met Arg Glu Leu Val His Ile Gln Gly Gly Gln Cys Gly Asn Gln Ile  
           1                  5                  10                  15  
 Gly Ala Lys Phe Trp Glu Val Val Ser Asp Glu His Gly Val Asp  
                   20                  25                  30

<210> 49  
 <211> 20  
 <212> PRT  
 <213> Phytophthora cinnamomi

<400> 49  
 Phe Arg Thr Leu Lys Leu Thr Thr Pro Thr Tyr Gly Asp Leu Asn His  
           1                  5                  10                  15  
 Leu Val Cys Ala  
                   20

<210> 50  
 <211> 31  
 <212> PRT  
 <213> Achlya klebsiana

10365/07304

&lt;400&gt; 50

Met Arg Glu Leu Val His Ile Gln Gly Gly Gln Cys Gly Asn Gln Ile  
 1 5 10 15

Gly Ala Lys Phe Trp Glu Val Ile Ser Asp Glu His Gly Val Asp  
 20 25 30

&lt;210&gt; 51

&lt;211&gt; 20

&lt;212&gt; PRT

<213> *Achlya klebsiana*

&lt;400&gt; 51

Phe Arg Thr Leu Lys Leu Thr Asn Pro Thr Tyr Gly Asp Leu Asn His  
 1 5 10 15

Leu Val Cys Ala  
 20

&lt;210&gt; 52

&lt;211&gt; 31

&lt;212&gt; PRT

<213> *Pestalotiopsis microspora*

&lt;400&gt; 52

Met Arg Glu Ile Val His Leu Gln Thr Gly Gln Cys Gly Asn Gln Ile  
 1 5 10 15

Gly Ala Ala Phe Trp Gln Thr Ile Ser Gly Glu His Gly Leu Asp  
 20 25 30

&lt;210&gt; 53

&lt;211&gt; 20

&lt;212&gt; PRT

<213> *Pestalotiopsis microspora*

&lt;400&gt; 53

Met Arg Thr Leu Lys Leu Ser Asn Pro Ser Tyr Gly Asp Leu Asn His  
 1 5 10 15

Leu Val Ser Ala  
 20

&lt;210&gt; 54

&lt;211&gt; 31

&lt;212&gt; PRT

<213> *Aspergillus nidulans*

&lt;400&gt; 54

Met Arg Glu Ile Val His Leu Gln Thr Gly Gln Cys Gly Asn Gln Ile  
 1 5 10 15